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Abstract
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Symptomatic (Sy) aortic stenosis (AS) is a malignant condition with a five year 
survival of <50% but the prognosis in Asymptomatic (Asy) AS is relatively good. 
Aortic valve replacem ent (AVR) is virtually a curative procedure for those who 
survive the peri-operative period. AVR is recom m ended for symptomatic patients 
but the timing of surgery is critical to optimise outcome. M echanisms underlying 
exercise intolerance and symptom generation in AS are poorly understood. This 
study investigated non-invasive predictors of exercise capacity in 37 patients with 
significant AS (peak PG >25mmHg) and 20 matched controls. M ethods: Full 
echocardiography, cardiopulmonary exercise testing, skeletal muscle strength and 
endurance, arm and leg ergoreflex activation, brain natriuretic peptide (BNP) and 
endothelin-1 (ET-1) before and after maximal exercise, were m easured. AS was 
classified by both d isease (mild/severe) severity and symptomatic (Sy/Asy) status. 
Echocardiographic, anthropometric and exercise variables were examined as  
predictors of aerobic exercise capacity by univariate and multivariate regression 
analysis. R esu lts: AS and control subjects were well matched for age, body size 
and sex. Sy patients (67.9±11, n=19) were older than Asy AS (47.6±19, n=18) 
and controls (50.4±17 years), p=0.001. Exercise capacity (% predicted) w as 
reduced in Sy AS (52±27%) compared to Asy AS (86±28%) and controls 
(126±17%), p<0.0001. Exercise VEA/CO2 w as increased in severe (34.5±8) and 
Sy AS (35.1 ±7) v mild (30.2±5), Asy AS (29.8±5) and controls (28.6±4) p<0.01. 
SBP response to exercise was reduced in severe and Sy AS v controls and 
Asy/mild AS (P<0.001). Isometric quadriceps strength (Sym 470±169N v Asy AS 
564±251N v controls 567±199N) and isokinetic endurance (Sym 83.4±16% v Asy 
AS 71.9±14% v controls 76.1 ±7%) were not significantly different between AS and 
controls. Arm ergoreflex activation was not significantly increased in AS. Leg 
ergoreflex activation (ventilation, % peak) was enhanced in Sym AS (67±50) v Asy 
AS (20±46) and controls (17±48), p=0.01 but did not predict exercise capacity or 
VEA/CO2 . BNP w as increased in severe and Sym AS v mild/Asy AS and controls, 
p<0.0001. ET-1 was comparable at rest and after exercise in AS and controls. LV 
m ass/m ass index and BNP were independent predictors of exercise capacity in 
AS. C onclusions: Several variables have been identified which differ in 
symptomatic and asymptomatic AS. These (BNP, exercise capacity and SBP 
response ) should be a sse ssed  for prognostic value in a prospective study of AS.
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Definitions and abbreviations
AS: Aortic stenosis
AVA Aortic valve area
VTI Velocity Time Integral
BP: Blood pressure
SBP Systolic blood pressure
VO2 : Oxygen consumption
V02max- Maximal or peak oxygen consumption
CHF: Chronic heart failure
VEA/CO2 : The slope of exercise ventilation versus expired carbon dioxide
Ergoreflex A work (or metabolic) sensitive reflex arising in skeletal muscle and
involved in the control of ventilation and blood pressure.
RCO: Regional circulatory occlusion
BNP: Brain natriuretic peptide
NT-BNP Amino-terminal pro-BNP
ET-1: Endothelin-1
LBM: Lean body m ass
Ml: Myocardial infarction
CABG: Coronary artery bypass grafting
RER Respiratory exchange ratio
ECG Electrocardiography
AR Aortic regurgitation
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1.1 Aortic Stenosis (AS)
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1.1.1 The normal aortic valve
The normal aortic valve has three cusps that are thin, flexible structures, which are 
covered by endothelium on both ventricular and aortic surfaces(1 ,2). Each leaflet 
is com posed of three layers. The strength of the leaflets is provided by the fibrosa, 
a dense  layer of collagen fibres arranged parallel to the leaflet edges. The 
flexibility is provided by the ventricularis layer of elastic fibres arranged 
perpendicular to the leaflets. The spongiosa is an area of loose connective tissue 
located in the basal third of each leaflet. The normal aortic valve has an area 
between 2.5cm2-4.0cm2(3,4).
AS is defined as  a reduction in the area of the aortic valve orifice.
1.1.2 Aetiology
In adults there are three main causes of AS(5-7):
i. Post-Inflammatory (rheumatic)
ii. Primary degenerative (calcific/senile)
iii. Secondary calcification of a congenital bicuspid aortic valve
Other rare causes include: unicommisural and hypoplastic valves.
Inflammatory AS develops 20-30 years after acute rheumatic fever. The disease 
process is initiated by thrombotic deposits affecting the free edges of valve cusps, 
which subsequently lead to early commisural fusion. Usually all commisures are 
affected and after the age of 40 years, calcification is also found within the valve 
cusps.
Calcific -  this term is usually reserved for primary degenerative/senile AS but can 
also be used to describe calcification occurring in a bicuspid valve during 
adulthood. In congenital bicuspid AS, the calcification develops at the free edges 
of the cusps and progresses towards the base. Degenerative (senile) AS is
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commonly found in the eighth and ninth decades of life. Calcification progresses 
from the base of the valve leaflets towards the cusp edges, contrary to that in 
congenital and inflammatory AS.
As can be seen from the above description, nearly all adults with significant AS 
have calcified cusps(7). The significance of this finding is that those with 
rheumatic and bicuspid aetiologies have commisural fusion, whereas in those with 
degenerative AS, the cusps open up to the aortic ring, but their mobility is limited 
by the presence of calcification.
1.1.2.1 Interaction of ag e  and  aetio logy of AS.
There is a marked difference in the aetiology of AS depending on the age of 
subjects at the time of operation(5). There is a preponderance of bicuspid aortic 
valves in those patients under 70 years of age and degenerative valves in those 
older than 70 years(5) (figure 1-1). Patients with bicuspid AS are typically 
operated on 10 years earlier (mean age 64 years) than those with degenerative 
disease (74 years)(5,6).
Figure 1-1: Effect of age on aetiology of AS requiring surgery.
<70yrn=324 >70yr n=322
□  bicuspid
■  post- 
inflammatory
□  degenerative
□  other
Adapted from (5).
1.1.2.2 Aetiological fac to rs  in developm ent of degenera tive  AS
The development of senile/calcific AS has traditionally been considered to be a 
purely degenerative condition occurring with advancing age. More recently, it has 
become apparent that the inflammatory response may play an important 
aetiological role(8-11). Case control studies have demonstrated elevated levels of 
soluble adhesion molecules in patients with AS(9) and the presence of chlamydia
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pneum oniae in early lesions of AS(8). There are also histological similarities to 
atherosclerosis, with oxidised low density lipoprotein deposition, lymphocyte and 
m acrophage infiltration as  well as  basem ent m em brane disruption(10-12). 
Patients with degenerative AS are twice as  likely to require coronary artery bypass 
grafts compared to those with bicuspid valves, even when differences in age are 
taken in to consideration^). Several risk factors for the development of AS are 
shared with coronary artery disease(1): Hypercholesterolaemia(13,14), male 
gender, hypertension, body m ass index, smoking and diabetes mellitus. It has 
been proposed that degenerative AS may in fact be an atherosclerotic 
disease(15).
D iseases associated with hypercalcaemia (chronic renal failure, Paget’s  disease, 
hyperparathyroidism) are also risk factors(6).
1.1.2.3 Temporal changes in the aetiology of AS.
There has been a dramatic shift in the contribution of each the three main causes 
of AS in the last 30-40 years(5). As can be seen  from figure1-2, based on 656 
consecutive surgical specim ens from a single centre in the USA, the proportion of 
patients requiring aortic valve replacem ent for degenerative AS has steadily 
increased(5).
This increase is likely to reflect both the ageing population and the willingness of 
cardiac surgeons to operate on older patients(3,5). The frequency of rheumatic AS 
has decreased  throughout this period and in a recent British report accounted for 
only 5% of 465 consecutively excised valves, reflecting the virtual disappearance 
of rheumatic fever in W estern societies(6).
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Figure 1-2: Temporal change in aetiology of AS.
□  Bicuspid
■  Postinflammatory
□  Degenerative
Adapted from (5).
1.2 Pathophysiology
1.2.1 Pressure differences
The reduction in aortic valve area results in a measurable difference in pressure 
between the left ventricle and the aorta. This pressure difference (pressure 
gradient or pressure drop) can be expressed in one of three ways, which are 
illustrated in figure 1-3 below.
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Figure 1-3: Methods of quantifying transvalvular aortic pressure gradient.
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Adapted from Braunwald(16).
1. The peak instantaneous pressure difference. This can be calculated by 
overlaying the pressure traces obtained in the left ventricle and aorta and 
corresponds to the peak pressure gradient measured by maximal aortic velocity on 
Doppler echocardiography.
2. The peak-to-peak pressure gradient. Usually measured by pullback of a 
catheter from the left ventricle into the aorta.
3. Mean pressure gradient. Calculated by overlaying simultaneous left 
ventricular and aortic pressure traces and the area of difference is calculated by 
planimetry.
The pressure gradient is directly related to flow, i.e. the cardiac output and 
especially stroke volume, but in a non-linear fashion. Flow is correlated to the 
square root of pressure gradient; therefore small increases in cardiac output lead 
to large increases in pressure gradient(see equations 2 and 4 below). Since aortic 
pressure is generally stable, controlled by peripheral vascular resistance, it is left 
ventricular systolic pressure that changes with increasing cardiac output.
1.2.2 Left ventricular hypertrophy and systolic function
Pressure overload leads to compensatory left ventricular hypertrophy to maintain 
wall stress, according to the law of La Place.
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Equation 1: the law of Laplace
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LV wall stress = Radius x Pressure
2 x wall thickness
Most patients (approximately 70%) develop concentric left ventricular hypertrophy, 
where there are increases in left ventricular wall thickness, left ventricular m ass 
index and an increase in the relative wall thickness(17,18). In such cases  the left 
ventricular end diastolic diameter is usually within normal limits. Over time both 
end diastolic and end systolic left ventricular diam eters increase slowly, although 
this may not be apparent in those with marked concentric left ventricular 
hypertrophy(17). A smaller percentage of patients tend to develop eccentric 
hypertrophy where there are increases in left ventricular end diastolic diameter 
and left ventricular m ass index, but the relative wall thickness is within normal 
limits(17). W hereas concentric left ventricular hypertrophy is regarded a s  a 
com pensatory adaptation, eccentric hypertrophy is thought to be a 
decom pensated response to the pressure overload and is associated with more 
severe valvular stenosis and left ventricular systolic dysfunction(17-21). As left 
ventricular systolic function is normal in the vast majority of patients(4,22-25), it is 
possible that those patients with eccentric hypertrophy and impairment of left 
ventricular contraction represent a more advanced stage in the d isease 
progression(26).
1.2.3 Left ventricular hypertrophy and diastolic function
Diastolic dysfunction is directly related to increases in left ventricular m ass(21,27) 
and occurs in approximately 50% of all patients with AS(27). Diastolic dysfunction 
is also present in virtually all patients who have objective evidence of reduced 
systolic function(27). In marked left ventricular hypertrophy, there may be 
evidence of subendocardial ischaemia, which contributes to both systolic and 
diastolic dysfunction(28). Increased end diastolic pressure requires a forceful 
atrial contraction to maintain optimal ventricular filling. The development of atrial 
fibrillation in such a situation is often followed by serious clinical deterioration(18).
1.2.3.1 Gender differences in left ventricular geometry and function
Recent echocardiographic and catheterisation studies have highlighted differences 
in geometric patterns and function of the left ventricle in fem ales compared to
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males(29-31). In elderly women especially, there is excessive left ventricular wall 
thickening, with generally lower wall s tresses  and preservation of systolic function 
despite similar degrees of stenosis severity(29-31). The m echanism s underlying 
these  gender differences are not clearly understood, but may be related to cellular 
changes in the structure and deposition of collagen fibres, which occur more 
frequently in males(31).
1.2.3.2 Left ventricular hypertrophy and altered repolarisation
QT dispersion, which has been shown to predict the occurrence of fatal ventricular 
arrhythmias, is increased in patients with AS prior to valve replacement(32,33). 
This inhomogeneity of repolarisation is most likely related to the presence of left 
ventricular hypertrophy(33).
1.2.4 Haemodynamics
Cardiac output at rest is reduced in up to 50% of patients, particularly in those with 
severe AS(4,22,34). In the vast majority of patients, systolic function will be 
normal a s  m easured by ejection fraction(22-24), although the systolic ejection 
period will be prolonged(22,34). The end diastolic left ventricular pressure is often 
elevated at rest(35) and the time constant for ventricular relaxation or the 
isovolumetric relaxation time are often lengthened(22,36) and may be related to 
increases in left ventricular mass(22).
1.2.4.1 Exercise haemodynamics
The cardiac output response to exercise is usually abnormal, with either no 
increase or blunting of the expected increase(34-36). Increased cardiac output is 
achieved primarily by an increase in heart rate, since stroke volume tends to be 
either static, or decreased(23,24,34). Stroke volume increases are directly 
proportional to changes in end diastolic volume and inversely proportional to left 
ventricular mass(23,24). At the beginning of exercise there are marked increases 
in end diastolic pressure(22,34,35) which also tend to be related to left ventricular 
hypertrophy(35) and rapid increases in both left atrial and pulmonary capillary 
wedge pressure(22). The isovolumetric relaxation time and systolic ejection 
periods may decrease on exercise, but typically do not reach control values(34- 
36). Mitral valve opening time is prolonged(36) but peak filling rates of the left
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ventricle during diastole are decreased(24,36). These studies indicate the 
important contribution of diastolic dysfunction to exercise limitation in patients with 
AS and left ventricular hypertrophy. Females, who have more evidence of left 
ventricular hypertrophy, tend to have greater reductions in predicted aerobic 
exercise capacity compared to males(37).
1.3 Classification of severity
The severity of AS can be classified by one of two m eans; aortic valve area or 
m easurem ent of transvalvular pressure gradient. These indices can be m easured 
either invasively or non-invasively.
1.3.1 Invasive assessment of AS
1.3.1.1 The Gorlin equation.
It has long been recognised that clinical signs, particularly in the elderly, may not 
adequately differentiate between mild and severe AS. Prior to echocardiography, 
the mainstay of assessm en t was by cardiac catheterisation and calculation of 
aortic valve area by the Gorlin equation(38):
Equation 2: the Gorlin formula for aortic valve area (AVA)
AVA = Cardiac output
(44.3 x SEP x HR x Vmean PG)
where: 44.3 is a constant
SEP = systolic ejection period 
PG = pressure gradient.
HR= heart rate in beats per minute
This method of assessm en t has several limitations. Firstly, it requires an invasive 
procedure with left heart catheterisation by either retrograde crossing of the aortic 
valve or by the transeptal technique. Secondly, as  the formula uses the square 
root of the mean pressure gradient it is more prone to errors measuring cardiac 
output than pressure gradient. For this reason cardiac output should be m easured 
by the Fick method since both the thermodilution and dye-dilution techniques can 
lead to overestimation, particularly in low output states(39). Thirdly, the 
assumptions in the equation have been questioned in recent years, particularly 
since the formula w as only validated in patients with mitral stenosis. It has been
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dem onstrated that the constant varies in low and high cardiac output states, 
although this may actually reflect changes in the effective aortic valve area with 
alterations in pressure gradient(35,40-42). The equation is also invalidated in the 
presence of significant valvular regurgitation because the cardiac output is 
increased without any change in aortic valve area(39).
1.3.1.2 Hakki formula
Hakki observed that for most subjects with AS the product of HR x SEP X 44.3 
w as approximately 1000 and proposed a simplified equation for determination of 
aortic valve area(43):
Equation 3: the Hakki formula
AVA = CO
Vmean PG
Where: AVA=aortic valve area
CO=cardiac output in L/min
Vmean PG= square root of the mean pressure gradient
This simplified formula, like the Gorlin equation, has not been adequately validated 
in patient populations(39).
1.4 Echocardiographic assessment
The development of echocardiographic technology has transformed the 
assessm en t of AS. Echocardiography is the investigation of choice in the 
diagnosis and quantification of native and prosthetic valve disease(44).
1.4.1 M-Mode and two dimensional echocardiography
As early a s  1975 M-mode echocardiography w as proposed a s  a reliable m eans of 
assessing the severity of AS(45). The authors of this paper were able to show 
statistical differences in the degree of aortic valve leaflet separation in 28 adults 
with either mild, moderate or severe AS. This technique is limited by the degree of 
overlap between individuals in different groups and the problems of 
underestimating the degree of leaflet separation in calcific d isease and 
overestimating separation in congenital AS(45).
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Two-dimensional cross-sectional (M-Mode) echocardiography has also been 
shown to successfully differentiate between normal and stenotic aortic valves(46). 
However, the degree of aortic leaflet separation w as not able to distinguish 
between severe (<0.75cm2) and m oderate AS (>0.75cm2) a s  m easured invasively 
by the Gorlin formula(46).
7.4.2 Doppler ultrasound measurement of transaortic pressure 
gradient
Doppler ultrasound allows m easurem ent of the velocity of blood in the left 
ventricular outflow tract and distal to the aortic valve. The pressure gradient 
(pressure in the left ventricle minus pressure in the aorta) across the aortic valve 
can be calculated by the Bernouilli equation(47):
Equation 4: the Bernouilli equation
PG = 4x(V 22- V ,2)
where: PG is pressure gradient in mmHg
V2= maximal velocity across aortic valve
Vl= is the velocity in the left ventricular outflow tract.
Since Vi is usually small, (0.6-0.7 m s'1) in comparison to V2 in AS, it can be 
discarded giving the simplified or modified Bernouilli equation:(47)
Equation 5: the modified or simplified Bernouilli equation(47)
PG = 4V2
where: V is the maximal aortic velocity in ms'1.
For accurate quantification, it is assum ed that the angle between the ultrasound 
beam  and the jet of blood is small, so that the cosine of the angle approaches 1.0 
(true for angles < 20°). The mean velocity across the aortic valve during systole 
can be calculated by planimetry of the spectral display of the Doppler tracing of the 
maximal aortic velocity and this is often known as  the velocity time integral (VTI). 
This allows calculation of peak and mean pressure gradients a s  shown in figure 1-
4.
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Figure 1-4: VTI of aortic valve maximal velocity
Measured from the apex by the stand alone CW Doppler probe.
The example above shows a peak aortic velocity of 5.64ms' . This velocity equates to a peak pressure 
gradient of 127.2mmHg employing the modified Bernouilli equation. The mean gradient is derived from the 
VTI (average velocity divided by the systolic ejection period) and equals 68.2 mmHg.
Warth et al applied this technique to the Gorlin equation, which meant that left 
heart catheterisation could be omitted using the following equation:(48)
Equation 6: aortic valve area calculation by semi-invasive method(48)
AVA = cardiac output
SEP X velocity.
Where: SEP is the systolic ejection period
velocity is mean transvalvular aortic velocity
This semi-invasive approach gave an excellent correlation (r = 0.99) with the aortic 
valve area obtained by the formal Gorlin equation in 16 patients with AS(48). 
Limits of agreement for the two methods, however, were not reported.
Numerous studies have confirmed that Doppler ultrasound can give accurate 
assessment of transaortic peak and mean pressure gradients, provided that 
multiple echocardiographic windows (apical, suprasternal, sub-diaphragmatic and 
right intercostal) are searched and maximal velocities are used(49-53). The single 
best study compared catheter measured gradients with simultaneously obtained
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Doppler gradients in 100 adults aged over 50 years of age with AS(49). The 
correlation coefficients for instantaneous (catheter) gradient and maximal pressure 
gradients (Doppler) were 0.92, and 0.93 for m ean gradient. The correlation 
between peak gradient (Doppler) and peak-to-peak pressure w as still good 
(r=0.91) but the Doppler value over-estimated the invasive m easure by a large 
proportion and should not be compared directly to peak-to-peak gradient(49). The 
overestimation of Doppler compared to catheter derived gradients may be 
explained, at least in part, by the phenom enon of aortic pressure recovery(54-57). 
P ressure recovery is a  manifestation of the transfer of kinetic energy into potential 
energy seen  downstream from a stenosis; that is a s  the velocity of blood flow 
decreases so does the kinetic energy and therefore the potential energy m ust 
increase(54). A significant degree of pressure recovery, and therefore probable 
overestimation of Doppler pressure gradient, can be expected in patients with 
small aortic root diameters(54,55).
Despite excellent correlations for Doppler derived and catheter m easured 
gradients, the pressure gradient is not always a reliable m easure of AS severity. 
According to the modified Bernouilli equation, (equation 5) small increases in flow 
velocity (cardiac output) will result in large increases in m easured pressure 
gradient without a change in aortic valve area and this has been dem onstrated in 
vivo(58). The opposite applies for low output states, e.g. significant left ventricular 
dysfunction with reduced cardiac output, in the p resence of AS. This limitation in 
the assessm en t of pressure gradient for the severity of AS led to a totally non- 
invasive echocardiographic technique for calculating aortic valve area.
1,4.3 The continuity equation.
The equation of continuity, which governs flow in cylinders, w as first proposed a s  a 
method of calculating aortic valve area  (AVA) in 1985(50). The haemodynamic 
principles are outlined below.
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Figure 1-5: The continuity equation for determination of aortic valve area.
Adapted from ref(59)
Equation 7: The continuity equation
Q = A1 x VI = A2 x V2 
Therefore A1 = V2 
A2 VI 
A2 = A1 x VI 
V2
where: Q= flow or cardiac output
A1 = the cross-sectional area of the left ventricular outflow tract 
immediately below the aortic valve,
A2 is the area of the stenotic valve.
VI is the velocity of blood in the left ventricular outflow tract and 
V2 is the velocity of blood in the ascending aorta immediately 
above the aortic valve.
Theoretically, this equation should be affected by neither left ventricular
dysfunction nor by increased flow, a s  occurs in aortic incompetence. Depending
on whether peak velocity or mean velocity is used in the equation, either maximal 
aortic valve area or effective aortic valve area respectively will be calculated(SO). 
The validity of the continuity equation a s  a m easure of aortic valve area w as 
confirmed in 16 AS patients, som e of whom had significant aortic incompetence, 
with a  correlation coefficient of 0.89 with values determined by the Gorlin
equation(50). Subsequent studies have reported even higher correlation
coefficients (r=0.93-0.95) with subject numbers ranging from 39-100(55,59,60). 
Despite very high correlation coefficients, the limits of agreem ent may be wide 
(-0.56 - 0.38cm2) for predicting the aortic valve area in any given individual and it 
is suggested that area should be used in conjunction with pressure gradient(55). 
Two studies reported that using only non-invasive indices to determine severe AS 
resulted in very high sensitivities and specificities for appropriate recommendation 
of aortic valve replacement(59,60). Otto and Pearlman have suggested that using 
the continuity equation to a s se s s  the severity of AS, instead of cardiac 
catheterisation, would result in significant cost savings, even if coronary 
angiography had to be undertaken prior to aortic valve replacement(60).
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The major limitation in this technique is that accurate m easurem ent of the left 
ventricular outflow tract may be impossible in a small number of patients, 
particularly those with poor two dimensional im ages and heavily calcified 
valves(50,59,60).
1.4.3.1 Flow dependence of aortic valve area.
Theoretically, blood flow should not be a confounding factor in the determination of 
aortic valve area, calculated by the continuity equation. Recent investigations 
however have shown this not to be the case(61-66). Most studies have used 
dobutamine stress echocardiography(62-64,66) but Otto’s  group have used 
maximal exercise testing to increase flow in asymptomatic patients with significant 
AS to determine the effect on calculated aortic valve area(61,65). In 66 patients, 
the aortic valve area increased significantly post-exercise from 1.38 to 1.58 cm2 
(14%) with mean cardiac output increasing by 25%(61). The increase in mean 
pressure gradient was relatively higher (39%) and there were also significant 
increases in valve resistance and percent stroke work loss, both m easures of 
severity that do not have empiric constants in equations to calculate their value.
It has been suggested that tricuspid aortic valves of degenerative aetiology are 
more likely to dem onstrate a flow dependent increase in aortic valve area than 
bicuspid or rheumatic valves(62). This observation seem s logical since, typically, 
the commisures of degenerative aortic valves are not fused(7). This study was 
probably biased by the low numbers of subjects with definite rheumatic aetiology 
(n=3) and the exclusion of subjects who did not increase cardiac output in 
response to dobutamine infusion, thereby increasing the likelihood of excluding 
those with more severe d isease or left ventricular dysfunction(62).
1.4.3.2 Time dependence of calculated aortic valve area.
The calculated aortic valve area by the continuity equation will also vary 
depending at which time point during systole velocity m easurem ents are made. 
Badano et al m easured left ventricular outflow tract velocity at peak, mid­
acceleration and mid-deceleration in 26 AS subjects (AVA< 1.5 cm2) and 14 
healthy controls(64). They dem onstrated that in the patient group the aortic valve 
opened slowly and continued to open throughout systole, w hereas in the control 
subjects the aortic valve opened rapidly and maximally(64). There was no
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correlation between echocardiographic m easures of severity and the degree of 
aortic valve opening during systole(64). The w eakness of this study is that it is 
assum ed that left ventricular outflow tract area is unchanged throughout systole.
1.4.4 Other echocardiographic methods to determine stenosis 
severity
Several other methods for assessing  AS have been proposed but none of those 
outlined below have yet to be used widely in clinical practice. These include: 
pulsed wave Doppler flow mapping(67,68), valve area by planimetry with 
transoesophageal echocardiography(69) and valve resistance(41). These 
techniques have few, if any, advantages over the continuity equation and the 
usefulness of resistance as  a predictor of clinical outcome or recommendation for 
surgery has yet to be tested(70).
1.4.5 Doppler derived pressure gradients and aortic valve area
There is not absolute agreem ent am ongst authors regarding the grading of 
severity of AS(16,18,71-73). A simplified classification system  equating pressure 
gradients and aortic valve areas is outlined in the table below.
Severity Aortic Valve Area Transvalvular Peak 
Pressure Gradient
Transvalvular Mean 
Pressure Gradient
Mild > 1.1 cm2 < 40 mmHg <20mmHg
Moderate 0 .7 -1 .09  cm2 40 -69 mmHg 21-39mmHg
Severe < 0.7 cm2 > 70 mmHg >40mmHg
Table 1-1: Approximate equivalent values for determining severity of AS.
It must be em phasised that the above system  is simplistic, since all of the above 
values are arbitrary cut-offs and the limitations of each method of assessm en t 
must be borne in mind. It is also possible to have severe AS with a low pressure 
gradient, particularly in left ventricular dysfunction, and mild AS with a high 
pressure gradient(74). Therefore pressure gradients should be interpreted in 
combination with aortic valve areas. Confusion in this area  is not helped by the 
fact that the American College of Cardiology / American Heart Association 
(ACC/AHA) task force on m anagem ent uses aortic valve area for sports 
participation(18), peak pressure gradient in congenital AS but m ean pressure
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gradient in acquired AS(71). Another complicating factor is that som e suggest that 
aortic valve area should be corrected for body surface area, in the sam e way that 
cardiac output is corrected(18).
Otto has taken simplification to the extreme by suggesting that all patients with a 
peak velocity >4m s'1 should be classified as  having severe AS(73). We have 
pointed out that the this conclusion is flawed since the study is based on 
asymptomatic patients in the modern era(75), many of whom underwent aortic 
valve replacem ent because of reduced exercise capacity which has not been 
shown to predict outcome(76).
1.5 Epidemiology
1.5.1 Prevalence
The exact prevalence of AS in the general population is unknown, however 
abnormalities of the aortic valve are common in the elderly. Thickened aortic 
valve leaflets occur a s  part of the ageing process and echocardiographic studies 
have estim ated that calcification occurs in up to 40% of subjects over 75 years of 
age(77). The prevalence of AS (m easured by increased pressure gradient) in 
subjects aged over 60 years of age has been estim ated to be between 18%(78) 
and 26%(77). Severe AS (peak pressure gradient >50mmHg or aortic valve area 
<0.8cm2) is found in approximately 2-3% of all elderly subjects(77,78). AS is the 
com m onest reason for valve replacem ent in the USA with over 28,000 operations 
being performed in 1994(1). In the UK, 70 aortic valve replacem ents are 
performed each year per million population(79). The proportion of elderly patients 
over 70 years having surgery has increased dramatically: from 12% in 1986 to 
36.6% in 1997(79).
1.6 Presentation
The condition is more prevalent in men with an approximate male to female ratio 
of 70:30(4,80-84). The male to female ratio for congenitally bicuspid aortic valves 
is higher, approaching 4:1(85,86). Symptomatic patients typically present in later 
life, usually in the 6th, 7th, and 8th decades(4,80,81,87). The development of AS 
following rheumatic fever typically occurs up to 30 years after the initial illness,
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much later than for mitral stenosis(81). There is usually a long latent or 
presymptomatic stage with systolic murmurs often being present for more than 10 
years prior to p resen ta tion^ ,80).
1.6.1 Physical signs.
The physical signs in AS are: systolic thrill in the aortic area: a long or harsh 
systolic murmur in the aortic area; absence or diminished second heart sound, 
cardiac hypertrophy; a slow rising plateau pulse and a forceful and sustained apex 
beat(4,81,82,84,87). Other signs may be apparent with the development of 
chronic heart failure (CHF). The presence of the above physical signs are not 
present in all c ases  and even the systolic murmur may be inaudible in elderly 
subjects(4,78,87). The narrow pulse pressure described in many textbooks is 
uncommon(4); in one early series of 180 adult patients with definite AS, the 
average blood pressure (BP) was 145/84(81). The vast majority remain in sinus 
rhythm with less than 10% in atrial fibrillation(75,81). Although a reduced carotid 
pulse upstroke correlates with the echocardiographically derived pressure 
gradient, clinical examination is not a reliable method for differentiating mild 
d isease from severe AS(84).
1.7 Natural history
Since the ability to accurately a s se s s  AS, by cardiac catheterisation, occurred 
almost simultaneously with the introduction of surgical correction one must look 
largely to studies prior to this era to determine the natural history of the 
disease(80-82). Unfortunately these early reports do not, and could not, classify 
the patients according to severity of AS. In addition many of these  reports do not 
conform to the standards expected in the modern scientific journals. Several, 
more recent retrospective studies, have attem pted to characterise the natural 
course of the d isease by following patients who have not undergone surgical 
intervention(72,83,88,89) or initially were not referred for surgery(90,91).
1.7.1 Symptoms
Classically, there are three cardinal symptoms described in AS(80). T hese are:
Angina
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Symptoms of heart failure (marked dyspnoea, orthopnoea, paroxysmal nocturnal 
dyspnoea and peripheral oedem a).
The age at first presentation of symptoms was docum ented at 48 years in the 
Ross and Braunwald study(80) but had risen to 61 years in Lombard and Selzer’s 
large series published in 1987(4). This trend is also likely to be a reflection of the 
changes seen  in the aetiology of AS over the last 30 years.
1.7.1.1 Angina pectoris
Angina is a common symptom in AS occurring in approximately 30-50% of all 
patients at the time of a s se s sm e n ts ,81,83). Angina may not be indicative of 
underlying coronary artery d isease since many patients (30-40%) experience 
classical angina despite having angiographically normal coronary 
arteries(4,83,92,93). Conversely, the absence of angina does not imply that the 
major epicardial coronary arteries are free of atherosclerosis, since this symptom 
will be absent as  often as  present in those with significant coronary artery 
disease(4,94). The overall prevalence of significant coronary artery d isease in 
patients with AS is 40-60%(4,75,90,94,95). With such a high prevalence of 
atherosclerosis, it is therefore necessary  that most patients who undergo aortic 
valve replacem ent will require coronary angiography before surgery. (The inability 
of exercise testing to reliably distinguish CAD is discussed in section 1.8.8) The 
mechanism causing angina pectoris in patients with AS and normal coronary 
arteries remains controversial(96), although is likely to involve reduced coronary 
flow reserve associated with elevated myocardial wall stress(97).
1.7.1.2 Syncope
Syncope occurs a s  a first symptom in AS in approximately 15% of patients. The 
average time to death from the development of syncope has been reported as 
varying from 9 months(81) to 3 yrs(80). Several theories have been proposed for 
the mechanism of syncope in AS including: carotid sinus reflex hyperactivity(98), 
abrupt left ventricular failure(99), arrhythmias(IOO), and the currently accepted 
theory of inappropriate left ventricular baroreceptor activity first proposed by 
Johnson in 1971(101). Johnson suggested that baroreceptors in the left
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ventricular wall respond to severe rises in left ventricular systolic pressure 
occurring during exercise in patients with AS(101). The initiated vagal depressor 
reflex produces peripheral systemic vasodilatation, with possible dilatation of the 
splanchnic bed, and bradycardia. Diminished venous return with decreased 
cardiac output, together with decreased systemic vascular resistance leads to 
severe hypotension and syncope. Coronary arterial blood flow falls abruptly in the 
face of heavy left ventricular work and either cau ses  syncope or, potentially, 
ventricular arrhythmias leading to circulatory arrest and death. Indirect support for 
Johnson’s  theory com es from the observation that patients with left ventricular 
systolic pressures >200mmHG are more likely to experience syncope(4). There is 
good experimental evidence from both human and animal models to support 
Johnson’s  theory(102-104).
1.7.1.3 Dyspnoea and heart failure
Congestive heart failure is manifested late in the course of AS and in the vast 
majority of patients left ventricular systolic function is preserved(4,22-24). Once 
heart failure develops, the prognosis is very poor with average times to death of 1- 
2.0 years(80,81). Although dyspnoea is often regarded a s  the main symptom of 
heart failure, it occurs early in many cases  of AS(4,90) and may represent diastolic 
dysfunction. Dyspnoea may be present in up to 62% of all symptomatic 
patients(4,90). Patients who develop clinical or radiological heart failure have 
higher left ventricular wall stress and the majority will have an ejection fraction 
within the normal range although cardiac index is reduced(105).
1.7.2 Prognosis
1.7.2.1 Prognosis in symptomatic patients in the pre-surgical era
In Ross and Braunwald's classic description(80) of the natural history of AS in the 
era before operative intervention, average survival from onset of first symptom 
was as  follows:
i. Angina -  3-5 years
ii. Syncope -  3 years
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Angina and syncope have generally been regarded a s  early symptoms and 
dyspnoea/heart failure as  a late symptom(4,80). However, dyspnoea is often the 
first symptom to develop(4,106) and in one early series of 180 patients with AS the 
average survival after the development of syncope w as only nine months(81). The 
commonest causes of death in the pre-surgical era were progressive cardiac 
failure (approximately 65%), bacterial endocarditis (approximately 15%) and 
sudden cardiac death (approximately 20%)(80).
1.7.2.2 Prognosis in the modern era
Interpretation of the prognosis in patients in the modern era is more difficult. The 
relevant studies either try to a s se s s  the prognosis retrospectively or use data from 
patients who did not undergo surgery, either because they refused or aortic valve 
replacement was not offered. Such studies are likely to suffer from selection bias 
since these subjects are likely to represent groups of older patients or those with 
significant co-morbid conditions. The data are further confused by reports 
containing small numbers of patients with varying degrees of d isease  severity and 
those with and without symptoms. The major studies regarding the prognosis in 
the modern era are listed in table 1-2.
Symptomatic patients usually have moderate to severe AS, although som e of 
those with severe AS may be entirely asymptomatic(3,72,82-84,90,91). Severe 
AS is associated with significant morbidity and mortality: the five and 10-year 
mortality for symptomatic patients are approximately 60-80% and 90% 
respectively(72,83). The prognosis for m oderate symptomatic d isease 
approaches that of severe AS(90). CHF is associated with increased risk: mean 
survival is less than I year compared to 4.6 years for angina and 2.6 years for 
syncope(88). The majority of deaths are secondary to progressive CHF and 
approximately 25% of deaths are regarded a s  sudden(25,72,75,106).
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Author Year No. of 
subjects
Symptoms Severity Mean
Follow-
Up
Prognosis:
Mortality/
Morbidity*
Frank(83) 1973 15 12 Sy 
3 Asy
Mod-severe 2 years 66%
Chizner(72) 1980 42 32 Sy 
10 Asy
Mod-severe 5 years 2yr 48% 
5yr 64% 
lOyr 90%
Horskotte(88) 1988 35 Mixed Severe ?>10years 2yr 50% 
5yr 18%
VA Coop(89) 1988 106 >50%Sym Mild-severe 5 years 5yr 57%
Kelly(106) 1988 90 39 Sy 
51 Asy
Mod-severe 1.2 years sym 38% 
asy 16%
Pellika(91) 1990 113 Asy Mod-severe 1.7 years lyr 14%* 
2yr 38%*
Kennedy(90) 1991 66 58 Sy 
8 Asy
Severe 3 years 21% 
asy 0%
Otto(75) 1997 123 Asy Mild-severe 2.5 years lyr 7%* 
3yr 38%* 
5yr 74%*
Rosenhek(25) 2000 126 Asy Severe 1.8 years lyr 33%* 
2yr 44%* 
4yr 67%*
Table 1-2: Prognosis in the modern era.
VA Coop= Veterans Cooperative study, Sy=symptomatic, Asy=Asymptomatic. *Denotes studies in which 
the end point was either death or aortic valve replacement.
Left ventricular systolic impairment, elevated end diastolic pressure and aortic 
valve area index(90), mean pressure gradient, CHF and the presence of d isease 
in the proximal LAD have been shown to confer a worse prognosis. Even mildly 
symptomatic patients have a high mortality (44%) at 5 years(72).
In the elderly, AS is an independent risk factor for new cardiac events including 
myocardial infarction and sudden cardiac death(107, 108). Even aortic sclerosis, 
which was previously regarded a s  a benign condition, has recently been shown to 
confer a relative risk of 1.5 for subsequent cardiac death, even when corrected for 
the presence of symptomatic coronary artery disease(108).
1.7.2.3 Prognosis in asymptomatic patients
In assessing the natural history in asymptomatic patients most reports include 
large proportions of patients who have undergone aortic valve replacement, either
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because of reduced exercise capacity or progression of haemodynamic 
severity(25>75,90>91). Such studies often use the combined end-point of cardiac 
events (defined as  either sudden cardiac death or aortic valve replacement) in 
assessing predictors of prognosis. The use of such end-points must be 
questioned, since in all of these reports many patients (20-40%) have undergone 
aortic valve replacem ent even though they were asymptomatic at the time of 
operation(25,75,90>91). With these points in mind, the prognosis in such studies is 
discussed below.
The prognosis in asymptomatic AS is generally regarded as  very 
good(3,4,25,80,109,110). In one study of eight asymptomatic patients, all of 
whom were less than 30 years of age, with m oderate to severe d isease  there were 
no deaths during at least five years of follow-up, although five patients 
subsequently underwent aortic valve replacement(72). Further evidence of the 
excellent prognosis in young adults com es from the second natural history of 
congenital AS(111). For subjects with a peak pressure gradient <25mmHg the 25 
year survival was 92.4% compared to the average population survival of 96% for 
the sam e age group(111). Otto’s group have also dem onstrated that age is an 
independent predictor of future events as  is increasing pressure gradient 
m easured by Doppler echocardiography(75). In the small study by Frank and 
Johnson one of three asymptomatic patients with m oderate to severe d isease died 
during follow-up over a period of at least two years(83). However, in patients with 
severe AS recommended surgery three of 35 (8.6%) died whilst still 
asymptomatic(88).
Pellikka et al compared the prognosis in 30 patients who underwent aortic valve 
replacement within three months of assessm en t with 113 who were m anaged 
medically(91). The one and two year event free survival w as 90% for the group 
operated on compared to 86% and 62% for the non-operated group(91). The 
authors concluded that asymptomatic patients should be m anaged conservatively 
because there was a low incidence of sudden cardiac death(2%), despite the 
poorer prognosis in the conservatively m anaged group. Independent predictors of 
outcome were peak velocity and ejection frac tional).
In a large series of asymptomatic subjects (defined a s  the absence  of chest pain, 
syncope and dyspnoea on m oderate exertion), with severe AS (velocity>4ms'1) the 
outcome in 22 patients who had early aortic valve replacem ent w as compared to
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that in 106 who were initially m anaged medically(25). There were six cardiac 
deaths in the 106 m anaged conservatively, five of whom had developed 
symptoms, with an estimated rate of sudden cardiac death of <1%(25). The 
outcom es for the two groups were similar with mortality figures close to that for the 
general population. This study highlights the methodological difficulties with such 
reports. The surgical group were older (71 v 57 years) and had more severe 
d isease (peak velocity 5.0 v 4 .5m s'1) than those m anaged medically. 
Furthermore, 59 patients in the medically m anaged group subsequently had aortic 
valve replacement, all apparently because of the development of symptoms. This 
is rather surprising considering that 22 of the original cohort had surgery whilst still 
asymptomatic. The true incidence of sudden death in all asymptomatic subjects is 
likely therefore to be higher than that reported in the modern literature since many 
patients, presumably those with the severest d isease and therefore highest risk, 
undergo aortic valve replacement whilst still asymptomatic.
In summary, m oderate and severe AS, which is symptomatic, confers a high risk 
of complications in a short follow up period. Those with reduced ejection fraction 
and increased symptomatology are at higher risk. The prognosis for 
asymptomatic AS, particularly in young adults, is significantly better than for 
symptomatic d isease but is not neglible. For all degrees of severity the outlook is 
worse with evidence of left ventricular dysfunction and increased pressure 
gradient, particularly in elderly subjects.
1.7.3 Progression of AS
Many reports have addressed the rate of haemodynamic progression in AS (see 
Table 1-3).
The peak pressure gradient increases by approximately 7mmHg per year and the 
aortic valve area decreases approximately 0.1 cm2 per year. Isolated cases  of 
rapidly progressive AS have been re ported (122).
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First
Author
Year No. Case
Mix
Cath / 
Echo
Peak
PG
Tp g
year
I a v a /
year
(cm2)
Faster
progression
Wagner(112) 1982 50 - C 38 5.4 - tAge, Calc
Nitta(l 13) 1987 11 - C 23 7.7 - tAge
Turina(l 14) 1987 29 - C 50 3.4 - None
Otto(115) 1989 42 - D 54 12 0.1 t  Symptoms
Roger(116) 1990 112 - D 35 4.8 - t  Symptoms
Davies(117) 1991 65 - C 10 6.5 - Calc
Faggiano(l 18) 1992 45 - D 64 15 0.1 LVSD
Peter(119) 1993 49 - D 38 7.2 - tCAD
Beppu(120) 1993 75 Con D NA 1.8 - Eccentric
Brener(19) 1995 394 - D NA 8.3 0.14 MR
Otto(75) 1997 123 Asy D 29(x) 7 0.12 None
Palta(121) 2000 170 - D 29 0.10 AVA, Choi, 
Smoking
Rosenhek(25) 2000 126 Asy D 125 - Cardiac 
events, Calc
Table 1-3: Echocardiographic progression in AS.
Adapted from ref(l 10). Con=congenital, Asy=asymptomatic, AVA=aortic valve area D= Doppler, 
C= cardiac catheterisation, (x)=mean PG, LVSD=left ventricular systolic dysfunction, 
calc=calcification, MR=mitral regurgitation. NA=not available, Chol= elevated serum cholesterol, 
Calc=calcification of valve
Several factors have been associated with increased rates of progression. These 
are: age(112,113), calcification in the valve(25,112,117), smoking, increased aortic 
valve area and hypercholesterolaemia(121), increased NYHA functional 
class(115,116), left ventricular systolic dysfunction(118), coronary artery 
d isease(119), eccentric cusps(120) and cardiac events(25). Recently, a slow rate 
of change in aortic valve area during a cardiac cycle has been implicated in faster 
progression in mild asymptomatic AS(123). In the single largest study on
progression, in 394 adult patients, Brener et al dem onstrated that hypertrophy 
protected against left ventricular dilatation but worsening mitral regurgitation 
seem ed to be a maladaptive response to increasing AS severity(19).
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Traditionally m oderate to severe AS has been regarded a s  either a relative or 
absolute contraindication to exercise testing(18,124-126). The rationale for 
excluding patients with AS from exercise testing is based  on the already 
documented occurrence of syncope and sudden death (neither of which occur 
exclusively on exertion) and isolated case  reports of deaths during exercise or 
exercise testing(100,127,128). As early as  1969 exercise haemodynamics were 
suggested as  a useful indicator of when to recommend aortic valve 
rep lacem ent 129). More recently several authors have advocated the use of 
exercise testing in AS, particularly in the assessm en t of asymptomatic patients 
prior to aortic valve replacem ent^ 8,126,130,131).
1.8.1 Safety of exercise testing in AS
Exercise testing in AS is performed routinely in som e countries, particularly in 
Sweden(132). Table 1-4 lists the major studies of exercise tolerance testing in 
adults with AS.
First
Author
Year No. of 
Subjects
Status Type of 
exercise
Exercise
endpoint
Complications
Atterhog(133) 1979 ?AS
>50,000
Pre-cath Bicycle Symptom 1 Death 
3 VT
Almendral(135) 1982 16 Pre-
AVR
Treadmill 85%max 
pred HR
1 VT 
1 AF
Niemela(136) 1983 19 Pre-
AVR
Bicycle Symptom None
Linderholm(92) 1985 35
(+500)*
Pre-
AVR
Bicycle Symptom None
Nylander(93) 1986 76 Sym Bicycle Symptom None
Clyne(24) 1991 14 Asy Treadmill Symptom None
Driscoll(86) 1993 134 Adult
cong.
Treadmill Symptom 2 Arrhythmia 
1 Syncope
Otto(75) 1997 123 Asy Treadmill Symptom None
Gencbay(137) 1999 42 Asy Treadmill Max pred 
HR
None
Table 1-4: Studies demonstrating the safety of exercise testing in AS.
Sym = symptomatic; Asy = asymptomatic; cath = cardiac catheterisation; AVR = aortic valve replacement; 
TM = treadmill; Adult cong. = adult congenital AS. *Detailed results given for 35 patients but authors 
comment that over 500 tests carried out in AS without a fatality.
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Many studies, in addition to those examining exercise haemodynamics, have 
dem onstrated the safety of exercise testing in a controlled hospital environment 
with careful attention to BP response.
Only one death has been reported in the literature(133). Unfortunately, although 
AS w as said to confer a higher risk of complications during this very large 
prospective study of over 10,000 exercise tests, the number of patients with AS 
and the frequency of adverse events were not reported(133).
Most studies have reported infrequent and self-limiting complications and used 
similar criteria for termination of the test: fall in systolic BP(SBP), >5mm ST 
depression and persistent arrhythmia. Atwood has estim ated that the mortality for 
exercise testing in AS is approximately one fifth of that for coronary artery 
disease(134).
Exercise is usually performed on an electrically braked bicycle or motorised 
treadmill and a wide range of protocols have been employed. A fall in systolic BP, 
which may indicate left ventricular baroreceptor activation, is an indication for 
termination of the test but is sometim es reported as  a complication(75,133). All of 
the studies have continuously monitored the electrocardiogram and BP has been 
recorded at three minute intervals or more frequently.
1.8.2 Exercise capacity in AS
1.8.2.1 Maximal aerobic capacity
There has only been one reported study, which directly com pares exercise 
capacity with age, and sex matched controls(24). (See table 1-5). Clyne et al 
exercised 14 asymptomatic adults with moderate to severe AS and 14 healthy 
control subjects(24). The patient group had normal left ventricular systolic but 
abnormal diastolic function. The aortic patients had significantly reduced 
maximum oxygen consumption, maximum SBP and a borderline significant 
reduction in exercise duration. There were no significant differences in resting 
heart rate, systolic BP or maximum heart rate. Four patients in whom exercise 
ejection fraction w as reduced had significantly impaired V0 2 max compared to those 
with normal left ventricular function (20 v 29ml/kg/min)(24).
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Controls AS P Value
Age 46 42 ns
M/F 12/2 12/2 ns
Resting Heart Rate (bpm) 79 73 ns
Resting SBP (mmHg) 136 141 ns
Peak Exercise HR (bpm) 171 177 ns
Peak Exercise SBP (mmHg) 192 167 < 0.001
VChmax (ml/kg/min) 36.3 26.7 0.004
Exercise duration (min) 13.3 10.7 0.06
Table 1-5: Exercise capacity in AS compared to matched controls.
ns= non-significant
Several studies have compared exercise capacity with predicted values for normal 
populations using standardised protocols(75,86,93,135), whilst others have simply 
reported results pre and post-surgery(136). In a large series of 123 adults with 
asymptomatic AS, exercise capacity w as reduced by only 10%(75) in contrast to 
the 26% reduction in m easured Vc>2max seen  in Clyne’s study(24). Similarly, in the 
NHS II study of congenital AS, many of whom had undergone aortic surgery, 
exercise capacity was on average 86.5% of that predicted(86). On the other hand, 
in elderly subjects with severe AS, 95% will have an exercise capacity < 80% of 
that predicted for age(93).
The majority of AS patients will achieve close to their predicted maximum heart 
rate(34,75,86,93). Those patients with severe AS will tend to have an attenuated 
increase in systolic BP on exercise(135) and may have a greater amount of ST 
segm ent depression during exercise testing(86).
1.8.3 Symptoms limiting exercise capacity
Most patients with untreated AS are symptom-limited on exercise tolerance 
testing(75,93,136). Those with severe d isease  are more likely to develop 
symptoms than those with mild to m oderate AS(34). Dyspnoea and fatigue 
account for 60% of test terminations due to symptoms. Other less frequently 
occurring symptoms requiring test termination are angina (3-25%) and dizziness, 
approximately 1%(75,93). Medical termination of exercise tests  is uncommon 
(approximately 8%) with the most frequent indications being a reduction in
McCann, G.P. 2001 Chapter 1 45
SBP(93), and rarely, either sustained ventricular arrhythmias or ST segment
depression > 5 mm(93).
1.8.4 NYHA functional class and exercise capacity
Interestingly, symptomatic status, as  judged by NYHA functional class, is a poor 
predictor of exercise capacity in AS. In Nylander’s elderly symptomatic group, 
many patients in NYHA class II had < 50% of their predicted exercise capacity, 
w hereas som e in class III only had a moderate restriction(93). There was a large 
overlap between the groups of patients in each functional class(93). In a smaller 
study, there was no correlation between NYHA class and exercise duration(135). 
In completely asymptomatic individuals, i.e. NYHA class I, predicted exercise 
capacity was reduced by 10% + 33%(75). In 14 asymptomatic patients with 
m oderate-severe d isease V02max was reduced by 26%(24). This discrepancy 
between symptomatic status and objective m easurem ent of exercise capacity 
suggests that as  the degree of AS severity increases, patients may becom e more 
sedentary, perhaps subconsciously avoiding activities which make them feel 
unwell or attribute their reduced exercise tolerance to the ageing process.
1.8.5 Predictors of exercise capacity
Resting haemodynamic m easurem ents such a s  pressure gradient(135) ejection 
fraction, cardiac index and pulmonary artery pressure(136) do not correlate 
significantly with aerobic exercise capacity. In Clyne’s small study of 14 patients, 
exercise capacity w as correlated with increasing cardiac output, m easured by 
radionuclide ventriculography(24).
1.8.6 Reproducibility of cardiopulmonary exercise testing
Only one study has addressed the question of reproducibility of cardiopulmonary 
exercise testing in patients with valvular heart disease(138). Six patients with AS, 
out of a total of 17, performed two treadmill exercise tests  according to the Norton 
protocol, under standardised conditions with expired gas analysis. Total walking 
time, peak oxygen consumption, heart rate at anaerobic threshold, ventilatory 
equivalents for oxygen (VEA/O2 ) and carbon dioxide (VEA/CO2 ) all showed 
excellent correlations with r values between the two tests  approaching one(138).
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1.8.7 Exercise capacity after aortic vaive replacement
Following aortic valve replacem ent an improvement in exercise capacity is seen  
whether patients attend a formal exercise rehabilitation programme or 
not(139,140). Improvements tend to occur slowly despite the immediate 
improvements in haemodynamics(141-165). Exercise capacity does not return to 
normal however. In one study of patients with left ventricular hypertrophy following 
aortic valve replacement, exercise capacity w as only 63% of predicted despite 
subjects achieving their predicted maximum heart rate(36). This probably reflects 
incomplete regression of left ventricular hypertrophy and persistent diastolic 
dysfunction (see section 1.9.5). Another possibility is that patients have 
abnormalities of skeletal muscle similar to those seen  in chronic heart failure 
(CHF), see  section 1.10.4, which have not been investigated previously.
1.8.8 Exercise testing in the detection o f coronary artery disease
As has been previously discussed, angina pectoris is a common symptom without 
evidence of coronary artery d isease in patients with AS. Similarly, the 
development of ST segm ent depression during exercise tolerance testing does not 
indicate obstructive coronary artery disease. In 104 asymptomatic patients 
performing a total of 274 treadmill tests, 188 tests  were complicated by significant 
horizontal or down sloping ST segm ent depression(75). Fifty-two patients 
subsequently had coronary angiography. Only 50% of these subjects had 
evidence of obstructive coronary artery d isease  and there w as no correlation 
between the development of ST segm ent depression and angiographically proven 
disease(75). In patients with symptomatic m oderate to severe AS, 10 of 14 
subjects developed ST segm ent depression, but only 3 had reversible defects on 
thallium scanning(24). In 42 patients with a m ean age of 37, with mild to moderate 
AS, 81% of the group developed > 1 mm of ST segm ent depression on exercise 
despite all of the subjects having normal coronary angiography(137). ST segm ent 
depression seem s to occur equally frequently in those with a s  opposed to those 
without ECG determined left ventricular hypertrophy(24). Patients with coronary 
artery d isease tend to be older and have more marked ST segm ent depression, 
with a greater reduction in maximum workload(92). However, no single equation 
can reliably predict the presence of coronary artery d isease  in any individual 
subject(92).
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There is no medical therapy which is of proven benefit in the treatment of AS. 
Surgery, with aortic valve replacement, has led to vast improvements in 
prognosis(144), although there are no randomised control trials comparing surgical 
versus medical m anagem ent. The peri-operative mortality for aortic valve 
replacement is dependent on the risk factor profile of the subject undergoing 
surgery.
1.9.1 Mortality
The peri-operative mortality for all patients is approximately 6.6%(145). In the 
United Kingdom the mortality for all aortic valve replacem ents without coronary 
artery bypass grafting(CABG) is 4% and with CABG 6%(146). In low risk patients, 
i.e. those without extra cardiac co-morbidity or coronary artery disease, the 
operative mortality is approximately 2-3%(130,147,148). For those patients who 
survive the peri-operative period, the age predicted survival is similar to that for the 
general population(147,149,150).
1.9.1.1 Age
In elderly patients peri-operative mortality is higher; for those over 80 years 
mortality varies between 5 and 18%(151,150,152,153). In 675 consecutive 
patients undergoing aortic valve replacement, the peri-operative mortality was 
12.4%, but dropped to < 5% for those under 70 years of age(151). In 140 
consecutive patients in France, aged over 80 years, 42% of whom had significant 
coronary artery disease, the inpatient mortality w as 9.3%(152). Five year survival 
was 56% and 80% of survivors were able to live independently at home(152). In a 
similar study from the UK, in 103 patients, peri-operative mortality w as 18% but 
there was a very good symptomatic outcome in survivors, with most patients in 
NYHA class I or 11(150).
1.9.1.2 Left ventricular dysfunction and coronary artery disease
In two large series of patients with left ventricular systolic dysfunction, and severe 
AS, the peri-operative mortality w as 9-11 %(154,155). The five year survival after 
aortic valve replacem ent for patients without coronary artery d isease, but left
McCann, G.P. 2001 Chapter 1 48
ventricular systolic dysfunction pre-operatively is between 69 and 88%(154,155). 
For those with coronary artery d isease and left ventricular systolic dysfunction 
survival is between 40-51 %(154,155). In another series of 55 patients, all with 
severe left ventricular dysfunction the 30 day mortality w as 18%(156). The only 
independent predictor of mortality w as prior myocardial infarction, conferring a 
relative risk of 14.5 for peri-operative death(156).
1.9.1.3 Predictors of peri-operative mortality
The strongest predictors of peri-operative mortality are the presence of coronary 
artery disease(147,154,155) and increasing age(145,147,151). Other factors 
which are shown to independently predict mortality include a reduced cardiac 
output prior to valve replacement(155), the presence of severe left ventricular 
hypertrophy(147,157), an increase in left ventricular relative wall thickness(157) 
and impairment of systolic(145,151) and diastolic function(145). Gender is 
probably not an independent risk factor once other differences in haemodynamic 
and structural indices are taken into account(158).
1.9.1.4 Surgical waiting list- morbidity and mortality
With limited operating resources, there is inevitably a delay in the time to surgery 
from the decision being m ade to operate. For patients with severe AS, there were 
12 deaths out of 99 patients listed for aortic valve replacem ent during a six month 
waiting list(159). The death rate whilst on the waiting w as 13.5 per 100 patient 
years versus only 4.9 per 100 patient years for those undergoing aortic valve 
replacem ents 59). During the delay for operative intervention there w as also a 
significant worsening of prognostic profile in eleven patients. Expected seven year 
survival in this group fell from 72% at the time of listing for surgery to 61% pre- 
operatively. Predictors of death whilst awaiting surgery were: increasing age, 
short duration of symptoms, severe left ventricular hypertrophy on ECG, female 
gender and diastolic dysfunction(159).
1.9.1.5 Late mortality
There is still an excess mortality for patients who survive the peri-operative 
period(149,160,161). This is primarily related to an increase in cardiac failure(149) 
and complications related to the valve prosthesis(149,161). Predictors of late
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mortality are residual left ventricular hypertrophy, impairment of systolic left 
ventricular function and diastolic dysfunction indicated by a reduction in peak filling 
rate on radionuclide ventriculography(160).
1.9.2 Morbidity associated with aortic valve replacement
As well as  the excess mortality previously discussed, there are several significant 
complications related to the valve prosthesis. Thromboembolism has a 
prevalence of 1.7/100 patient years, haem orrhage related to anticoagulants, 1.5% 
per patient year, sudden cardiac events, including arrhythmias and myocardial 
infarction, 1.8 per 100 patient years, and prosthetic endocarditis occurs 0.5/100 
patient year(149).
1.9.3 Alterations in ventricular repolarisation abnormalities
Following valve replacem ent there is a reduction in QT dispersion early and late 
after surgery(32,33). Valve replacem ent has also been shown to increase heart 
rate variability in 12 patients who underwent surgery(162). These favourable 
alterations may in part be responsible for the reductions in sudden death after 
aortic valve replacement.
1.9.4 Symptomatic Status
The vast majority of patients who survive the peri-operative period will benefit from 
an improvement in symptomatic status(150,155,163). This applies to those with 
impairment of left ventricular function(155) and in elderly subjects with severe 
symptomatic AS(150).
1.9.5 Alterations in left ventricular structure and function
1.9.5.1 Left ventricular structure
Valve replacem ent leads to an immediate reduction in increased afterload, 
affecting left ventricular haemodynamics(164). Structural changes occur in the left 
ventricle within a few days and continued remodelling occurs for years after valve 
replacem ent(32,164-169). There is an early reduction in left ventricular 
hypertrophy and left ventricular m ass index which does not usually return to
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normal(32,33,165-169). This is mainly achieved by a reduction in myocardial fibre
diameter and a reduction in interstitial fibrosis(168,169).
1.9.5.2 Left ventricular function
If left ventricular systolic function is impaired, the ejection fraction usually 
increases post surgery(155,163,165,166). In patients with normal systolic 
function, the ejection fraction remains preserved(167). Improvements in ejection 
fraction may be expected in patients with obstructive coronary artery disease(155). 
There are also immediate improvements in diastolic function which continue over 
several years, but do not return to normal values(169). Diastolic dysfunction 
appears to be related to the degree of persisting interstitial fibrosis late after 
surgery(168,169).
1.9.6 Balloon Aortic Valvuloplasty for AS
The outcome of aortic balloon valvuloplasty, unlike mitral valvuloplasty, is very 
poor(153,170). In 674 consecutive patients undergoing valvuloplasty in a multi­
centre report from the United States, it w as shown that 3 year survival was only 
23%(170). There was a small improvement in symptomatic status, but frequent 
re-hospitalisation and haemodynamic restenosis w as very common(170). In the 
severely symptomatic patient, valvuloplasty may be used as  a temporary m easure 
prior to definitive surgery(153). The survival post valvuloplasty is not significantly 
different for patients with m oderate to severe symptomatic AS.
1.9.7 Timing of surgery
It is universally accepted that surgery is indicated for symptomatic patients with 
significant AS because of the very poor prognosis in this condition(16,18,73). The 
single most controversial area of m anagem ent in AS is whether to recommend 
surgery in those with severe but asymptomatic d isease  and what is the optimal 
timing of aortic valve replacem ent? Clearly, even in centres of excellence with 
vast experience of the m anagem ent of these  patients, significant differences in 
clinical practice are seen(25,75,171).
Braunwald has changed his attitude somewhat, from not recommending aortic 
valve replacem ent in any asymptomatic individuals but to keep them under careful
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surveillance(171). He now recom m ends aortic valve replacem ent for 
asymptomatic individuals with evidence of left ventricular systolic dysfunction and 
those with blunted or reduced systolic BP response to exercise(16).
Chambers in a recent editorial has suggested that asymptomatic patients undergo 
exercise tolerance testing and those developing angina pectoris should be referred 
for surgery(131). This suggestion does not, however, take into account those 
patients who may develop angina as a result of underlying obstructive coronary 
artery d isease and, more importantly, classically patients with angina pectoris 
have a moderately good prognosis, compared to the symptom of dyspnoea and 
heart failure(80).
Otto has implied that patients with a peak aortic velocity of > 4 ms-1 undergo aortic 
valve replacem ent because of the low survival rate (21%) without surgery at 2 
years(73). Once again these data are clouded by the fact that almost 50% of the 
patients undergoing surgery did so because of reduced exercise capacity or 
haemodynamic progression, neither of which have been shown prospectively to be 
associated with increased mortality. In a further recent editorial, Otto more 
emphatically does not recommend surgery for asymptomatic AS on the basis that 
sudden cardiac death in such patients is rare(<1%)(172). The data on which this 
conclusion is based are flawed. Almost 20% of the initial cohort were referred for 
surgery whilst still asymptomatic and they contained the highest risk patients; a 
more elderly cohort with higher pressure gradients than those m anaged 
medically(25).
Lund has suggested that patients should be operated on earlier, possibly whilst 
still asymptomatic(159). This is based on the worsening operative risk profile and 
mortality during the inevitable waiting time for surgery(159). Rahimtoola also 
recommends earlier AVR, possibly in asymptomatic patients, in those with 
evidence of left ventricular dysfunction, coronary artery d isease  or other serious 
co-morbidity(74). The majority opinion seem s to favour waiting until subjects 
become symptomatic and then recommending aortic valve replacem ent a s  quickly 
as possible thereafter(16,18,172,173). This strategy is far from ideal as  evidenced 
from the number of patients who develop symptoms and die before surgery can be 
performed(25,83,91,106)
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1.10 Exercise limitation in (CHF)
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In the normal subjects maximal aerobic exercise capacity is limited by cardiac 
output(174). During incremental exercise testing, oxygen consumption reaches a 
plateau despite an increase in workload and this phenom enon is termed maximal 
oxygen consumption (V0 2 max). Vc>2 max is an objective m easure of 
cardiopulmonary fitness and aerobic exercise capacity. CHF patients often do not 
reach a plateau in their oxygen consumption before cessation of maximum leg 
exercise(175). Furthermore, the addition of arm to maximum leg exercise in such 
patients produced a further increment in VO2 which did not occur in control 
subjects(175). Since the CHF patients did not exhaust their cardiopulmonary 
reserve at the point of fatigue, it is apparent that their exercise capacity may have 
been limited by factors other than cardiac output. As patient groups often do not 
reach a plateau in oxygen consumption, the term peak VO2 is applied to the 
maximal value obtained.
1.10.1 Haemodynamic predictors of exercise capacity
Resting indices of cardiac function such a s  ejection fraction, cardiac output and 
pulmonary artery capillary wedge pressure are poorly correlated with maximal 
exercise capacity in heart failure(176,177). Furthermore, interventions which lead 
to immediate improvements in cardiac haem odynam ics do not translate into 
improved exercise capacity. On the other hand quadriceps muscle strength and 
endurance have been found to be good predictors of peak VO2 in CHF(176-180).
1.10.2 Symptoms limiting exercise in CHF
Patients with heart failure are most often limited by dyspnoea and fatigue. 
Patients terminating exercise because of fatigue do not show differences in central 
haemodynamic m easures compared to those stopping because of 
breathlessness(181). In addition, any individual patient is frequently limited by 
different symptoms produced by different forms of exercise or by varying speeds in 
incremental tests(182). These data suggest that the different symptoms limiting 
exercise capacity in CHF may be generated by the sam e underlying 
mechanism(s).
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1.10.3 Exercise ventilation in CHF
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In CHF there is an exaggerated ventilatory response to exercise indicated by an 
increase in the VE/VCO2 slope(183,184,182) (figure 1-6). The Ve/Vco2 slope 
correlates inversely with peak Vc>2(182). The mechanisms responsible remain 
controversial. Several authors have suggested that this exaggerated ventilatory 
response to exercise is a result of increased lung dead space in CHF 
patients(184,185,186) plus a combination of earlier lactic acidosis(186). Clark and 
Coats have argued that trying to explain the increased Ve/Vco2 slope on the basis 
of the alveolar ventilation equation will always result in elevated dead space being 
increased(184). We have demonstrated that altering the exercise position from 
erect to supine, which should alter the ventilation perfusion ratio and, hence dead 
space, did not change the VE/VCO2 slope in either normal controls(187) or in 
patients with CHF(188). Also alteration of breathing pattern did not result in 
changes in the slope of VEA/CO2 in normal subjects(189).
Figure 1-6: Ventilatory response to exercise in CHF
Exercise Ve/VcO; in 2 patients with CHF and a healthy control.
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It is also true that arterial blood gases rarely change in CHF patients during 
exercise despite the fact that ventilation continues to increase(182,183,187). It 
seems from these findings that neither arterial PCO2 nor altered dead space is 
responsible for the increased ventilatory response to exercise seen in heart failure.
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The slope of VE/VCO2 also confers prognostic information(190). In 303 patients 
with CHF, VE/VCO2 slope was an independent predictor of mortality in a 
multivariate model, including age, ejection fraction and NYHA functional 
classification, during a median follow up of seven months(190).
1.10.4 Skeletal muscle abnormalities in CHF
Skeletal muscle changes in CHF are well documented(184,191-193). A decrease 
in muscle bulk is seen , which may occur a s  a result of a catabolic state, 
characterised by high levels of tumour necrosis factor-a, insulin resistance, 
intestinal malabsorption and deranged intracellular thyroid hormone 
handling(184,191,194). A shift in the composition of the muscle fibres also occurs. 
There is an increase in the number of type MB fibres (anaerobic fast twitch), and a 
reduction in type I fibres, which are slow twitch and oxidative(193,195). These 
changes are similar to those of a de-training effect and consequently result in 
reduced oxidative capacity and a lower lactate threshold. Although total number of 
skeletal muscle capillaries may be reduced, the number per unit of area is 
normal(192). Reduced physical activity levels may contributes to the development 
of skeletal muscle abnormalities in CHF although no study has specifically 
addressed  this possibility.
1.10.4.1 Functional changes in skeletal muscle in CHF
The histological and biochemical abnormalities present in skeletal muscle result in 
abnormal metabolism during exercise. There is early lactate 
acidosis(185,196,197), increased inorganic phosphate/phosphocreatine 
concentrations^ 92,193,195,198), decreased  oxygen utilisation by muscle(193), 
an early fall in intracellular pH(184,199) and delayed phosphocreatine recovery 
post exercise(184,199). These changes are consistent with a shift towards 
increased dependency on anaerobic metabolism.
1.10.4.2 Muscle strength in CHF
It has been dem onstrated that both static (isometric) and dynamic strength of the 
quadriceps and hamstring muscle groups are significantly reduced in heart failure 
patients compared to matched controls(200). Contradictory results have also 
been published(178). The strength of small muscle groups such as  foot
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dorsiflexors, intrinsic hand muscles, arm extensors and flexors are usually well 
preserved in CHF(201-203). W hen strength of the large muscle groups is 
corrected for body size or muscle m ass, strength per unit area of muscle is 
normalised(180,180). In patients with cardiac cachexia, it seem s that muscle 
strength is reduced, even when corrected for muscle m ass, implying an intrinsic 
abnormality in the force generation apparatus(179).
1.10.4.3 Muscle endurance in CHF
Muscular endurance is defined a s  the ability of the contracting muscles to perform 
repeated contractions against a load(172). Muscular endurance is a sse ssed  using 
an isokinetic dynamometer which continually records torque during muscle 
contractions at a selected angular velocity(204). Several studies have confirmed a 
reduction in quadriceps muscle endurance in patients with CHF(178-180,202).
1.10.5 Endothelial dysfunction and exercise limitation in CHF
It has long been recognised that vasodilation in CHF in response to various stimuli 
is abnormal(205). Both endothelium-dependent and endothelium-independent 
processes are affected(206-208). Skeletal muscle blood flow during exercise has 
been shown to be reduced in several reports(179,196,197,209). Blood flow has 
not usually been corrected for muscle m ass, which may result in normalisation of 
flow per unit of muscle. Several other investigators have reported normal 
exercising blood flows, even in som e patients with reduced exercise capacity 
and/or abnormal muscle metabolism(179,196,210,). During exercise with regional 
circulatory occlusion (RCO) fatigue remains more pronounced in CHF than 
controls(178,202). These data lend further support to the theory that there is an 
intrinsic abnormality in skeletal muscle rather than changes a s  a result of hypo­
perfusion.
1.10.5.1 Endothelial function in valvular heart disease
Endothelium-dependent and endothelium-independent vasodilation are abnormal 
in patients with CHF secondary to valvular heart d isease(211,212). The 
endothelium-dependent vasodilation is subsequently improved by valve 
replacem ent and this is associated with a corresponding increase in exercise 
capacity(212).
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1.10.6 Ergoreflex activation
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There is strong evidence from both human(213-219) and animal(220-224) models 
demonstrating a neural connection between skeletal muscle and the control of 
ventilation during exercise. This reflex, which has been termed the ergoreflex, 
contributes to the maintenance of ventilation(214,215,219), heart rate(216,221), 
BP(214,216) and peripheral vascular resistance(213,217). The reflex is most 
likely transmitted from skeletal muscle to the central nervous system via small 
nerve fibres(221,224). The ergoreflex is stimulated by both mechanical 
stretch(221,225) and the products of metabolism(222).
1.10.6.1 Ergoreflex activation in CHF
Ergoreflex activity has recently been dem onstrated to be enhanced in patients with 
CHF(213). Twelve patients with heart failure were com pared to ten control 
subjects during and following handgrip exercise at 50% of maximum voluntary 
contraction until exhaustion. Exercise w as performed on two occasions and after 
one test RCO was obtained, by inflating a sphygm om anom eter cuff to 30mmHg 
greater than BP, for three minutes(213). Ventilation (86.5 v 54.5%), systolic BP(89 
v 59%), diastolic BP(97.8 v 53.5%) and leg vascular resistance(108.1 v 48.9%) 
were significantly increased in CHF patients com pared to controls after RCO(213). 
W e have subsequently shown that an exaggerated ergoreflex also exists in the 
lower leg musculature in CHF(226).
1.10.6.2 Ergoreflex and the muscle hypothesis
The demonstration of enhanced ergoreflexes in CHF has proven an attractive 
hypothesis in unifying the ventilatory and skeletal muscle abnormalities seen  in 
CHF(191). According to this theory, when heart failure patients exercise early 
metabolic distress occurs in the abnormal skeletal muscles, which stimulates 
ventilation and the sympathetic nervous system. Ergoreflex activity results in the 
increased ventilation and may be perceived a s  dyspnoea and fatigue leading to 
exercise cessation before the cardiovascular system  is maximally taxed. Left 
ventricular systolic dysfunction is the initiating insult in a cascading system of 
maladaptive responses, but in what order the other pathophysiological 
adaptations, e.g. endothelial dysfunction, skeletal muscle atrophy, catabolic state 
and neurohormonal activation, occur is uncertain(191).
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1.11 Brain Natriuretic Peptide (BNP) and cardiac disease
1.11.1 BNP
BNP is one of three members in the natriuretic peptide hormone family along with 
atrial natriuretic peptide (ANP) and C type natriuretic peptide (CNP). The 
molecular biology, synthesis, secretion and effects of BNP have been reviewed in 
detail elsewhere(227,228,229,230). Briefly, BNP is a peptide consisting of 32 
amino acids which circulates in plasma. BNP is very similar in structure to ANP 
(figure 1-7) and both peptides are derived from larger pro-hormones; in BNP's 
case an 108 amino acid sequence called pro-BNP.
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Figure 1-7: Structure of natriuretic peptides
a - h u m a n  ANP 1 h u m an  BNP p o rc in e  CNP
Pro-BNP is cleaved into the amino (N)-terminal pro-BNP (NT-BNP) and the 32- 
amino acid BNP. BNP is contained in secretory granules in both the atria and the 
ventricles, but unlike ANP the primary source is from the left ventricle (figurel-8).
Figure 1-8: Synthesis and storage of ANP and BNP.
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Adapted from ref(231). Values are expressed as a percentage of the atrial ANP value.
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Although a small amount of BNP is secreted from storage granules, the majority of 
circulating BNP is produced from a constitutive pathway which is probably 
stimulated by myocyte stretch. It is unclear whether myocyte stretch acts directly 
or indirectly via endothelin, nitric oxide or angiotensin(230). Circulating BNP levels 
in cardiac d isease, particularly heart failure, are correlated with left ventricular end 
diastolic pressure, pulmonary capillary wedge pressure, right atrial pressure and 
inversely correlated with ejection fraction.
1.11.1.1 Actions of BNP
BNP acts at 3-natriuretic peptide receptors. Receptor subtypes A and B, when 
stimulated activate transm em brane guanyl cyclases that mediate the biological 
effects. The C type receptor is thought to be a clearance receptor, but may also 
play a role in regulating vascular smooth muscle cell proliferation. The effects of 
both BNP and ANP are: natriuresis; diuresis; vasorelaxation with resultant 
reductions in peripheral vascular resistance, pulmonary artery and capillary wedge 
pressures; and an increase in cardiac index in heart failure patients. ANP and 
BNP also inhibit the renin-angiotensin aldosterone system , endothelin and 
vasopressin. In isolated heart preparations subjected to increased volume load, 
BNP synthesis and secretion respond more quickly than ANP secretion.
1.11.2 BNP responses to exercise
The pattern of change in BNP plasma levels on exercise is similar to that of ANP, 
but the magnitude of response is smaller(232-237). Studies examining responses 
of BNP to exercise in both normal subjects and in those with cardiac d isease are 
summ arised in the table 1-6. The results appear to be very consistent and most of 
the variation in results can be explained by differences in subject groups, mode of 
exercise employed, sampling time of BNP and the use of different assays for 
m easurem ent.
1.11.2.1 Normal Subjects
In healthy subjects undergoing exercise, there is a small increase in plasma BNP 
in response to various forms of exercise, although this does not always reach 
statistical significance(234-236,238-240).
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1.11.2.2 BNP Response to Exercise in Cardiac Disease
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Virtually all the studies which have examined exercise-induced responses of BNP 
in patients with cardiac d isease have reported significant increases (table 1-6). 
Resting and post-exercise values are highest in patients with CHF or left 
ventricular systolic function(233,237-239>241-243).
Author Year Exercise
Mode
Subjects Status 
No Age M/F
BNP (pg/ml) 
Rest Ex
Normals
Nicholson(232) 1993 TM Inc Healthy 5 48 4/1 5.5 6.8*
Wambach(240) 1995 B Inc Healthy 20 25 M 31+ 45
Tanaka(245) 1995 B Inc Healthy 14 40 12/2 1.5 2.8*
Steele(238) 1997 B Inc Healthy 10 67 M 20 22*
Friedl(239) 1996 BS Inc Healthy 32 58 22/10 22.8 30.8
Moromoto(237) 1997 B SS Healthy 8 46 M 5 7
Nishikimi(246) 1997 BS SS Healthy 10 49 M 7 7*
Geny(234) 1998 B Inc Healthy 8 42 M 7.4 8.5*
pmol/L pmol/L
Barletta(236) 1998 B Inc Healthy 8 30 M 1.6 2.48
1998 HG Iso Healthy 8 30 M 1.85 2.40
Onuaha(235) 1998 TM Inc Healthy 10 71 F 9.1 11.7
Cardiac Disease
Nicholson(232) 1993 TM Inc CAD 16 59 12/4 10.5 13.2
pmol/L pmol/L
Friedl(242) 1998 BS Inc CAD 34 58 ? 18 23
CAD/LVSD 62 58 ? 43 62
Yokoyama(241) 1996 TM Inc Post MI 60 62 55/5 66.5 82.3
Morimoto(237) 1997 B SS Post MI 9 59 8/1 72 96
Friedl(233) 1999 B Inc LVSD 16 61 15/1 86 104
Friedl(239) 1996 BS Inc ALVSD 37 58 30/8 42.3 61.2
CHF 32 62 30/7 72.6 92.1
Steele(238) 1997 B Inc CHF 10 66 M 42 46
Clarkson(247) 1996 BS Inc Diastolic HF 6 62 4/2 9.1 12.3
pmol/L pmol/L
Matsumoto(243) 1995 B Inc DCM 7 48 6/1 221 378
MS 9 53 4/5 37 54
Geny(234) 1998 B Inc HTx 8 44.9 8/0 14.3 19.0
pmol/L pmol/L
HvDertension
Kohno(248) 1992 B Inc EH 9 56 4/4 6 13
Tanaka(245) 1995 B Inc EH 19 44 15/4 4.8 9.0
Tomiyama(249) 1995 HG Iso HTN 21 45 18/3 2.7 3.4*
Kohno(244) 1995 B Inc EH+LVH 21 57 8/13 7.3 22.3
EH no LVH 24 56 9/15 4.6 10.9
Nishikimi(246) 1997 BS SS EH 15 56 12/3 13 19
Table 1-6: BNP responses to exercise.
All differences in BNP levels between rest and exercise are statistically significant unless marked*. Abbr: 
TM=treadmill; B=bicycle ergometry; BS: supine ergometry; HG=handgrip; Inc=incremental; Iso=isometric; 
SS=steady state; EH=essential hypertension; LVH=Left ventricular hypertrophy: LVSD=left ventricular 
systolic dysfunction; ALVSD =asymptomatic left ventricular systolic dysfunction; CHF=chronic heart 
failure; DCM=dilated cardiomyopathy; MS=mitral stenosis; HTx= heart transplant. Values in italics were 
estimated from graphical illustrations. ^ N P  levels after 5 days high salt diet.
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In hypertensive subjects the resting and exercise BNP are higher in those with left 
ventricular hypertrophy than in those without(244). BNP plasm a concentrations 
seem  to rise with increasing age, even in healthy subjects.
BNP at rest and on exercise has been shown to correlate with various param eters 
of left ventricular function. In patients with heart failure or left ventricular systolic 
dysfunction, BNP correlates with left ventricular end diastolic pressure(237,243), 
left ventricular end diastolic volume(236,243) and there are inverse correlations 
with ejection fraction(233,238,239) and left ventricular peak filling rate(238). 
Several reports have shown that the increase in plasm a BNP on exercise is 
correlated with left ventricular m ass index in hypertensive subjects(244,246) and in 
heart transplant recipients(234). In CHF or post Ml, increased BNP plasma levels 
are associated with reduced aerobic exercise capacity a s  m easured by peak 
oxygen consumption(238,241,250) and anaerobic threshold(241). Importantly, the 
increases seen  in BNP in response to exercise are closely correlated to resting 
BNP levels(232,244,246).
These studies collectively suggest that BNP is released in response to increases 
in left ventricular volume and pressure, which result in elevation of left ventricular 
wall tension. The fact that those who have high resting levels of BNP dem onstrate 
the greatest response to exercise suggests that these  patients have up-regulation 
of m essenger RNA which allow them to synthesise BNP at a greater rate. None of 
the studies on exercise can definitely exclude reduced clearance of BNP as  a 
possible mechanism for the increased plasma levels.
1.11.2.3 Comparison of BNP and ANP on Exercise
BNP is shown to correlate better with indices of left ventricular function than 
ANP(233,236,243). The BNP response to exercise is not related to angiotensin 
converting enzyme genotype (insertion/deletion alleles) although there was a weak 
association for ANP response to exercise(242). The maximum increase in BNP is 
seen at or within a few minutes of peak exercise(232,235,236,238,243).
1.11.3 BNP and AS
There have been only two published reports of alterations in natriuretic peptides in 
patients with AS(251,252).
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Prasad et al studied 30 patients with a m ean age of 70 and a peak aortic valve 
pressure gradient of 69.8 mmHg(251). They dem onstrated increased levels of 
BNP compared to age matched controls (13.9 vs. 3.7 pmol/L respectively). The 
increase in BNP w as not a s  high as  that seen  for ANP, a s  has been dem onstrated 
in other cardiac diseases. Increased BNP levels were correlated with NYHA 
functional class, left ventricular m ass index, mean aortic valve pressure gradient, 
left ventricular end diastolic pressure and peak-to-peak pressure gradient 
m easured at cardiac catheterisation(251). On multiple regression analysis, 
however, only mean aortic valve pressure gradient w as significantly correlated 
with BNP.
Ikeda et al have reported on a group of 13 patients with more severe d isease 
undergoing aortic valve replacement(252). They dem onstrated much higher mean 
levels of BNP in AS patients (367.2 pg/ml) compared to age matched patients 
undergoing coronary artery bypass grafting (53.8 pg/ml) and a group of slightly 
younger controls (16.9 pg/ml)(252). The BNP levels in AS patients were > four 
fold higher than ANP levels, which were also raised (77.9 pg/ml). There was an 
exceptionally strong correlation of both log transformed (to normalise the data) 
BNP and log ANP with end systolic wall stress calculated from echocardiographic 
and simultaneous blood pressure m easurem ents (r=0.96 for BNP and r=0.94 for 
ANP)(252). Reductions in BNP following aortic valve replacem ent were also 
strongly associated (r=0.8) with reductions in end systolic wall stress. These data 
suggest that in patients with marked pressure overload, BNP synthesis and 
secretion is primarily regulated by end systolic wall stress. There were very similar 
correlations for ANP and end systolic wall stress, which may indicate that in 
severe AS, the ventricular production of ANP exceeds that of atrial production.
1.11.4 BNP as a Prognostic Indicator
Two recent publications have dem onstrated that BNP is a very powerful predictor 
of outcome following myocardial infarction(253,254). In 131 patients suffering 
from an acute myocardial infarction, BNP has been shown to be a  strong predictor 
of cardiovascular mortality and the development of heart failure, and confers 
additional information to that of left ventricular ejection fraction(253). In this study, 
BNP was not associated with a reduced left ventricular ejection fraction, although 
ANP and N-terminal ANP were. In a further large series of 121 patients following 
myocardial infarction NT-BNP and BNP were both shown to be strong predictors
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of outcome at 2 years of follow up(254). NT-BNP and BNP (r = -0.63 and -0 .62  
respectively) both correlated relatively strongly with left ventricular ejection 
fraction, w hereas ANP w as not associated with left ventricular function. N-terminal 
BNP has also been shown to confer additional information in detecting high risk 
patients referred for echocardiography who were suspected of having left 
ventricular systolic dysfunction(255).
1.12 Endothelins and cardiac disease
The structure synthesis and biological actions of endothelins have been reviewed 
in detail elsewhere(256-258). Endothelin-1(ET-1), a 21-amino-acid peptide was 
first described in 1988. A pre-propeptide is secreted by the endothelium and may 
also be produced by the vascular smooth muscle cells. This pre-propeptide is 
cleaved to form big endothelin, which is subsequently cleaved by endothelin 
converting enzyme to the active 21-amino-acid peptide. There are three 
structurally distinct isoforms of this 21-amino-acid peptide, ET-1, endothelin-2 and 
endothelin-3. In humans, ET-1 appears to be the most biologically active of the 
three isoforms and is the most potent vasoconstrictor known. After exogenous 
administration, ET-1 increases peripheral resistance and BP in a dose-dependent 
manner. However, in the first few minutes after administration, there is initial 
vasodilation presum ed secondary to the release of nitric oxide and other 
vasodilators from the endothelium. ET-1 is also positively inotropic when studied 
in papillary muscle and cardiac myocyte preparations and can induce myocyte 
division and hypertrophy. The coronary, renal and cerebral circulations appear to 
be particularly sensitive to the actions of endothelins. Vasoconstriction occurs in 
both arteries and veins, but seem s to occur primarily in the resistance vessels. 
Vasoconstriction occurs by both a direct action and an indirect effect via 
augmentation of the pressor actions of angiotensin II, noradrenaline and serotonin.
1.12.1 Endothelin and CHF
Endothelins may play an important role in endothelial dysfunction, which has been 
clearly docum ented in CHF. Endothelin concentrations increase four-fold in 
moderate to severe heart failure and correlate with both haemodynamic severity 
and functional impairment(256,259). ET-1 predicts increased mortality from heart 
failure and the need for cardiac transplantation. Administration of endothelin
McCann, G.P. 2001 Chapter 1 63
antagonists result in favourable haemodynamic changes, with reductions in mean 
arterial pressure, pulmonary artery pressure, pulmonary capillary wedge pressure 
and an increase in cardiac index in patients with heart failure. Endothelin 
concentrations are also reduced after prolonged administration of carvedilol in 
CHF, which has been shown to reduce morbidity and mortality(256).
1.12.2 Endothelin and exercise responses
1.12.2.1 Response to exercise in normal subjects
In normal subjects undergoing various forms of exercise, the reported plasma 
endothelin response has been contradictory. Study results are summarised in the 
table 1-7.
Author Year Exercise
Mode Status
Subjects 
No Age M/F
ET-1 (pg/ml) 
Rest Ex
De
Groote(267)
1995 B Inc Healthy 15 35 13/2 2.0
pmol/L
1.7*
pmol/L
Ahlborg(262) 1995 B SS Healthy 7 26 M 4.0
pmol/L
6.5
pmol/L
Letizia(266) 1995 B Inc Healthy 7 53 M 10.8 11.3*
Predel(269) 1995 B Inc Healthy 10 ? M 5.5 5.5*
Rocker(261) 1996 B Inc Healthy 15 27 M 10.0 16.1
Cosenzi(270) 1996 B Inc Healthy 15 20-35 8/7 1.2 1.4*
Maeda(260) 1996 Ken - Athletes 5 19 M 1.3 2.0
Maeda(263) 1997 B SS Athletes 5 19 M 1.4 2.2
Mangieri(271) 1997 HG Iso Healthy 12 43 M 0.7 0.9*
Fontana(272) 1997 B Inc Healthy 8 45-60 6/2 4.4 3.0
Ishikawa(264) 1998 TM Inc Healthy 5 10 ? 1.1 1.9
Mangieri(266) 1998 HG Iso Healthy 10 27 M 0.6 0.8
Table 1-7: ET-1 responses to exercise in normal subjects.
All differences in ET-1 levels are statistically significant unless marked*. Abbr: TM=treadmill; B=bicycle 
ergometry; HG=handgrip; Ken=kendo; Inc=incremental; Iso=isometric; SS=steady state
The majority of studies have shown that ET-1 increases immediately following 
exercise(260-266). During incremental exercise, the peak plasma endothelin 
response may not occur for up to 30 minutes following cessation of exercise(263). 
However, during steady state exercise at 70% V0 2 max ET-1 starts to increase by
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10 minutes and peaks at approximately 20 minutes and then falls back towards 
baseline values(262).
The magnitude of ET-1 increase correlates with both reductions in left atrial 
diameter and body weight and with increases in plasm a arginine vasopressin, 
suggesting that reductions in blood volume may stimulate endothelin 
secretion(260). Other factors that may contribute to the secretion of ET-1 during 
exercise are elevated levels of angiotensin II, skeletal muscle blood flow and 
catecholamine release(270).
Several studies have shown either non-significant increases in ET-1 following 
exercise(266,269,270) or an actual fall in concentration(272). Som e of the 
variations in results may be accounted for by different exercise protocols, time of 
sampling and more conservative analysis, e.g. by analysis of variance rather than 
paired t-tests(266).
1.12.2.2 CHF
Several studies have examined the effect of various types of exercise on plasma 
endothelin concentrations(267,271,273,274), Results are displayed in table 1-8.
First Author Year Exercise
Mode Status
Subjects 
No Age M/F
ET-1 (pg/ml) 
Rest Ex
McMurray(274) 1992 TM Inc CHF 8 67 6/2 11.0 10.8*
pmol/L pmol/L
De Groote(267) 1995 B Inc DCM 20 52 18/2 2.9 2.9*
pmol/L pmol/L
Mangieri(271) 1997 HG Iso CHF 10 37 M 8.4 11.9
Ishikawa(273) 1995 TM Inc Cong 7 13 6/1 1.2 1.0
HD
Mangieri(266) 1998 HG Iso FHx 11 25 M 1.1 1.9
HTN
Ishikawa(264) 1998 TM Inc Cong 6 10 ? 1.2 1.2*
HD
Cong 8 12 ? 1.2 1.1*
HD
Table 1-8: ET-1 responses to exercise in cardiac disease.
All differences in ET-1 levels between rest and exercise are statistically significant unless marked *. Abbr: 
TM=treadmill; B=bicycle ergometry; HG=handgrip; Ken=kendo; Inc=incremental; Iso=isometric; SS=steady 
state; IHD=ischaemic heart disease, (-)/(+) negative/positive for reversible ischaemia; CHF=chronic heart 
failure; DCM=dilated cardiomyopathy; Cong HD=congenital heart disease; FHx HTN=sons of patients with 
hypertension.
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Two studies, one using bicycle exercise(275) and one employing handgrip 
exercise(271) have shown increases in ET-1 at peak exercise. There have been 
conflicting results however in patients with dilated cardiomyopathy and CHF where 
no increase in endothelin w as seen(267,274). It is difficult to explain these 
contradictory results since similar groups of patients and protocols were employed 
but both type I and II statistical errors are possible due to the small sample sizes.
Krum et al did dem onstrate that peak plasma concentrations of ET-1 w as inversely 
correlated(r = -0.65) with peak VO2 in heart failure patients and also (r = -0.68) in 
healthy controls(275). There was also a significant correlation between peak 
plasma levels of ET-1 and VE/VCO2 (r = -0.72) in 12 patients with NYHA class II 
and III heart failure(275). This study does suggest that endothelin may play an 
important role in the regulation of local muscular blood flow, possibly contributing 
to exercise intolerance in CHF.
In a large study looking at prognosis in CHF, endothelin w as also shown to be a 
predictor of adverse outcome(276). In 23 patients with all c lasses  of heart failure, 
who had undergone cardiopulmonary exercise testing, only ET-1, NYHA functional 
class, maximal workload achieved and plasma ANP were independent predictors 
of outcome, but not peak VO2 itself(276).
1.12.3 Endothelin and coronary artery disease
In patients with coronary artery d isease and normal left ventricular function resting 
plasma endothelin concentrations are similar to age matched 
controls(268,269,272). In response to incremental bicycle exercise, however, 
patients with coronary artery d isease dem onstrate a significant increase in ET-1 
concentrations compared to controls(268,269,272)(see table 1-9).
These results suggest that ET-1 may play an important role in exercise induced 
myocardial ischaemia. Interestingly there are conflicting results a s  to whether 
those with reversible ischaemia are more likely to have increases of ET-1 on 
exercise(268,272).
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Author Year Exercise
Mode Status
Subjects 
No Age M/F
ET-1 (pg/ml) 
Rest Ex
Letizia(268) 1995 B Inc IHD(-) 13 53 ? 7.8 13.6
IHD (+) 7 53 ? 8.7 9.6*
Fontana(272) 1997 B Inc IHD(-) 12 ? ? 4.6 3.2
IHD (+) 8 ? ? 4.0 6.0
Predel(269) 1995 B Inc IHD 10 ? M 6.1 7.3
Table 1-9: ET-1 responses to exercise in coronary artery disease
All differences in ET-1 levels between rest and exercise are statistically significant unless marked *. Abbr: 
B=bicycle ergometry; Inc=incremental; IHD=ischaemic heart disease, (-)/(+) negative/positive for reversible 
ischaemia.
In patients with a clinical diagnosis of angina pectoris with cardiac syndrome X, 
resting ET-1 concentrations have been reported to be significantly higher than 
matched controls(277,278). Thus, ET-1 may be a marker of endothelial 
dysfunction in this group of patients.
1.13 Neurohormonal adaptations in AS
Unlike CHF there are only a few published reports of neurohormonal adaptations 
in AS.
1.13.1 ET-1 and AS
Resting ET-1 plasma concentrations have also been shown to be elevated in AS 
patients without overt heart failure(279,280). ET-1 levels correlated with 
pulmonary capillary wedge pressure, mean pulmonary artery pressure, left atrial 
diameter and inversely correlated with aortic valve area(279). In 15 patients with 
pulmonary hypertension secondary to rheumatic heart d isease  undergoing valve 
replacement, ET-1 w as also elevated (281). ET-1 w as significantly correlated with 
pulmonary artery and pulmonary capillary wedge pressure and returned towards 
normal two w eeks after surgery(281). The ET-1 response to exercise in AS has 
not been studied to date.
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1.13.2 Catecholamines/renin-angiotensin system
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Plasma noradrenaline(279,282) and dopamine(279) are elevated in patients with 
haemodynamically significant AS without signs of CHF. Plasm a renin and 
angiotensin were reported as  being elevated in 14 aortic patients(280) but not in 
two other studies(279,282). However one of these latter studies did show 
aldosterone concentrations were raised(282) which would be consistent with 
activation of the renin-angiotensin system.
1.13.3 Tumour necrosis factor-a (TNF-a)
TNF-a has been shown to be elevated in 21 patients with significant AS but no 
coronary artery disease(283). Those in NYHA class II had greater levels than 
asymptomatic subjects and TNF-a levels correlated significantly with mean 
pressure gradient in 16 of the patients with normal left ventricular systolic 
function(283).
1.14 Similarities between valvular heart disease and CHF
1.14.1 Mitral stenosis
Mitral balloon valvuloplasty, an intervention which leads to immediate 
improvements in haemodynamic indices, does not result in early increases in 
exercise capacity(284,285). However, three-four months following mitral balloon 
valvuloplasty peak VO2 had significantly improved and the exercise VEA/CO2 slope 
had reduced(284,285). These favourable alterations were associated with 
changes in skeletal muscle structure and function(284). Quadriceps muscle 
strength and area increased and there was a shift in fibre type from type II 
(anaerobic) to type I (aerobic). These data suggest that similar m echanisms limit 
exercise capacity in CHF and mitral stenosis, despite the fact that left ventricular 
function in mitral stenosis is generally preserved.
1.14.2 AS
It is unclear why some patients with AS are symptomatic and others asymptomatic 
despite similar degrees of haemodynamic severity. The symptoms of AS are
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similar to those of CHF. Exercise cardiac output is limited and increases in 
pulmonary capillary wedge pressure, are similar in these  two common cardiac 
conditions. Dyspnoea and fatigue are the com m onest reasons for test termination 
during exercise tolerance testing. Resting haemodynamic indices are poor 
predictors of V0 2 max and interventions which improve haemodynamics (aortic 
valve replacem ent in AS, vasodilators in CHF) result in slow improvements in 
exercise capacity.
Neuro-hormonal adaptations to AS and CHF may also be similar. Both are 
associated with elevated natriuretic peptides, endothelin, tumour necrosis factor-a, 
catecholamines and activation of the renin angiotensin system  also occurs in both 
disease states. Abnormalities of arterial vasodilation are well docum ented in CHF 
and have been confirmed in patients with severe valvular d isease  requiring valve 
replacement. Undoubtedly there are only a few such reports in AS but CHF 
patients have been more extensively and intensively investigated, particularly with 
respect to exercise. These vascular and neuro-endocrine adaptations may play 
important aetiological roles in exercise limitation, perhaps by their effects on the 
development of skeletal muscle abnormalities which may contribute to exercise 
tolerance and symptom generation.
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1.15 Summary
AS is a common disorder and the prevalence of this d isease  is increasing, 
particularly in elderly patients. Symptomatic AS is a malignant condition with a five 
year survival of <50%. Aortic valve replacem ent is virtually a curative procedure 
for those who survive the peri-operative period. Asymptomatic AS has a relatively 
good prognosis although the exact morbidity and mortality figures are uncertain 
due to the natural history of the d isease  in the modern era being interrupted by 
surgery. Aortic valve replacem ent is recom m ended for symptomatic patients but 
the timing of surgery is critical to optimise outcome. The m echanism s underlying 
symptom generation and exercise limitation in AS are poorly understood, but are 
likely to be closely related. An ability to reliably predict the development of 
symptoms would greatly help in determining the exact timing of aortic valve 
replacem ent in patients with significant AS.
The importance of peripheral, and in particular skeletal muscle, adaptations in the 
role of exercise limitation in CHF and mitral stenosis have been well documented. 
Piepoli and colleagues have recently dem onstrated enhanced ergoreflex activity 
on exercise which allows a unified mechanism to explain both the skeletal muscle 
and ventilatory abnormalities seen  in CHF(213). AS has many similarities to CHF 
in symptoms, pathophysiological adaptations and exercise haemodynamics.
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This thesis investigates non-invasive predictors of exercise capacity in patients 
with haemodynamically significant AS, who will be com pared to control subjects. 
The aims are to identify factors which may be associated with exercise intolerance 
and symptoms. Special attention will focus on predictors of exercise capacity and 
the relationship between skeletal muscle work-sensitive receptors and a neural 
connection for the control of ventilation (ergoreflex). BNP and ET-1 responses to 
maximal exercise will be examined. Patients will be classified by both disease 
severity and symptomatic status.
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1.17 Hypotheses
The following hypotheses will be tested:
1.17.1 Cardiopulmonary exercise testing
1.17.1.1 Exercise capacity
H: Treadmill exercise duration and V0 2 max are reduced in AS patients compared 
to matched controls.
Ho: Treadmill exercise duration and Vo2max are not significantly different in AS 
patients compared to matched controls.
1.17.1.2 Ventilatory response to exercise
H: The slope of exercise VeA/C0 2 is increased in AS patients compared to 
matched controls.
Ho: The slope of exercise VEA/CO2 is not significantly different in AS patients 
compared to matched controls.
1.17.2 Skeletal muscle strength and endurance
H: Quadriceps strength and endurance are reduced in AS patients compared to 
m atched controls.
Ho: Quadriceps strength and endurance are not significantly different in AS 
patients compared to matched controls.
1.17.3 Ergoreflex
1.17.3.1 Arm exercise
H: The magnitude of ergoreflex activity after handgrip exercise is increased in AS 
patients compared to matched controls.
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Ho: The magnitude of ergoreflex activity after handgrip exercise is not significantly 
different in AS patients compared to matched controls.
1.17.3.2 Leg exercise
H: The magnitude of the ergoreflex activity after lower leg exercise is increased in 
AS patients compared to matched controls.
H0: The magnitude of the ergoreflex activity after lower leg exercise will not be 
significantly different in AS patients compared to matched controls.
1.17.4 BNP
1.17.4.1 Resting and exercise BNP
H: Plasm a BNP is greater at rest and after exercise in AS patients compared to 
matched controls.
Ho: Plasm a BNP at rest and on exercise is not significantly different in AS patients 
compared to matched controls.
1.17.4.2 BNP and exercise capacity
H: Plasm a BNP is associated with reduced exercise capacity in AS patients.
H0 : Plasm a BNP is not associated with reduced exercise capacity in AS patients.
1.17.5 Endothelin
1.17.5.1 Rest and exercise ET-1
H: Plasm a ET-1 is increased at rest and on exercise in AS patients compared to 
matched controls.
Ho: Plasm a ET-1 at rest and on exercise is not significantly different in AS patients 
compared to matched controls.
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1.17.5.2 ET-1 and exercise capacity
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H: Plasm a ET-1 is associated with reduced exercise capacity in AS patients.
Ho: Plasm a ET-1 is not associated with reduced exercise capacity in AS patients.
1.17.6 Predictors of exercise capacity
1.17.6.1 Haemodynamic indices
H: Haemodynamic indicators of AS severity (pressure gradient, aortic valve area, 
ejection fraction) will not be significant predictors of aerobic exercise capacity.
H0: Haemodynamic indicators of AS severity (pressure gradient, aortic valve area, 
ejection fraction) are significant predictors of aerobic exercise capacity.
1.17.6.2 Ventilatory indices
H: The slope of exercise VEA/CO2 and the magnitude of the ergoreflex are 
significant predictors of aerobic exercise capacity in AS.
H0: The slope of exercise VeA/co2 and the magnitude of the ergoreflex are not 
significant predictors of aerobic exercise capacity in AS.
METHODS
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2.1.1 Patients
The case-notes of patients attending the General Cardiology and Adult Congenital 
Heart D isease clinics at the W estern Infirmary, Glasgow were screened to 
determine eligibility for inclusion in the study. If deem ed eligible, the patients were 
sent a letter giving brief details of the study, and requested to return a tear-off slip 
if they were interested in participating in the study. If patients indicated an interest 
they were contacted by telephone and an appointment w as arranged to visit the 
hospital. Recruitment w as also undertaken of those patients who met the criteria 
and were already on the W estern Infirmary waiting list for aortic valve 
replacement. The cardiothoracic unit art the W estern Infirmary is a tertiary referral 
centre covering Southwest Scotland and covering a population of approximately 
two million. Several patients were also recruited from the Cardiology clinics at the 
Royal Alexandra Hospital, Paisley.
2.1.2 Healthy volunteers
Twenty asymptomatic control healthy subjects were recruited from staff, friends 
and family m em bers of the Department of Medicine and Therapeutics.
2.1.3 Inclusion Criteria for Patients
1. Aortic valve peak pressure gradient > 25 mmHg
2. Ability to perform treadmill exercise
2.1.4 Exclusion Criteria patients and controls
1. Obstructive coronary artery d isease (previous Ml, CABG or > 70% luminal 
stenosis on coronary angiography)
2. Atrial fibrillation
3. Exertional syncope
4. Uncontrolled heart failure or arrhythmias
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5. Other significant valvular or structural heart d isease
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6. Uncontrolled hypertension > 180 mmHg systolic or 110 mmHg diastolic
7. Symptomatic hypotension or systolic BP < 90 mmHg
8. Diabetes mellitus
9. Peripheral neuropathy or myopathy
10. Chronic obstructive pulmonary d isease
11. Pregnancy
12. Current warfarin therapy
Written, informed consent was obtained from all subjects prior to testing. The 
following Ethics Committees approved the study in full: the W est Glasgow Hospital 
University NHS Trust, the Royal Alexandra Hospital and Ayr. Testing was split 
into two or three visits to the hospital, each lasting 2 1/2-3 hrs. A brief medical 
history was taken to ensure that subjects did not fulfil any of the exclusion criteria, 
for determination of NYHA class and documentation of medication.
2.1.5 Patient recruitment
A total of 226 patients with a diagnosis of AS were screened for eligibility by 
personal contact or case-note review. The com m onest reasons for exclusion were 
other structural heart d isease or previous valve surgery (56), peak pressure 
gradient <25mmHg (34) obstructive CAD (21), COPD (16), atrial fibrillation (8), 
other medical conditions (16) and already had aortic valve replacem ent (3). 
Seventy-two patients satisfied the study inclusion/exclusion criteria and were 
invited by letter to participate in the study. Fifty-one (71%) patients responded. Of 
these, 41 were and ten were not interested in taking part. Four of the 41 were 
unable to participate in the study: one was scheduled for aortic valve replacement 
the following week, one becam e pregnant, one was unable to get time off work 
and another lived too distant from the hospital.
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Height was recorded using a metre stick and weight w as m easured on a SECA 
balance scale. Skinfold thickness w as m easured to the nearest 1 mm at four sites 
to determine percentage body fat according to the Durnin technique(286). Lean 
body m ass (LBM) w as calculated from the standard formula below:
Equation 8: Calculation of LBM
LBM = weight (in kg) -  (weight x % body fat)
2.3 Echocardiography
All subjects underwent echocardiography carried out according to the ACC/AHA 
guidelines(44) and M-mode m easurem ents were m ade a s  recommended by the 
American Society of Echocardiography(287). An Acuson 128XP/10c medical 
diagnostic ultrasound system  w as used to record all im ages on super VHS 
videotape for later analysis. This machine is equipped with a multi-hertz 
transducer capable of operating at 4, 3.5 and 2.5 MHz. Two dimensional and 
colour flow Doppler images were obtained from (1) parasternal long axis (2) 
parasternal short axis (3) apical four and five-chamber views and (4) apical two 
cham ber view.
M mode recordings from the parasternal long axis were used for m easurem ent of 
aortic root, left atrium and left ventricular dimensions, using leading edge for 
m easurem ent as  previously described. Penn convention w as used to determine 
left ventricular mass(288). This w as corrected for body surface area to give a left 
ventricular m ass index.
Valvular competency w as a sse ssed  in parasternal long axis and apical and two 
cham ber views with colour Doppler (see figure 2-1). Left ventricular outflow tract 
was m easured on the long axis parasternal view in midsystole employing the cine 
function. Aortic valve area was calculated according to the continuity equation 
with use of the peak and mean aortic velocity and left ventricular outflow tract 
velocity, m easured with pulse wave Doppler(50,59).
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Figure 2-1: Mild aortic incompetence in parasternal long axis view
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Trans-mitral left ventricular inflow patterns were measured using pulse wave 
Doppler located just below the tips of the mitral leaflets to record early (E) and 
atrial (A) diastolic filling and their ratio, E/A. Peak aortic velocity was assessed 
from multiple positions (apical, parasternal, suprasternal and subcostal views) 
using the non-imaging continuous wave transducer. The integral of the velocity 
obtained was determined to calculate mean velocity. Ejection fraction was 
calculated by Simpson’s biplane method(289) (figure 2-2). All echocardiographic 
measurements were made in triplicate and the average was taken as the final 
value.
Figure 2-2: Simpson’s method of left ventricular volume calculation
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The left ventricular endocardial surface is traced in end-diastole and end-systole in both 4 chamber and 2 
chamber views.
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2.4.1 Equipment
Isometric and isokinetic testing was performed on the Kin-Com II (500H, version 
5.16) dynamometer (Chattex Corporation, Chattenooga, T ennessee, USA). The 
test took place in a laboratory within the Kelvin Building at Glasgow University 
which adjoins the W estern Infirmary. All tests  were performed on the right leg 
only, a s  previous investigations had found no significant difference between right 
and left legs(200). Right quadriceps muscles were a sse sse d  both isometrically 
and isokinetically, w hereas the right hamstrings m uscles were assessed  
isokinetically only.
2.4.2 Patient set up
The patient was seated  in the Kin-Com chair with a seatbelt around the waist and 
a strap over the thigh for stabilisation. The lateral femoral condyle of the subject’s 
right knee was visually aligned with the axis of rotation of the isokinetic 
dynamometer, by adjusting the position of the seat. The lower leg w as attached to 
the distal end of the lever arm using a shin pad, positioned approximately 3 cm 
above the ankle and allowing full dorsiflexion of the ankle.
2.4.3 Computer set up
The subject's details and weight were entered on to the computer. Gravitational 
corrections were made for the effect of limb weight on both torque (isokinetic test) 
and force production (isometric test).
2.4.4 Isometric test
An isometric test w as used to evaluate static quadriceps strength. The lever arm 
of the Kin-Com w as positioned at 105° ( for the first isometric contraction) and then 
110° (for the second isometric contraction). The subjects performed two 
submaximal isometric contractions at the designated angles in order to familiarise 
them selves with the protocol. The protocol consisted of 1 maximal voluntary 
contraction with the knee at 105° flexion and then another maximal contraction at
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110°, each lasting for five seconds. There was a 30s recovery period between 
each contraction. During the test the subject was instructed to push against the 
immovable lever arm as  hard as  possible for five seconds and standardised verbal 
encouragem ent w as given throughout. The dynam om eter continuously recorded 
the force (N) produced by the quadriceps during the isometric contraction.
2.4.5 Isokinetic test
Firstly the subjects completed 4-5 submaximal contractions to familiarise 
them selves with isokinetic contractions. This test w as utilised to a s se s s  dynamic 
strength and endurance of both the quadriceps and hamstring muscles. The start 
position for the test was with the knee in 90° flexion. The subject determined the 
stop angle: as  the angle to which they could comfortably extend their knee. The 
isokinetic protocol consisted of 25 continuous flexion/extension concentric 
contractions at an angular velocity of 180°/sec. Subjects were instructed to kick 
and pull against the lever arm through the entire range of motion, as  hard and as  
fast a s  possible. Since this was a maximal test, the subjects were informed not to 
pace them selves in order to complete the 25 repetitions. During the test 
standardised, strong verbal encouragem ent was given to maximise effort. The 
reliability of this isokinetic protocol in assessing various param eters of muscular 
endurance has previously been reported(290).
The dynamometer continuously recorded torque generated by the quadriceps and 
the hamstring muscles during the isokinetic test. Peak torque (Nm) produced by 
both muscle groups was used to m easure dynamic strength. The decline in peak 
torque throughout the isokinetic test and total work a sse ssed  dynamic endurance. 
On cessation of the test, the straps were loosened allowing the subject to relax 
their leg.
2.4.6 Caiculation of strength and endurance
2.4.6.1 Static quadriceps strength
1. Isometric peak force (N): the highest value of the peak force recorded during 
either of the two maximal contractions
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2. Isometric average force (N): the highest value of the average force recorded 
during the two maximal contractions
2.4.6.2 Dynamic quadriceps and hamstring strength
1. Peak torque (Nm): the highest value of the peak torque generated during the 25 
isokinetic contractions
2.4.6.3 Dynamic quadriceps and hamstrings endurance
Calculations used were a s  previously suggested (291)
1. Fatigue index (percentage): this w as calculated a s  the m ean peak torque of the 
last 5 contractions, expressed a s  a percentage of the m ean peak torque of the 
best 3 of the first 5 contractions (the first five were not used a s  often peak torque is 
not achieved until the second or third contraction) (290).
2. Average work (W): the average work produced during the 25 contractions.
3. Total work (J): the total work generated during all 25 contractions.
M easures of static and dynamic strength, average power and total work were 
divided by lean body m ass to correct for variations in muscle m ass.
2.5 Ventilatory gas measurement
Ventilatory gas exchange variables were m easured by a Medgraphics CPX/D 
breath by breath analyser utilising Breeze3 software (Medical Graphics Corp., St. 
Paul, Minnesota, USA). Subjects, wearing noseclips, breathed through a 
mouthpiece connected to a pneumotachograph which calculates expired gas 
volumes. Expired oxygen (O2 ) and carbon dioxide (CO2 ) were sampled 
continuously. The breath by breath analyser allows determination of minute 
ventilation (Ve) minute O2 consumption (VO2 ), minute CO2 excretion (VCO2 ), and 
calculates respiratory exchange ratio(RER), respiratory rate, tidal volume and O2 
pulse from these variables. Data can be displayed breath by breath or averaged 
over 10s or multiples thereof. G as exchange w as m easured during treadmill 
testing and throughout arm and leg ergoreflex studies.
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The tem perature and humidity at the time of testing w as recorded (Oregon 
Scientific Model BA-116) and entered into the analyser computer. G as 
m easurem ents are stated standardised for tem perature and humidity. Prior to 
each test the CO2 and O2 analysers were calibrated against standard 
concentrations and the pneumotachograph w as calibrated at five different flow 
rates with a three litre syringe.
2.6 Treadmill exercise tolerance testing
2.6.1 Protocol
A maximal symptom limited incremental exercise test w as performed according to 
the Bruce protocol(292) in 36 AS subjects and all controls. Subjects were 
connected to a 12 lead ECG exercise recorder(Quinton 4000) with an integrated 
control panel for the treadmill(Quinton 65). Prior to formal testing each subject 
had a familiarisation walk on the treadmill at 1.7mph with 10° incline (stage 1). 
One patient could not walk at this pace and therefore the Modified Bruce protocol 
was used. They were then allowed to recover for 10 minutes. Subjects were 
allowed to rest their hands on the bar at the front of the treadmill to aid balance but 
were instructed not to lean on the bar or grip it tightly. During the test each subject 
was given standardised verbal encouragem ent by the investigator to continue for 
as  long a s  possible. The test w as terminated on a hand signal from the subject 
and the treadmill belt slowed over a period of 45s, allowing a warm down. 
Recovery data were taken for a further three minutes at which point the 
mouthpiece and noseclips were removed and subjects were asked what caused 
them to stop exercising. Tiredness and leg discomfort were classified as  fatigue. 
Medication w as not discontinued prior to testing.
Peak VO2 was determined a s  the highest value averaged over 30s. The slope of 
VEA/CO2 was calculated using simple linear regression. The slope w as calculated 
only for exercise data corresponding to a respiratory exchange ratio <1.0 since 
ventilation rises exponentially towards maximal exercise(174).
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2.6.2 Medical indications for termination of the treadmill test:
1. A fall in SBP
2. Horizontal or downsloping ST depression >5mm
3. Any sustained arrhythmias
2.7 Ergoreflex
All tests were performed in the sam e quiet exercise laboratory without distraction. 
The order of leg and arm protocols was randomised.
2.7.1 Hand grip exercise
The protocol w as based on that used by Piepoli(213).
2.7.1.1 Exercise position
The subject w as seated  with their right arm flexed to 90° and resting on a flat 
surface. Each subject performed 2 maximal handgrip dynam om eter (Takei TKK 
5001 Grip A) contractions with the right hand in order to a s se s s  peak force 
production. An inflatable cuff was placed above the right elbow and connected to 
a rapid cuff inflator (Hokanson E20, Hokanson AG-101 cuff inflator air source). A 
BP cuff was positioned above the left elbow to enable BP m easurem ents to be 
taken (Accoson sphygmomanometer). The subject w as then connected to the 
breath by breath analyser.
Three runs with data collection were completed in the following manner:
2.7.1.2 Control run
Baseline data were recorded for three minutes. The cuff on the right arm was then 
inflated to 30 mmHg above systolic BP for three minutes using the rapid cuff 
inflator to induce regional circulatory occlusion (RCO). The cuff w as then deflated 
and three minutes of recovery data were obtained. This exercise free run served 
as  a control run to determine any possible confounding effect of cuff inflation on 
ventilation and BP.
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Resting data were obtained for three minutes. Right hand grip contractions were 
then commenced at 50% of the determined peak force at 60 repetitions/min 
(determined by digital metronome, Seiko DM-10) until volitional exhaustion. On 
termination of exercise, the cuff w as inflated to 30 mmHg above systolic pressure, 
creating RCO for three minutes. After three minutes the cuff w as deflated and a 
further 3 min recovery data were obtained.
2.7.1.4 Non-cuff run
The non-cuff run consisted of an identical protocol to the cuff run except the cuff 
was not inflated at the end of exercise, thus producing a protocol of: three minutes 
rest data, handgrip dynamometer at 50% peak force, 60 repetitions/min until 
exhaustion, 6 min recovery data (without RCO)
The control run w as always performed first, however, the order of cuff and non-cuff 
was randomised with 15 minutes between each exercise run to minimise possible 
effects of fatigue.
2.7.2 Lower leg Exercise
2.7.2.1 Exercise position
The exercise undertaken was aimed at exercising the m uscles below the knee 
only. The subject lay supine on a bed with the upper body inclined at 30° and was 
asked to remain as  still a s  possible with the exception of the exercising lower limb. 
The subject isotonically dorsiflexed/plantarflexed the right foot to the beat of a 
metronome at 44 beats per minute with a weight (200g/10kg lean body m ass) 
attached to the shoe by a rope. The weight w as suspended over the end of the 
bed via a pulley system. Two pillows were placed under the calf, raising the leg 
and allowing movement of the foot without the heel striking the bed. The subject 
gave a hand signal to indicate when fatigued, at which point the weight was 
detached from the rope allowing the recovery period to commence.
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W e have previously described the protocol used which is identical to that for 
handgrip exercise except lower leg exercise is performed instead(226). RCO was 
obtained by inflating an adult thigh sphygmom anom eter cuff, attached to the right 
thigh, to 30mm above SBP. BP was m easured in the right arm. The order of cuff 
and non-cuff runs w as randomised.
2.7.3 Data analysis
2.7.3.1 Ventilatory data
For the purposes of analyses, data were averaged over 10s periods. Peak 
ventilatory data were taken averaged over the final 30s of exercise. As the 
recovery data (both cuff and non-cuff runs) are likely to be influenced by the peak 
exercise m easurem ent, analysis was performed according to the method 
suggested by Altman and colleagues(293). The first three minutes of data after 
exercise were averaged to give cuff recovery and non-cuff recovery values. To 
compare the magnitude of the effect of RCO on recovery ventilation between the 
groups the following equation was used:
Equation 9: Ergoreflex (cuff) magnitude calculation
Magnitude of ergoreflex = (3 min cuff value- resting value) X 100
(Peak exercise value - resting value)
The degree of ergoreflex activation during recovery without cuff inflation w as also 
a sse ssed  representing a more physiological m easure of ‘normal’ recovery:
Equation 10: Ergoreflex (non-cuff) magnitude calculation
Magnitude of ergoreflex = (3 min non-cuff value -  resting value) x  100
(Peak exercise value - resting value)
The magnitude of ergoreflex therefore equates to the percentage of the peak 
exercise increase persisting during the first 3 minutes recovery.
McCann, G.P. 2001
2.7.3.2 BP data
Chapter 2 86
The final BP reading prior to exercise was deem ed the resting BP. The last BP 
recording prior to exercise termination was taken as  the peak BP and the three BP 
recordings during recovery were averaged and used for cuff and non-cuff 
recovery. Magnitude of ergoreflex was calculated as  for ventilation.
2.8 Neurohormonal sampling and analysis
2.8.1 Blood sampling
Blood sam ples (20mL) were drawn by venepuncture with the subject in a seated  
position after resting for 30 minutes. Post-exercise venepuncture was performed 
immediately after the treadmill stopped. Ten mL was placed into a pre-chilled tube 
with EDTA containing 1000IU trasylol (for BNP) and 5mL into EDTA (for ET-1), 
both of which were immediately placed on ice. The sam ples were centrifuged, 
within 15 minutes, at 3000 rotation per minute for 10 minutes and the plasma was 
stored in aliquots at -20°C  until thawing for analysis.
2.8.2 BNP analysis
BNP w as m easured using a Shionoria immunoradiometric assay  (CIS Bio 
International, France). This assay  has a limit of detection of 1 pg/ml, a coefficient 
of variation of <7.5% and a normal range of 2 - 20 pg/ml.
2.8.3 ET-1
ET-1 was m easured using an ELISA kit ( Biomedica, Austria). This has a limit of 
detection of 0.05 fmol/ml, a coefficient of variation of <7.6% and a normal range of 
0.2 - 0.7 fmol/ml.
2.9 Physical activity levels
All subjects were asked to complete the Scottish physical activity questionnaire 
(SPAQ) and return it in a pre-paid envelope. SPAQ is a seven day recall 
questionnaire in which subjects estim ate their daily leisure time and work physical 
activity(294). SPAQ has been validated in a healthy Scottish population(294).
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The order of testing is outlined in diagrammatic form in appendix A.
2.10 Data analysis
2.10.1 AS severity and symptomatic status
For analysis of the severity of AS, the patients were divided into 2 groups based 
on an arbitrary cut-off in mean pressure gradient: m oderate to severe (severe) > 
30 mmHg and mild to moderate (mild) < than 30 mmHg (see table 1-1 for 
classification). Subjects were also divided into asym ptom atic  and sym ptom atic 
groups by direct questioning. As previously, patients with only mild dyspnoea or 
fatigue (on at least moderate exertion) and no chest pain or syncope were 
classified as  asymptomatic due to the non-specific nature of these 
symptoms(25,91).
2.10.2 Statistical tests
Analyses were performed utilising the computer software package Minitab, version
11.21. Normality of all data were a sse ssed  by examination of box plots. Paired 
student’s  t test was used to analyse the intra-group data and between group 
analysis was carried out by non-paired students t test. The chi-square test was 
employed in com parisons of proportions. Oneway analysis of variance with 
Tukey’s family error rate at 5% w as used when the patient subgroups were 
compared to controls. Non-parametric intra-group data were compared by the 
Wilcoxon signed rank test, and Kruskal-Wallis test for comparison of group 
medians with further analysis by Mann-Whitney test if results were 
significant.(295). Pearson’s  correlation coefficient w as used to correlate individual 
variables with exercise capacity. Multiple regression w as performed to a sse ss  
independent predictors of exercise capacity incorporating variables that had a 
significant or near significant correlation. BNP results were log transformed to 
normalise the data. P < 0.05 was considered statistically significant. Twelve 
echocardiograms were analysed on two separate  occasions by the investigator 
and intra-observer correlation coefficients were calculated. Data are expressed as  
m ean±standard deviation or median and interquartile range.
3. ANTHROPOMETRIC, ECHOCARDIOGRAPHIC 
AND PHYSICAL ACTIVITY PROFILE
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Thirty-seven patients attended at least one study visit. Twenty volunteers agreed 
to undergo testing to serve as a control group. The individual anthropometric 
details of the control group are displayed in table 3-1 and those of the patient 
group are detailed in table 3-2.
Subject
No Sex
Age
(years)
Height
(m)
Weight
(kg)
LBM BMI NYHA
C01 M 21 1.77 68.4 61.6 21.8 1
C02 M 28 1.69 80.0 60.0 28.0 1
C03 F 25 1.77 77.1 56.7 24.6 1
C04 F 29 1.70 53.3 41.0 18.4 1
C05 F 81 1.52 78.6 48.2 34.0 1
C06 M 38 1.70 85.7 63.8 29.7 1
C07 M 39 1.67 63.6 49.6 22.8 1
C08 M 60 1.74 84.5 57.5 27.9 1
C09 M 48 1.70 81.5 58.3 28.2 1
C10 M 54 1.74 78.7 53.5 26.0 1
C11 M 54 1.76 74.5 54.4 24.1 1
C12 M 50 1.80 92.2 59.0 28.5 1
C13 F 54 1.53 50.4 34.0 21.5 1
C14 F 50 1.59 61.7 37.0 24.4 1
C15 M 49 1.74 94.6 66.1 31.2 1
C16 M 66 1.85 78.4 57.1 22.9 1
C17 M 77 1.77 90.6 63.6 28.9 1
C18 F 54 1.54 61.3 36.2 25.8 1
C19 F 74 1.51 61.4 38.7 26.9 1
C20 M 57 1.57 62.5 45.8 25.4 1
Table 3-1: Individual anthropometric data for control subjects
C= control
3.2 Medication
3.2.1 Controls medication
All of the control subjects were asymptomatic although 2 subjects (C05, C15) were 
being treated for essential hypertension. One subject(C08) was taking 
pravastatin for hypercholesterolaemia.
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Subject Sex 
No
Age
(years)
Height
(m)
Weight
(kg)
LBM BMI NYHA Sym
Asv AS
as01 M 20 1.84 77.0 62.8 22.7 2 D
as02 M 40 1.78 81.8 60.1 25.8 1 -
as03 M 41 1.74 94.9 65.3 31.3 1 -
as05 M 81 1.68 78.2 54.0 27.7 1 -
as08 F 25 1.64 59.0 42.6 21.9 1 -
as11 F 39 1.66 81.1 50.7 29.6 2 D
as13 F 61 1.63 61.4 40.8 23.1 2 D,F
as16 M 70 1.67 71.9 51.4 25.8 1 -
as17 M 23 1.77 71.0 59.4 22.7 1 -
as18 M 57 1.80 83.9 61.7 25.9 1 -
as19 F 64 1.60 78.5 43.7 30.7 2 D
as20 M 73 1.69 76.8 55.8 26.9 2 D
as25 F 50 1.70 82.7 50.1 28.6 2 D,F
as26 F 32 1.58 55.3 37.2 22.2 1 -
as28 F 69 1.54 69.4 41.8 29.3 2 F
as30 F 55 1.54 63.2 37.4 26.6 2 D,F
as34 M 30 1.84 65.7 55.7 19.4 1 -
as35 M 27 1.73 120.9 * 40.4 2 D.F
Svm AS
as04 F 82 1.46 58.6 39.3 27.5 2 D.F, CP, 
Pre-S
as06 F 58 1.67 88.5 52.2 31.7 2 CP,D
as07 F 69 1.60 75.2 46.6 29.4 2 CP
as09 M 69 1.67 75.4 51.6 27.0 2 CP.D.F
as10 M 62 1.58 68.7 51.1 27.7 2 CP.D,
as12 M 66 1.78 107.0 70.6 34.0 3 D,F
as14 M 60 1.64 64.2 47.2 23.9 2 CP.D.F
as15 M 57 1.66 92.9 55.3 33.9 3 D.F
as21 M 75 1.88 77.7 61.0 22.0 3 D
as22 M 83 1.52 57.3 39.5 25.0 3 F
as23 M 82 1.73 72.5 52.8 24.2 3 CP.D.F
as24 F 70 1.66 72.9 48.1 26.5 2 D,CP
as27 M 83 1.67 70.1 48.9 25.1 3 D,F
as29 M 59 1.81 98.3 62.3 30.0 3 D,F
as31 F 70 1.57 51.9 34.5 21.1 3 CP.D,
Pre-S
as32 F 56 1.66 62.8 40.4 22.8 3 CP.D.F
as33 F 71 1.56 38.0 28.7 15.6 3 D,F
as36 F 40 1.54 59.2 38.4 25.0 3 CP,D,F
as37 M 78 1.63 56.5 47.5 21.3 3 D,F
Table 3-2: Individual anthropometric data for patient group.
Abbr: Sym= symptoms; D = dyspnoea; F= fatigue, CP= chest pain, Pre-S= pre-syncope. *Accurate skin fold 
thickness could not be obtained due to body habitus.
Of the patient group, nine were in NYHA functional class I, 16 in class II, 12 in 
class III and none in class IV. Dyspnoea was reported by 25, fatigue by 18, 
ischaemic sounding chest pain in 10 and pre-syncope in 2 patients. Of the 18 
patients classed as  being asymptomatic four had mild symptoms of dyspnoea, four 
had dyspnoea and fatigue and one had fatigue only.
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Twenty-six of the 37 AS patients were regularly taking som e form of medication. 
The cardiovascular drugs were: aspirin (13), diuretics (6), beta-blockers (5), 
calcium channel blockers (3), statins (3), ace-inhibitors (2), other anti-hypertensive 
(2), nitrate (1) and digoxin (1) although all were in sinus rhythm. Six patients were 
also taking a non-steroidal anti-inflammatories.
3.3 Comparison of patients and controls
As can be seen  from the table 3-3 the AS patients are slightly older than the 
controls but this difference does not reach statistical significance. The two groups 
are well matched for height, weight, body m ass index(BMI), lean body mass(LBM) 
and male to female ratio.
Age
(years)
Height
(m)
Weight
(kg)
BMI LBM
(kg)
M/F
AS 58.0±18.6 1.67±0.10 73.5±16.1 26.3±4.6 49.6±9.7# 21/16
n=37
Controls 50.4±16.8 1.68±0.10 74.0±12.9 26.0±3.7 52.1±10.2 13/7
n=20
95% Cl -2.2,17.4 -0.07, 0.04 -8.3, 7.5 -2.0, 2.5 -8.1, 3.2
P value 0.12 ns ns ns ns ns
Table 3-3 : Anthropometric data, patients v controls.
All values given as mean±SD. 95% CI= 95% confidence interval for the difference between means. # n=36.
3.4 Electrocardiography (ECG)
3.4.1 AS
All patients were in sinus rhythm. Ten subjects had a normal ECG. The following 
abnormalities were present: left ventricular hypertrophy (6), left ventricular 
hypertrophy plus strain (6), repolarisation abnormalities (12), pathological Q waves 
or poor R wave progression (6), left bundle branch block (2) and first degree block 
(2 ).
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All subjects were in sinus rhythm. Two had repolarisation abnormalities and two 
had voltage criteria for left ventricular hypertrophy.
3.5 Echocardiography
All subjects underwent echocardiography. There were no significant abnormalities 
of valvular or left ventricular structure and function in the control group.
3.5.1 Intra-observer correlations
The intra-observer correlation coefficients are shown in table 3-4. They are good 
to excellent except those for ejection fraction by Sim pson’s  biplane method and 
aortic valve area using the velocity time integral.
Variable r
Ejection fraction (Simpson’s ) 0.63
Left ventricular mass 0.95
Left ventricular mass index 0.94
Maximal aortic velocity 0.90
Peak pressure gradient 0.83
Mean pressure gradient 0.91
Aortic valve area (V max) 0.83
Aortic valve area (VTI) 0.59
PeakE 0.89
Peak A 0.93
E /A 0.95
Table 3-4: Echocardiography: intra-observer correlation coefficients
3.5.2 Suitability of images for quantification
Seven of the patient group and three control subjects had M-mode recordings of 
inadequate quality to allow accurate determination of left ventricular dimensions. 
Three apical views in aortic patients and one in a control subject were unsuitable 
for determination of ejection fraction by Sim pson’s  biplane method. Similarly, an 
inadequate Doppler signal across the mitral valve w as obtained in one patient and 
the aortic velocity was not recorded in one control.
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3.5.3 Echocardiographic characteristics of AS group
3.5.3.1 Aortic valve morphology
Calcification w as present in the aortic valve leaflets of 26 of the 37 patients with 
AS, and in the others the valve was thickened (see table 3-5). Eight had a 
bicuspid valve morphologically, but calcification causing distortion of valve 
anatomy m ade it impossible to determine the number of leaflets in several others. 
The mitral valve annulus was calcified in four subjects but none had mitral 
stenosis.
3.5.3.2 Aortic incompetence
There w as no aortic incompetence in twenty of the patients. Aortic incompetence, 
as  a sse ssed  by colour flow Doppler imaging, w as trivial in eight, mild in four, mild 
to moderate in three and m oderate in two. Both subjects with m oderate aortic 
incompetence had severe AS with aortic valve a reas of 0.28cm2 (as20) and 
0.59cm2 (as32) and mean pressure gradients of 56.6 and 44.4mmHg respectively.
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Subject Severity
1=mild,
2=severe
Calc Al EF
%
LVMI
g/m2
AVAMAX
(cm2)
Mean PG 
(mmHg)
Peak PG 
(mmHg)
Asv AS
AS01 1 + 49 112 0.89 12.2 35
AS02 2 + - 54 - 0.60 65.4 123
AS03 1 + - 41 212 1.01 27.1 46
AS05 1 + - - - 0.68 18.9 39
AS08 1 - - 58 54 1.56 13.7 32
AS11 1 - - 41 64 0.63 14.5 28
AS13 1 + + 83 93 1.24 24.1 46
AS16 1 - - 54 170 0.81 13.4 26
AS17 1 + +++ 59 135 0.95 25.1 50
AS18 2 - - 56 - 0.29 45.3 74
AS19 2 - +++ 63 116 0.35 31.0 54
AS20 2 - ++++ 35 229 0.28 56.6 87
AS25 2 + ++ 50 107 0.44 41.6 67
AS26 1 - + 43 98 0.61 20.1 36
AS28 2 + + - 107 0.27 36.4 65
AS30 2 + + 38 275 0.46 33.6 56
AS34 2 - ++ 60 85 0.63 37.5 66
AS35 1 - +++ 41 150 1.04 28.5 55
Svm AS
AS04 2 + + 80 0.29 38.9 71
AS06 2 + - 48 174 0.84 78.9 114
AS07 1 + ++ 55 84 0.48 23.4 42
AS09 2 + - 57 - 0.94 32.5 74
AS10 2 + - 52 290 0.52 34.8 57
AS12 1 + - - 220 1.04 19.4 35
AS14 1 + - 53 104 0.58 19.0 33
AS15 1 - - - 233 0.55 27.6 57
AS21 1 + - 51 - 0.49 12.7 28
AS22 1 + ++ 55 - 0.13 19.7 34
AS23 2 + - 47 111 0.19 36.0 68
AS24 2 + - 51 131 0.34 50.6 82
AS27 2 - - 38 112 0.30 52.4 85
AS29 2 + + 48 145 0.67 49.5 75
AS31 2 + - 46 187 0.44 89.3 143
AS32 2 + ++++ 54 154 0.59 44.4 68
AS33 2 + + 37 222 0.32 59.4 96
AS36 2 + - 67 159 0.33 101.7 157
AS37 2 + + 40 182 0.35 55.2 88
Table 3-5: Individual echocardiographic characteristics for AS.
1= Mild-moderate AS; 2= moderate-severe AS; Calc= aortic valve calcification; AI= aortic incompetence: - 
none, + trivial, ++ mild, +++ mild-moderate, moderate ++++.
3.5.3.3 Left ventricular function
Two patients had obvious left ventricular wall motion abnormalities. Overall 
systolic function w as mild-moderately impaired in one (as20), who had severe but
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asymptomatic AS and mildly impaired in the other (as12), who had mild but 
symptomatic AS. In three further patients (as28, as30, as33) left ventricular 
contraction appeared sluggish but with overall preservation of systolic function.
3.5.4 Patients versus controls
3.5.4.1 Cardiac structure and function
The data for the size of the left atrium, left ventricle, ejection fraction and left 
ventricular m ass/m ass index are shown in table 3-6. There were no statistically 
significant differences in the size of the left atrium or the E/A Doppler ratio across 
the mitral valve. The AS patients have significantly greater left ventricular m ass 
and m ass index. The controls have significantly higher ejection fraction although 
the mean value for the AS group would be considered to be within the normal 
range.
LA (mm) E/A LV mass LVMI EF (%)
Controls 35.5±0.4 1.15±0.34 196±82 104±36 61.8±8.8
(n=19) (n=17) (n=17) (n=19)
AS 34.4±0.6 1.01±0.59 271+117 152±60 51.6±11.1
(n=36) (n=36) (n=30) (n=30) (n=33)
95% Cl -4.1, 1.7 -0.38, 0.11 16,133 1,76 -15.8, -4.6
P ns ns 0.014 0.002 <0.001
Table 3-6: LV structure and function, patients v controls.
LA= left atrium; LVMI= left ventricular mass index; EF= ejection fraction
3.5.4.2 Aortic valve area and pressure gradient
The patient group had significantly greater aortic valve velocity, peak and mean 
pressure gradients and reduced aortic valve area com pared to the control group 
(table 3-7). The mean values of pressure gradients and aortic valve area would 
classify the group as  having m oderate-severe AS (see table 1-1), although the 
range w as large (peak pressure gradient 26-157mmHg and aortic valve area 0.2- 
1.6cm2). Ten control subjects had calculated aortic valve a reas  (<1.5cm2) which 
would normally be indicative of aortic stenosis although anatomically the valves 
were normal. There were no differences in left ventricular outflow tract diameter, 
area or velocity between the two groups.
McCann, G.P. 2001 Chapter 3 96
LVOT
(mm)
Max V 
(ms'1)
Peak PG 
(mmHg)
Mean PG 
(mmHg)
AVA 
(max V) 
cm2
AVA
(VTI)
cm2
Controls 16.5±3.8 1.27±0.2 6.6±2.3 3.8±0.7 1.5±0.5 1.6±0.6
AS 17.1 ±3.9 3.92±0.9 64.7±32 37.6±21 0.6±0.3 0.7±0.4
95% Cl -1.6,0.28 2.3, 3.0 47, 68 26, 69 -1.2,-0.6 -1.2, 0.6
P ns <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Table 3-7: Indices of AS severity.
LVOT= left ventricular outflow tract diameter; Max V= maximal aortic valve velocity; AVA= aortic valve 
area; VTI= velocity time integral
Figure 3-1 demonstrates the strong correlation between aortic valve area 
measurement by the two Doppler methods. Bland and Altman plot shows that VTI 
areas tend to be slightly higher than Vmax values, particularly at higher areas
Figure 3-1: Comparison of AVA by V(VTI) and V(max) in AS.
Top panel: correlation of AVA by the two methods. Bottom panel Bland and Altman plots indicating degree 
of agreement
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3.6.1 AS severity: mild versus severe
Twenty-one patients were classified in the m oderate-severe (severe) group and 
16 in the mild-moderate (mild) group according to a mean pressure gradient 
>30mmHg or <30mmHg respectively, see  tables 3-2 and 3-5.
If severity had been determined by aortic valve area (<0.75 cm2) then a total of 27 
patients would have been classified as  having severe AS and only 10 having mild 
AS (see table 3-5). Eight patients (05,07,11,14,15,21,22,26) would have been re­
classified from the mild to severe groups and two (06,09) would have moved from 
the severe to the mild group (see table 3-5).
3.6.1.1 ECG
Of the ten patients with normal ECG’s seven had mild and three had severe AS. 
An abnormal ECG w as significantly more likely to be associated with severe AS 
(18/21) than mild AS (9/16), y2 = 4.0, p<0.05.
3.6.1.2 Anthropometric and left ventricular function
The three groups remain well matched for body size and the proportion of females 
in each group is not significantly different (table 3-8). The severe AS group were 
slightly but not significantly older than both other groups. E/A ratio w as similar for 
all groups. Ejection fraction was higher in the controls com pared to both aortic 
groups but there was no difference between those with mild and severe AS.
M/F Age BMI EF E/A
Controls 13/7 50.4±17 26±4 61.8±9 1.15±0.3
(n=20) (n=19) (n=20)
Mild AS 11/5 51.8±22 27.2±6 52.5±11 1.12±0.7
(n=16) (n=13)
Severe AS 10/11 62.7±14 25.6±4 51.0±11 0.92±0.5
(n=21) (n=20) (n=20)
P 0.13 0.06 ns 0.005* ns
Table 3-8: Age, BMI, EF and E/A ratio in mild versus severe AS.
♦Controls significantly different from severe and mild AS .
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Left ventricular mass indices for the subject groups are displayed in figure 3-2. 
Left ventricular mass index was significantly greater in the severe group (n=17) 
compared to the controls (n=17) but not the mild AS (n=13) group (163±61 v 
104±36 v 130±64 g/m2 respectively, p=0.01). Left ventricular mass was similarly 
distributed: severe 282±96 v mild 253±146 v controls 196±82g although these 
differences just fail to reach statistical significance (p=0.07). Left ventricular mass 
index did not significantly correlate with mean pressure gradient, aortic valve area 
or age in AS patients.
Figure 3-2: LVMI by subject group
*Severe AS significantly different from controls
(means are indicated by solid circles)
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3.6.1.4 AS severity
The distribution of aortic valve areas in the groups are shown in figure 3-3. The 
three groups are significantly different from each other: severe 0.45±0.2 v mild 
0.79±0.4 v controls 1.52±0.5 cm2, p<0.0001.
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Figure 3-3: Aortic valve area by subject group.
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(means are indicated by solid circles)
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Peak aortic valve velocity (4.5±0.7 v 3.1 ±0.4 m s'1), peak pressure gradient 
(84.3±28 v 38.9±9.6 mmHg) and mean pressure gradient (51.0±19 v 20.0±5.6 
mmHg) were all significantly (p<0.0001) higher in the severe AS group than mild 
group.
3.6.1.5 Left ventricular outflow tract diameter, area and velocity
There were no significant differences in left ventricular outflow tract diameter 
between groups: severe AS (1.73±0.4) v mild AS (1.69±0.4) v controls 
(1.65±0.4cm). The eight patients who would have been re-classified as  having 
severe AS according to aortic valve area had significantly smaller left ventricular 
outflow tract diameter (1.48±0.30) than the other AS patients (1.78±0.39cm), 
p=0.04. The two patients who would have been re-classified a s  having mild AS 
according to aortic valve area had left ventricular outflow tract diam eters of 
2.71 (AS06) and 2 .11cm (AS09), considerably higher than average.
Left ventricular outflow tract area is significantly smaller in the eight patients who 
would have been re-classified a s  having severe AS (1.78±0.7cm2), according to 
aortic valve area, compared to the other AS patients (2.60±1.1), p=0.02. There 
were no significant differences in left ventricular outflow tract velocities between 
groups, including the subjects who tended to have more severe AS calculated by 
aortic valve area than by mean pressure gradient.
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NYHA
I II III
Mild 6 7 3
Severe 3 9 9
Table 3-9: NYHA functional class and AS severity.
The number of subjects in each NYHA functional class according to severity of AS 
is displayed in table 3-9. There is a non-significant trend for patients in the severe 
group to be more symptomatic than the mild group (X2 3.64, p=0.16).
3.6.1.7 Predictors of severe AS
None of body m ass index, symptomatic status, sex, left ventricular m ass/m ass 
index, ejection fraction or E/A ratio were significantly associated with severity of 
AS as  defined by a mean pressure gradient >30mmHg. NYHA functional 
classification (odds ratio 2.45, 95% Cl 0.94, 0.63 p=0.054) and age (odds ratio 
1.03, 95% Cl 1.0, 1.07 p=0.07) were of borderline significance.
3.6.2 Symptomatic versus asymptomatic AS
Nineteen patients were in the symptomatic group and 18 in the asymptomatic 
group, see  tables 3-2 and 3-5. Thirteen subjects had both severe and 
symptomatic AS. The nine patients in NYHA class I were significantly younger 
(44.3±21) than those in class II (60.1±18, n=16) and class III (66.6±13, n=12), p= 
0.03. The nine patients in NYHA class 1 had similar characteristics to those with 
mild symptoms who were classed as  asymptomatic: age  44.3±21 v 51 ±19 years; 
mean pressure gradient 29.6±17 v 30.1±14mmHg; peak pressure gradient 
54.6±30 v 54.7±18mmHg and aortic valve area 0.79±0.4 v 0.62±0.4cm2 
respectively. There was a non-significant trend for the mildly symptomatic group 
to have more fem ales (6 v 2) than those in NYHA I.
3.6.2.1 ECG
Of the ten patients with a normal ECG, three were asymptomatic and seven 
symptomatic. Only two of the nine patients in NYHA class I had a normal ECG.
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The proportion of subjects with an abnormal ECG w as not significantly different 
between asymptomatic (15/18) and symptomatic AS (12/19), x2 = 1.71, p=017.
3.6.2.2 Anthropometries and left ventricular function
Results are displayed in table 3-10. The symptomatic patients are significantly 
older than both the controls and asymptomatic AS, although the subjects remain 
well matched for body m ass index and male to female ratio. There is no statistical 
difference in the E/A ratio between groups. The controls have significantly greater 
ejection fraction than both AS groups.
MZF Age BMI EF E/A
Controls 13/7 50.4±17 26±4 61.8±9 1.15±0.3
(n=20) (n=17) (n=20)
Asy AS 10/8 47.6±19 27.0±5 51.6±12 1.13±0.7
(n=18) (n=16) (n=18)
Sym AS 11/8 67.9±11 25.8±5 51.7±10 0.89±0.5
(n=19) (n=19) (n=18)
P ns 0.001* ns 0.006** ns
Table 3-10: Anthropometric and left ventricular function by symptomatic groups.
Symp= symptomatic AS, Asy= asymptomatic AS. * Sym group significantly different from both other 
groups. **Control group significantly different from both aortic groups
3.6.2.3 AS severity
Left ventricular m ass index was greater in those with symptomatic AS compared to 
controls but not compared to the asymptomatic group (table 3-11). Left ventricular 
m ass w as also greater in the symptomatic group (296±110g) than the controls 
(196±82g) but not the asymptomatic group(243±126g), p=0.04.
LVMI
(g/m2)
Peak V 
(m/s)
Peak PG 
(mmHg)
Mean PG 
(mmHg)
AVAV
max
(cm2)
AVA
VTI
(cm2)
Asy AS 131±67 3.6±0.8 54.7±24 30.3±15 0.71±0.4 0.85±0.5
(n=18) (n=15)
Sym AS 167±57 4.2±1.0 74.1±36 44.5±25 0.49±0.2 0.56±0.3
(n=19) (n=15)
95% Cl -82, 11 -1.16, 0.03 -39.6, 0.8 -27.8, -0.6 0.01,0.42 0.02, 0.56
P 0.13 0.06 0.06 0.04 0.04 0.03
Table 3-11: AS severity, symptomatic v asymptomatic patients
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The symptomatic patients have more severe disease. They have significantly 
lower aortic valve area and higher mean pressure gradient, although peak aortic 
velocity and peak pressure gradient are of borderline significance.
3.6.3 Predictors of symptomatic status
Age and aortic valve area were significantly correlated with the presence of 
symptomatic AS, see  table 3-12. None of body m ass index, sex, severity of AS 
(>30mmHg), ejection fraction, left ventricular m ass/index or E/A ratio was 
significantly correlated.
Odds Ratio 95% Cl P
Age 1.08 1.03, 1.15 0.004
>60 years 8.2 1.4,49.4 0.02
LVMI 1.01 1.00, 102 0.13
E/A 0.45 0.11,0.79 0.2
V max 2.1 0.93,4.81 0.07
Peak PG 1.02 1.0, 1.05 0.08
Mean PG 1.04 1.0, 1.08 0.06
AVA (Vmax) 0.08 0.01, 1.03 0.03
AVA (VTI) 0.13 0.02, 0.97 0.02
Table 3-12: Echocardiographic predictors of AS symptomatic status.
Mean and peak pressure gradient were both of borderline significance in 
predicting symptomatic disease. In a multivariate model with age, aortic valve 
area, mean and peak pressure gradient, and maximum aortic velocity, only age 
(odds ratio 1.11, p=0.005) was an independent predictor of symptomatic disease.
3.7 Physical activity levels
Scottish Physical activity questionnaires were returned by 24 (65%) of the patient 
group and 15 controls (75%). There was no significant differences in either total or 
leisure time physical activity between the controls, mild and severe AS or 
symptomatic and asymptomatic AS (see table 3-13).
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Leisure PA Total PA
Controls (n=15) 412±318 6011475
Mild AS (n=10) 403±303 7801811
Severe AS (n=14) 536±503 6781586
Asymptomatic AS (n=10) 303±171 6741478
Symptomatic AS (n=14) 613±514 7581822
Table 3-13: Mean physical activity (minutes/week) by subject group
PA= physical activity
There was no correlation between either leisure or total physical activity level and 
any anthropometric, symptomatic status or echocardiographic m easure in AS or 
controls.
3.8 Summary of chapter results
Patients and controls were well matched for age, sex  and body size.
AS patients had increased LV m ass, reduced ejection fraction and aortic valve 
area compared to controls.
An abnormal ECG w as common in mild and asymptomatic AS. Patients with 
severe AS were more likely to have an abnormal ECG com pared to those in the 
mild group.
The severe AS group had reduced aortic valve area  and increased pressure 
gradient compared to the mild and control groups.
The symptomatic AS group were older and had more severe AS than the 
asymptomatic group.
Age, but not aortic valve area or pressure gradient, w as independently associated 
with symptomatic status in AS.
Physical activity levels, a s  m easured by the Scottish Physical Activity 
Questionnaire, were not significantly different between groups.
4. CARDIOPULMONARY EXERCISE TOLERANCE
TESTING
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All subjects underwent treadmill exercise testing (see section 2.6 for methods). 
One patient (AS19) could not tolerate the mouthpiece and noseclips and therefore 
gas exchange was not m easured in this subject.
No adverse events were encountered on treadmill exercise testing. Two controls 
(C12 and C14) developed asymptomatic horizontal or downsloping ST segm ent 
depression > 1 mm on exercise. These subjects were not excluded from analysis.
4.1 Resting haemodynamics
There was no difference in resting heart rate between controls (69±14bpm) and 
patients (mild AS 74±14, severe AS 72±13bpm). Mean systolic and diastolic BP 
were also similar across the groups: controls 135±15/86±8 v mild AS 
142±23/85±12 v severe AS 138±22/84±11mmHg.
4.2 Symptoms limiting exercise capacity
The 37 AS patients reported the following symptoms a s  the main reason for 
exercise termination: fatigue (n=18), dyspnoea (n=14) dyspnoea and fatigue (n=2), 
dyspnoea and chest pain (n=2) and leg pain (n=1). Two controls stated they were 
limited by breathlessness and the others were limited by fatigue.
4.2.1 Mild v severe AS
There was a non-significant trend for patients in the severe group to be limited 
more by dyspnoea/chest pain (14/20) than by fatigue (6/20) compared to the mild 
AS group (6/16 dyspnoea/chest pain, 10/16 fatigue), x2=3.1, p=0.08.
4.2.1.1 Symptomatic v asymptomatic AS
Symptomatic AS patients were not more likely to be limited by dyspnoea/chest 
pain (11/18) than asymptomatic AS (8/18), x2=1 -3, p=0.25. Similarly, there was no 
difference when patients were examined by NYHA class: I (6/9 fatigue, 3/9 
dyspnoea), II (7/15 fatigue, 8/15 chest pain/dyspnoea) and III (4/12 fatigue, 8/12 
dyspnoea/chest pain) x2=2-3, p=0.31.
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All controls increased their systolic blood pressure on exercise by at least 
40mmHg. Twenty-six patients had a normal increase in SBP (>30mmHg), nine 
had a blunted response (<30mmHg) and two had a fall in systolic blood pressure 
during exercise. Both subjects (AS31 and AS37) with a decrease in blood 
pressure on exercise had severe, symptomatic AS. Patients with a blunted blood 
pressure response were fairly evenly divided between groups (5 symptomatic, 4 
asymptomatic, 6 severe AS and 3 mild AS).
4.4 Exercise ECG
Twenty-two of the AS patients developed new or worsening horizontal or 
downsloping ST segm ent depression > 1mm on exercise. There w as no sustained 
arrhythmia in any patient.
4.4.1 Mild v severe AS
The exercise ECG responses for the mild and severe AS groups are displayed in 
the table below. The severe group were significantly more likely to have an 
abnormal ECG with worsening ST depression during exercise, x2 = 10.48, 
p=0.005.
Rest - exercise ECG Mild AS Severe AS
Normal - normal 9 4
Normal -ST depression 6 4
Abnormal -worsening ST 
depression
1 11
LBBB 0 2
Table 4-1: Exercise ECG responses: mild v severe AS.
Normal = no ST-T abnormalities; ST-depression = horizontal or downsloping >1.0 mm
4.4.2 Symptomatic v asymptomatic AS
The exercise ECG responses for the asymptomatic and symptomatic AS groups 
are displayed in table 4-2. The proportion of patients with new or worsening ST
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depression w as not significantly different between the symptomatic and 
asymptomatic AS groups, x2 = 0.78, p=ns.
Rest - exercise ECG Asy AS Sym AS
Normal - normal 7 6
Normal rest-ST depression 6 4
Abnormal -worsening ST 
depression
5 7
LBBB 0 2
Table 4-2: Exercise ECG responses: asymptomatic v symptomatic AS.
Normal = no ST-T abnormalities; ST-depression = horizontal or downsloping >1.0 mm
4.5 Exercise capacity and ventilatory response
4.5.1 Mild v severe AS
Results are displayed in table 4-3.
4.5.1.1 Haemodynamic responses
Maximum and predicted maximum heart rate were reduced in both patient groups 
compared to controls. Maximum systolic blood pressure on exercise w as lower in 
the severe AS group compared to both controls and mild AS. The increase in 
systolic blood pressure w as significantly attenuated in the severe AS group 
compared to mild AS and in both AS groups com pared to controls.
4.5.1.2 Exercise capacity and cardiopulmonary responses to exercise
Exercise capacity, as  reflected in exercise duration, predicted exercise time and 
V0 2 max was significantly reduced in AS patients com pared to controls. Maximal 
exercise ventilation and peak respiratory exchange ratio (RER) were also reduced 
in both AS groups compared to controls. The slope of exercise VEA/CO2 was 
higher and oxygen pulse lower in severe AS compared to controls but not mild AS.
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Controls Mild AS Severe AS P
(n=20) (n=16) (n=21)
Max HR 
(Predicted.)
170±16
(100±8%)
149±28
(89±13%)
132126
(84114%)
0.0001++
0.0001++
Peak Ex. 198±20 180±26 158125 <0.0001**
SBP(mmHg)
Peak-rest SBP 64±19 38±25 20122 <0.0001+
(mmHg)
Ex time(min) 12.1±3.0 7.3±3.9 4.913.3 ^.OOOl^
(Predicted) (126±17%) (78±36%) (61127%) 0.0001**
VChmax 31.3±12.0 23.0+9.3 18.618.0 0.001++
(ml/kg/min) (n=20)
Ve (L/min) 94.1±34 65.3±26 48.8119
(n=20)
0.0001++
RER 1.20±0.13 1.0810.10 1.0610.11
(n=20)
0.001++
0 2 pulse 14.1+6 11.914 10.014
(n=20)
0.025*
VE/VCO2 28.6±4 30.215 34.518 0.01*
Table 4-3: Maximal exercise variables by severity of AS
♦Severe AS significantly different from controls but not mild AS. **Severe AS significantly different from 
mild AS and controls. +Each group significantly different from each other. "^Controls significantly different 
from mild and severe AS.
4.5.2 Symptomatic v asymptomatic AS
Results are displayed in table 4-4.
4.5.2.1 Haemodynamic response to exercise
Maximum heart rate w as significantly reduced in symptomatic AS compared to 
asymptomatic AS and controls. Predicted maximum heart rate w as lower in both 
AS patient groups compared to controls. Maximal exercise SBP w as reduced in 
both AS groups compared to controls. Increase in exercise SBP w as attenuated 
in the aortic patients and this w as significantly more pronounced in the 
symptomatic AS group.
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Controls
(n=20)
Asy AS 
(n=18)
Sym AS 
(n=19)
P
Max HR 170±16 155±29 124117 <0.0001**
(Predicted) (100±8%) (90±15%) (83112%) <0.0001^
Peak Ex. SBP 
(mmHg)
198±20 173±30 162125 <0.0001^
Peak-rest SBP 
(mmHg)
64±19 37±25 19121 <0.0001+
Ex time(min) 12.1±3.0 8.313.6 3.712.1 <0.0001+
(Pred) (126±17%) (86128%) (52127%) <0.0001+
VChmax
(ml/kg/min)
31.3±12.0 25.3110.4 16.413.5 (n=18) <0.0001**
VE (L/min) 94.1 ±34 70.5124 43.3114 (n=18) <0.0001+
RER 1.20±0.13 1.1210.07 1.0210.10
(n=18)
<0.0001**
O2 pulse 14.1±6 12.214 9.6±4 0.015*
VE/VCO2 28.6±4 29.815 35.1±7
(n=18)
0.003**
Table 4-4: Maximal exercise variables by symptomatic group.
Sym= Symptomatic; Asy= asymptomatic; *Sym AS significantly different from controls but not 
asymptomatic AS. **Sym AS significantly different from Asy AS and controls. +Each group significantly 
different from each other. ^Controls significantly different from mild and severe AS.
4.5.2.2 Exercise capacity and cardiopulmonary responses
Exercise duration and predicted exercise time were significantly reduced in 
symptomatic AS compared to asymptomatic AS and in both com pared to controls 
(table 4-4). Maximal aerobic capacity and peak RER were reduced and VEA/CO2 
(figure 4-1) was increased in symptomatic AS com pared to controls and 
asymptomatic AS. Maximal ventilation w as reduced in symptomatic AS compared 
to asymptomatic AS and in both compared to controls. Oxygen pulse at peak 
exercise was lower in symptomatic AS compared to controls but not asymptomatic 
AS.
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Figure 4-1: Slope of VE/VCO2 by symptomatic group
Asy=asymptomatic AS, Sym AS=symptomatic AS
(means areindcated by solid drdes)
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4.5.2.3 Mildly sym ptom atic v asym ptom atic AS.
The nine patients with only mild symptoms responded differently to the nine 
completely asymptomatic patients despite similar baseline characteristics. 
Selected results are shown in table 4-5.
Controls
(n=20)
AS NYHAI 
(n=9)
AS Mild
Sym (n=9)
Sym AS 
(n=19)
P
Max HR (% ) 100±8 98±10 82± 14 83±12 <0.001**
% Pred Ex time 126±17 103±24 68±20 52±27 <0.001**
Ex-rest SBP 64±19 49±23 26±22 19±21 <0.001*
V02max 31.1±12 29.5±9 20.5±10 16.4±4 <0.001*
(ml/kg/min)
RER 1.20±0.13 1.16±0.06 1.09±0.07 1.02±0.10 <0.001*
0 2 pulse 14.1±6 12.9±4 11.4±3.8 9.6±3.5 0.03***
VE/VCO2 28.6±4 28.0±3 31.7±7 35.1±7.4 0.004*
Table 4-5: Exercise performance, asymptomatic v mildly symptomatic AS
AS Mild Sym =Dyspnoea or fatigue only on moderate exertion. *Con and Asy AS v Sym AS** Con and Asy 
AS v mild and Sym AS. ***Con v Sym AS
There were no significant differences in exercise performance between controls 
and patients in NYHA class I. There were no significant differences between 
patients with mild symptoms and those with more severe symptoms. The mildly 
symptomatic AS group had significantly reduced exercise capacity and lower
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exercise heart rate than asymptomatic AS. In general the patients with mild 
symptoms had exercise performance closer to the group with more severe 
symptoms rather than those in NYHA class I.
4.5.3 Predictors of aerobic exercise capacity
4.5.3.1 V02max
Significant echocardiographic, anthropometric and haemodynamic predictors of 
V0 2 max are shown in table 4-6. Age, NYHA, symptomatic status 
(asymptomatic/symptomatic see  2.10.1), VE/VC0 2 , increase in exercise SBP, 
aortic valve area/index, peak A and E/A were all significant univariate predictors of 
Vc>2max in patients. For controls age, peak E and E/A were significantly 
associated with Vc^max.
4.5.3.2 Multivariate predictors of V0 2 max
In a multivariate regression analysis with all of the significant univariate predictors 
in AS patients, age (p=0.001) and NYHA (p=0.02) were independent predictors of 
Vc^max.
AS
^ ( p )
Controls
Age (years) 55.5% (0.0001) 74.4% (0.0001)
NYHA 38.0% (0.0001) -
Symptomatic status 
(asy/sym)
27% (0.001) -
ve/vco2 32.5% (0.0001) 46.0% (0.001)
SBP response 28.7% (0.001) ns
AVA (V max) 23.6% (0.003) ns
AVAI 28.8% (0.001) ns
PeakE ns 27.7% (0.02)
Peak A 23.8% (0.003) ns
E/A 10.7% (0.06) 50.9% (0.001)
Table 4-4: Predictors of maximal aerobic capacity(V0 2 max) in AS and controls.
Asy= asymptomatic, sym= symptomatic AS.
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There was little overlap of Vo2max in patients in NYHA class II and III compared to 
those in class I (see figure 4-2). There is one exception, the outlier in the figure 
below in class II. This is (AS01) a young patient with mild AS whose only 
symptom was dyspnoea on heavy exercise and he continued to work in a 
manually demanding job. In controls only age is of independent significance 
(p=0.004).
Figure 4-2: NYHA class v VOimax in AS.
(means are indicated by solid circles)
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4.5.3.3 P redic ted  ex erc ise  tim e
Significant predictors of exercise time (% predicted) are shown in table 4-7. No 
echocardiographic or anthropometric measure was associated significantly with % 
predicted exercise time in control subjects.
In patients age, symptomatic status, left ventricular mass/mass index, AS severity 
(by gradient or area) and exercise VEA/CO2 and SBP response were all univariate 
predictors of exercise time.
4.5.3.4 M ultivariate p red ic to rs  of ex erc ise  tim e
In patients NYHA (p=0.04) (see figure 4-3), left ventricular mass (p=0.02) (figure 4- 
4), and left ventricular mass index (p=0.04) were independent predictors of 
exercise duration. SBP response was of borderline significance (p=0.07).
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R2 (P)
AS Controls
Age 12.5% (0.03) ns
NYHA 47.0% (<0.001) -
Symptomatic status 29.0% (0.001) -
(asym/symp)
v e /v c o 2 18.8% (0.008) 29.2% (0.017)
SBP response 32.8% (<0.001) ns
Mean pressure gradient 11.6% (0.04) ns
LV Mass 17.2% (0.02) ns
LVMI 12.4% (0.06) ns
Peak pressure gradient 9.0% (0.07) ns
AVAI 17.3% (0.01) ns
AVA (Vmax) 11.3% (0.04) ns
Table 4-5: Univariate predictors of exercise duration in AS and controls.
Figure 4-3: Predicted exercise time by NYHA in AS
(group means are indicated by lines)
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Figure 4-4:Predicted exercise time by left ventricular mass in AS.
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4.6 Summary of chapter results
No complications were encountered on maximal exercise testing in AS.
Fatigue and dyspnoea are the commonest symptoms on exercise testing in AS.
There was no significant difference in the proportion of symptomatic patients 
limited by dyspnoea/chest pain than by fatigue compared to asymptomatic AS.
Significant ST depression on exercise occurs with a similar frequency in mild and 
asymptomatic AS compared to severe and symptomatic AS.
Maximum heart rate, SBP response, exercise capacity, maximum Ve and RER 
were reduced in severe AS v mild AS and controls.
Maximum heart rate, SBP response, exercise capacity were reduced in 
symptomatic AS v asymptomatic AS and controls.
Maximum Ve, Vo2max and RER were reduced and VeA/C02 increased in 
symptomatic AS v asymptomatic AS and controls.
Mildly symptomatic patients generally had poorer exercise performance than 
completely asymptomatic patients.
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Age and NYHA classification were independent predictors of V0 2 max in AS.
NYHA functional classification and left ventricular m ass/ m ass index were 
independent predictors of exercise duration in AS.
5. MUSCLE STRENGTH AND ENDURANCE
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Thirty patients and 18 controls underwent skeletal muscle strength and endurance 
testing (see section 2.4 for methods).
5.1 Isometric strength
There were 13 subjects in the mild, 17 in the severe, 16 in the asymptomatic and 
14 in the symptomatic groups. There was no significant difference in age (controls 
48.7±17 v mild AS 53.5±20 v severe AS 59.6±14 years) or lean body m ass 
(controls 53.6±10 v mild AS 52.7±10 v severe AS 48.2±9kg) between the groups 
classified according to severity. The symptomatic patients (64.4±11) remained 
older than the controls (48.7±17) but not the asymptomatic group (50.4±19), 
p=0.02. There w as no difference in lean body m ass between symptomatic groups.
5.1.1 Mild v severe AS
Results are displayed in table 5-1. There was no significant difference in any of 
the isometric strength m easures between the three groups.
Peak Force 
(N)
Normalised 
Peak Force 
(N/Kg)
Average 
Force (N)
Normalised 
Average 
Force (N/Kg)
Controls 567±199 10.512.9 4961185 9.212.8
(n=18) 
Mild AS 527±224 9.813.2 4511195 8.412.9
(n=13) 
Severe AS 515±220 10.413.2 4301203 8.713.1
(n=17)
P ns ns ns ns
Table 5-1: Isometric strength by severity of AS
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Isometric strength results are displayed in table 5-2.
Peak Force 
(N)
Normalised 
Peak Force 
(N/Kg)
Average 
Force (N)
Normalised 
Average 
Force (N/Kg)
Controls
(n=18)
5671199 10.512.9 4961185 9.212.8
Asy AS 
(n=16)
5641251 10.913.6 4791221 9.213.2
Sym AS 
(n=14)
4701169 9.412.5 3941161 7.812.5
P . . ns ns ns ns
Table 5-2: Isometric strength by symptomatic status
Asym=asymptomatic; symp= symptomatic.
There were no significant differences in any of the m easures of isometric strength 
between the groups as  classified by symptomatic status.
5.2 Isokinetic muscle strength
Of the 30 patients, three fem ales (AS05, AS12, AS36) were unable to complete 
the isokinetic test. One control subject (C10) w as excluded from analysis because 
gravity correction was not performed at the time of testing. Symptomatic patients 
(66.3±9 years) were older than controls (48.4±17 years) and asymptomatic AS 
(48.4±17 years) p=0.006. There w as no difference in lean body m ass between 
any of the groups and age was not significantly different between groups classified 
by severity of AS.
5.2.1 Miid v severe AS
Results are displayed in table 5-3. There were no significant differences in 
isokinetic muscle strength in either quadriceps or hamstrings in the groups 
classified by severity of AS.
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Q Peak 
Torque 
(Nm)
Q Normalised 
Peak Torque 
(Nm/Kg)
H Peak 
Torque (N)
H Normalised 
Peak Torque 
(Nm/Kg)
Controls 138±45 2.6±0.6 75±28 1.4±0.4
(n=17) 
Mild AS 132±51 2.4+0.7 82±40 1.5±0.6
(n=12) 
Severe AS 116±46 2.3±0.5 64±30.7 1.3±0.4
(n=15)
P ns ns ns ns
Table 5-3: Isokinetic muscle strength by severity of AS.
Q= quadriceps; H= hamstrings; Asym= asymptomatic; symp= symptomatic.
5.2.2 Symptomatic v asymptomatic AS
Results are displayed in table 5-4. There w as no difference in quadriceps peak 
torque, hamstrings peak torque or normalised hamstrings peak torque between 
the groups. Quadriceps normalised peak torque w as significantly lower in the 
symptomatic group compared to both controls and the asymptomatic AS.
Q Peak 
Torque 
(Nm)
Q Normalised 
Peak Torque 
(Nm/Kg)
H Peak 
Torque (N)
H Normalised 
Peak Torque 
(Nm/Kg)
Controls 138±45 2.6±0.6 75±28 1.4±0.4
(n=17) 
Asy AS 136±48 2.6±0.6 80±42 1.5±0.6
(n=15) 
Sym AS 107±45 2.0±0.5 63±24 1.2±0.3
(n=12)
P ns 0.03* ns ns
Table 5-4: Isokinetic muscle strength by symptomatic groups.
Q= quadriceps; H= hamstrings; Asym= asymptomatic; symp= symptomatic. *Symptomatic significantly 
different from asymptomatic (95% Cl 0.1,1.0) and controls (95% Cl 0.1,1.0).
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5.3.1 Mild v severe AS
Results are displayed in table 5-5. Normalised total quadriceps work was 
significantly reduced in the severe group compared to controls. There were no 
other significant differences in endurance m easures between the three groups.
Controls
(n=17)
Mild AS 
(n=12)
Severe AS 
(n=15)
P
Q fatigue index (%) 76.1±7 82.8±17 72.4±14 ns
H fatigue index (%) 76.2±16 76.8±18 82.3±11 ns
Q Total work (J) 1977 1348 1108 0.11
(1355, 2697) (978, 2222) (818, 2389)
Q normalised total work 35.4 28.9 22.0 0.049*
(J/Kg) (30,45) (18,38) (20,40)
H Total work (J) 896 581 377 ns
(411,1307) (304, 631) (366, 863)
H normalised total work 16.4, 9.6 10.4 ns
(J/Kg).________ __________ (8,23) _ _ (6,12) (8,16)
Table 5-5: Isokinetic muscular endurance by severity of AS.
Measures o f total work expressed as median (IQ range). *Severe AS significantly different from controls 
(95% Cl 1.1, 17.1) but not mild AS (95% Cl -7.9, 9.5)
The distribution of total work and normalised total work m easures were non- 
parametric in the AS groups (see figure 5-1).
Figure 5-1: Isokinetic total hamstrings work by severity of AS.
(means are indcated by solid circles)
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McCann, G.P. 2001 Chapter 5
5.3.2 Symptomatic v asymptomatic
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Results are displayed in table 5-6. Total quadriceps and total normalised 
quadriceps work were significantly reduced in symptomatic AS compared to 
controls but not the asymptomatic AS. Q uadriceps fatigue index tended to be
Controls
(n=17)
Asy AS 
(n=15)
Sym AS 
(n=12)
P
Q fatigue index (%) 76.1±7 71.9±14 83.4±16 0.07
H fatigue index (%) 76.2±7 82.1±12 77.1± ns
Q Total work (J) 1977 1228 969, 0.05*
(1355,2697) (1015,2416) (732,1912)
Q normalised total work 35.4 (30,45) 29.9 (20,41) 16.4(16,32) 0.01**
(J/Kg)
H Total work (J) 896 578 510 ns
(411,1307) (366,1088) (370,728)
H normalised total work 16.4, (8,23) 10.4 (8,26) 9.4 (8,12) ns
(J/Kg)
Table 5-6: Measures of isokinetic endurance by symptomatic group.
Measures o f total work expressed as median (IQ range). *Symptomatic AS significantly less than controls 
(95% Cl 138, 1247); ** Symptomatic AS significantly less than controls (95% Cl 4.6, 20.9);
higher (i.e. demonstrating less fatigue) in symptomatic AS but this fails to reach 
statistical significance. As can be seen  from figure 5-2, som e subjects, particularly 
in the symptomatic group, had no discernible reduction in quadriceps muscle 
strength (close to 100 in the fatigue index) during the isokinetic test.
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Figure 5-2: Quadriceps fatigue index by symptomatic group
Asym= asymptomatic; symp= symptomatic AS.
(meens are indexed by sd id  cirdes)
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5.4 Skeletal muscle predictors of aerobic exercise 
capacity
5.4.1 Vo2max
All of the isometric and isokinetic strength variables were significant predictors of 
maximal aerobic capacity in patients and controls. S ee  table 5-7.
Variable
Controls
R*(P)
AS
Isometric strength (n=18) (n=29)
Peak force 38.5% (0.006) 27.2% (0.004)
Average force 40.8% (0.004) 25.8% (0.004)
Normalised peak force 29.3% (0.02) 30.2% (0.002)
Normalised average force 32.9% (0.01) 27.1% (0.004)
Isokinetic strength (n=17) (n=26)
Q peak torque 42.8% (0.004) 18.8% (0.03)
Q normalised peak torque 44.3% (0.004) 30.2% (0.004)
H peak torque 30.6% (0.02) 19.9% (0.02)
H normalised peak torque 28.7 (0.03) 26.8% (0.007)
Isokinetic endurance (n=17) (n=26)
Q Total work (J) 54.5% (0.001) 24.6% (0.01)
Q normalised total work (J/Kg) 44.9% (0.003) 35.0% (0.001)
H Total work (J) 28.1% (0.03) 28.1% (0.005)
H normalised total work (J/Kg) 23.7% (0.05) 31.8% (0.003)
Anthronometric (n=18) (n=29)
Age 72.8% (0.0001) 54.5% (<0.0001)
LBM 2.7% (ns) 10.1% (ns)
Table 5-7: Skeletal muscle predictors of VOimax.
Neither quadriceps nor hamstrings fatigue index w as a significant predictor of 
V0 2 max in patients or controls, although all other endurance m easures were. The 
correlations of isometric muscle strength with Vc>2max for patients and controls are 
shown in figure 5-3.
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Figure 5-3: Isometric strength as a predictor of Vo2max
AS top panel, Controls lower panel.
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5.4.1.1 M ultivariate analysis
In a multivariate model with peak strength, normalised peak strength, average and 
normalised average strength and age as predictors, only age was an independent 
predictor of Vc>2max in patients and controls (p<0.0001). Similarly when isokinetic 
variables were considered only age remained an independent predictor (p<0.003 
for AS and p<0.0001 for controls).
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5.4.2 Predicted exercise time
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None of the anthropometric, isometric or isokinetic strength m easures were 
significant predictors of predicted exercise time in either controls or patients.
5.4.3 VeNco2
All of the isometric strength m easures were inversely correlated with VEA/CO2 in 
patients and controls. All of the isokinetic variables were also predictors of 
VEA/CO2 in controls but only normalised total work w as significant in AS patients 
The strongest predictors are shown in table 5-8.
AS
R2 (p )
Controls
Isometric
Q Peak force 16.8% (0.03) 53.8% (0.001)
Q Normalised peak Force 27.8% (0.003) 43.8% (0.004)
Isokinetic
Q normalised peak torque 3.7% (ns) 46.9% (0.003)
Q normalised total work 25.5% (0.009) 36.6% (0.013)
Table 5-8: Skeletal muscle predictors of VE/VCO2
5.4.3.1 Multivariate predictors of VE/VCO2
W hen age, peak and normalised peak isometric force and quadriceps total work 
were considered in a multivariate model only normalised peak quadriceps strength 
(p=0.02) was an independent predictor of VEA/CO2 in AS. Peak strength is of 
borderline significance (p=0.07). In a multivariate regression analysis in control 
subjects none of the univariate predictors were of independent significance.
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5.5 Summary of chapter results
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Isometric quadriceps strength was not significantly different in AS groups and 
controls.
Isokinetic strength w as similar in AS and control groups. Normalised quadriceps 
isokinetic strength was reduced in severe and symptomatic AS v controls.
Total quadriceps work w as reduced in symptomatic AS v controls.
Skeletal muscle strength and endurance m easures were univariate predictors of 
V0 2 max in AS and controls but were not of independent significance when 
considered in a multivariate model with age.
Normalised isometric quadriceps strength w as an independent predictor of 
VEA/CO2 in AS but not controls.
6. ARM ERGOREFLEX
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Thirty-one AS patients and 17 controls completed the arm exercise studies (for 
methods see section 2.7). All subjects reported discomfort during cuff inflation but 
none required the cuff to be deflated during testing.
6.1 Control cuff inflation
There was no significant effect of cuff inflation on resting ventilation or SBP (figure 
6-1) in controls or patients. There was a small increase in DBP with cuff inflation 
which was significant for the mild (95% Cl 0.2, 3.0 p=0.03) and the symptomatic 
AS groups (95% Cl 0.2, 2.5 p=0.02).
Figure 6-l:Control cuff inflation: effect on resting ventilation and blood pressure
Top panel ventilation, middle panel SBP, bottom panel DBP. Data represent meanisem (error bars). Rl= 
first 3 min recovery with/without RCO, R2= recovery 4-6min.
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6.2 Cuff v non-cuff run
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6.2.1 Exercise duration and metaboiic demand
Results are displayed in table 6-1. There were no significant differences in resting 
or peak exercise m easures between cuff and non-cuff runs in any group. Exercise 
duration was similar for both runs in each subject group. There w as a trend for 
respiratory rate at rest to be higher in symptomatic AS com pared to controls but 
this difference fails to achieve significance, p=0.06. A similar metabolic load was 
placed on each group as there were no significant differences in m easured 
variables at peak exercise.
Ex. time (min) VO2 (ml/min) VC0 2  (ml/min) RR (bpm)
Cuff Non-cu Rest Ex Rest Ex Rest Ex
Controls 3.1±0.9 3.0±1.0 240±58 361±82 188±52 334±99 16.0±6 20.7±5
Mild AS 3.2±1.0 2.9±1.1 256±74 409±110 203±69 363±128 18.0±3 21.8±5
SevAS 2.6±0.4 2.7±0.5 226±56 365±80 182±48 340±92 17.7±3 23.9±6
Asy AS 2.8±0.9 2.7±1.1 246±76 397±101 195±65 371±119 16.8±3 21.9±5
Sym AS 2.9±0.6 2.9±0.5 233±56 376±94 189±54 334±99 18.7±3 23.8±6
Table 6-1: Cuff v non-cuff runs; exercise duration, VO2 , VCO2, and respiratory rate.
Ex= peak exercise, RR= respiratory rate, Sev= severe AS, Asy= asymptomatic AS, sym= symptomatic AS. 
VO2 and V co2 and RR presented as average o f cuff and non-cuff runs.
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6.2.2 Mild v severe AS
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The 17 AS patients in the severe group were significantly older (66.3±12) than the 
controls (48.7±17yrs) but not the 14 subjects with mild AS (52.6±23) p=0.02.
6.2.2.1 Ventilation
Results are displayed in figure 6-2. There was no significant differences in 
ventilation between groups at rest, peak exercise or during recovery.
Figure 6-2: Ventilation, non-cuff v cuff run: mild v severe AS
Data represent meanisem (error bars). NC= non-cuff, Cu= cuff run, Con= controls, Sev= severe AS. Rl = 
first 3 min recovery with/without RCO, R2= recovery 4-6min.
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Recovery ventilation in the cuff run was significantly increased in the severe AS 
group compared to the non-cuff run. However the magnitude of ergoreflex was
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not significantly different between the three groups, s e e  table 6-2 (and equations 9 
and 10 for ergoreflex calculation, section 2.7.3.1).
Ventilation Ergoreflex magnitude
Cuff
recovery
Non-cuff
recovery
95% Cl 
Cu-NC
P Cuff 
(% p eak )
Non-cuff 
(% peak )
Controls 9.8±1.7 9.3±1.8 -0.4, 1.3 ns 18±29 12±36
Mild AS 11.7±4.4 11.0±2.0 -1.0, 2.5 ns 45±60 33±25
Severe AS 11.8±3.7 10.5±2.2 0.0,2.6 0.05 44±49 29±22
P ns ns - - 0.19 0.10
Table 6-2: Cuff v non-cuff ventilation and magnitude of ergoreflex by severity of AS.
Cu= cuff recovery; NC= non-cuff recovery.
There were no significant differences in ergoreflex magnitude between non-cuff 
and cuff runs in any group.
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6.2.3 Blood pressure
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There was no significant difference in blood pressure between groups at rest, peak 
exercise or during recovery. SBP responses are shown in figure 6-3.
Figure 6-3: SBP non-cuff v cuff run, by severity of AS.
Top panel controls, middle panel mild AS and bottom panel severe AS. Data represent meanisem (error 
bars). Rl= first 3 min recovery with/without RCO, R2= recovery 4-6min.
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SBP was higher in each group during recovery with regional circulatory occlusion 
than without (see table 6-3). Diastolic blood pressure followed a similar pattern to 
SBP.
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The magnitude of ergoreflex activation for blood pressure w as not significantly 
different between groups for either cuff or non-cuff recovery (see table 6-3).
Average Blood pressure (mmHg) Ergoreflex magnitude
Cuff
Recovery
Non-Cu
Recovery
95% C l of 
Cu-NC
P Cuff 
(% peak)
Non-cuff 
(% peak)
Controls
SBP
DBP
152±21
98±11
134±15
86±10
14.9, 28.7 
7.6, 16.1
<0.0001
<0.0001
79±42 
81 ±67
25±19
8±30
Mild AS 
SBP 
DBP
160±29
98±14
141±26
88±13
10.6, 25.8 
6.0, 12.0
0.0002
<0.0001
92±40
58±40
20±30
2±34
Severe AS 
SBP 
DBP
165±33
95±14
143±27
86±13
13.7, 25.4 
5.6, 11.8
<0.0001
<0.0001
100±56
72±85
-1±65
6±3
Asv AS 
SBP 
DBP
158±33
96±15
137±25
85±14
10.4, 25.9 
7.6, 13.8
0.0002
<0.0001
88±33
55±42
14±27
0±24
Svm AS 
SBP 
DBP
166±28
95±13
147±27
87±12
11.9, 25.5
5.9, 11.3
<0.0001
<0.0001
103±58
74+84
4±68
7±37
Table 6-3: Blood pressure response by group; cuff v non-cuff and magnitude of 
ergoreflex.
Cu= cuff run, NC= non-cuff run. Asym= asymptomatic AS, Sym= symptomatic AS.
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6.2.4 Symptomatic v asymptomatic AS
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The 17 patients in the symptomatic AS group were significantly older (70.0±10) 
than both the asymptomatic AS group (n=14, 48.1 ±20) and the controls (48.7±17 
years), p<0.0001.
6.2.4.1 Ventilation
Results are displayed in figure 6-4. There were no significant differences in 
ventilation between groups at rest, peak exercise or in recovery.
Figure 6-4: Ventilation, non-cuff v cuff run; asymptomatic v symptomatic AS.
Top panel asymptomatic AS, bottom panel symptomatic AS. Data represent mean±sem (error bars). R l= first 
3 min recovery with/without RCO, R2= recovery 4-6min.
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There was an increase of borderline significance in ventilation in the symptomatic 
group in the cuff run compared to the non-cuff run (see table 6-4). There was a 
non significant trend for the magnitude of the ergoreflex to be higher in AS 
patients, see table 6-4. Intra-group analysis did not demonstrate any significant 
differences in the magnitude of cuff and non-cuff ergoreflex magnitude.
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Ventilation Ergoreflex magnitude
Cuff Non-cuff 95% Cl P Cuff Non-cuff
recovery recovery Cu-NC (% peak ) (% p eak )
Controls 9.8±1.7 9.3±1.8 -0.4, 1.3 ns 18±29 12±36
Asy AS 11.2±3.5 10.6±2.0 -0.8, 2.0 ns 36±30 32±28
Sym AS 12.2±4.3 10.8±2.2 -0.1, 3.0 0.06 51 ±67 29±19
P 0.11 0.08 0.12 0.10
Table 6-4: Cuff v non-cuff ventilation and magnitude of ergoreflex by symptomatic 
status.
Cu= cuff run, NC= non-cuff run
S.2.4.2 Blood p re ssu re
There was no significant differences in blood pressure between the AS 
symptomatic groups and controls at any time point. SBP blood pressure 
responses are displayed in figure 6-5.
Figure 6-5: Cuff v non cuff, effect on SBP; asymptomatic v symptomatic AS.
Top panel asymptomatic AS, bottom panel symptomatic AS. Rl= first 3 min recovery with/without RCO, 
R2= recovery 4-6min.
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The pattern of change of diastolic blood pressure was similar to that of SBP. 
Systolic and diastolic blood pressure was significantly elevated during recovery 
with regional circulatory occlusion compared to without in symptomatic and 
asymptomatic patients. There were no significant differences in the magnitude of 
ergoreflex between groups (see table 6-3).
6.3 Ergoreflex magnitude associations
No anthropometric or echocardiographic variables were significantly associated 
with the magnitude of ergoreflex activity. The slope of exercise Ve/Vco2 was not 
significantly correlated to the magnitude of arm ergoreflex (figure 6-6).
Figure 6-6: Association of exercise VE/VCO2 and magnitude of ergoreflex in AS.
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There was a non-significant trend for ergoreflex magnitude to increase with NYHA 
functional classification in the AS group (I 22±24, II 38±25 and III 65±81%, 
p=0.25).
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6.4 Summary of chapter results
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Arm ergoreflex contributes to the m aintenance of post-exercise BP in AS and 
controls.
Arm ergoreflex activation does not contribute to the m aintenance of post-exercise 
ventilation in AS or controls.
Arm ergoreflex activation w as not enhanced in AS v controls.
The magnitude of arm ergoreflex activation was not associated with exercise 
capacity in AS or controls.
LEG ERGOREFLEX
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Two subjects (AS21, AS22) could not tolerate control cuff inflation, all other 
subjects reported discomfort during recovery with RCO but none required the cuff 
to be deflated prematurely. Thirty-one AS patients and 17 controls completed the 
leg exercise studies (methods section 2.7.2).
7.1 Control cuff inflation
There was no significant effect of cuff inflation on resting ventilation (figure 7-1). 
SBP increased by a small but significant amount (6.2-8.4mmHg p<0.01) in all 
groups. There was also a significant increase in DBP with cuff inflation in all 
groups (2.9-4.7mmHg), p<0.03.
Figure 7-1: Leg ergoreflex: Control cuff inflation
Top panel ventilation, middle panel SBP, bottom panel DBP. Data represent meantsem (error bars). Rl = 
first 3 min recovery with/without RCO, R2= recovery 4-6min.
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7.2 Cuff v non-cuff run
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Two subjects were excluded from ergoreflex calculations because of their 
abnormal ventilatory responses to exercise. These data are shown in table 7-1. 
Both subjects had a very limited increase in ventilation on exercise but a relatively 
large further increase with cuff inflation, resulting in exceptionally high ergoreflex 
magnitudes. These results had undue influence on statistical testing (see figure 7- 
2 for effect on means) and were excluded from analysis.
Subject
Rest
Ventilation (L/min) 
Peak Ex Cuff
Ergoreflex Magnitude 
(% peak)
AS36 6.1 6.6 9.0 558
C08 8.1 8.4 9.8 459
Table 7-1: Outliers excluded from leg ergoreflex analysis.
Figure 7-2: Leg ergoreflex by severity of AS.
Top panel: all subjects. Bottom panel: one outlier excluded from control and severe AS groups.
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7.2.1 Exercise duration and metabolic demand.
I4l
Results are displayed in table 7-2. There were no significant differences in resting 
or peak exercise measures between cuff and non-cuff runs in any group. Exercise 
duration was similar for both runs in each subject group. The controls exercised 
slightly longer than AS subjects but this difference was not significant. Respiratory 
rate was increased in symptomatic AS compared to controls at rest but not at peak 
exercise. A similar metabolic load was placed on each group as there were no 
significant differences in measured variables at peak exercise.
Ex. time (min) VO2 (ml/min) VC02 (ml/min) RR (bpm)
Cuff Non-cu Rest Ex Rest Ex Rest Ex
Controls 4.5±2.0 4 .1±1.5 235±76 329±92 189±71 305±124 16.6±4 21.6±5
Mild AS 3.6±1.3 3.6±1.4 265±73 388±99 214±69 339±92 19.2±4 23.2±5
Sev AS 3.5±1.0 3.4±1.3 235±49 369±83 194±43 325±72 19.2+3 22.1±5
Asy AS 3.7±1.2 3.5±1.1 253±69 380±96 205±61 339±82 18.4±4 22.3±5
Sym AS 3.4±1.1 3.4±1.6 243±54 374±85 200±53 325±81 19.8±3* 22.8±5
Table 7-2: Cuff v non-cuff runs; exercise duration, VO2 , VCO2, and respiratory rate.
Ex= peak exercise, RR- respiratory rate. Vo2 and Vco2 and RR presented as average of cuff and non-cuff 
runs. *Sym AS > controls, p=0.02.
7.2.2 Mild v severe AS
There were 17 AS patients in the severe group who were significantly older 
(64.0±15) than the 16 controls (48.0±18 years) but not the 13 patients with mild AS 
(50.3±22), p=0.03.
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7.2.2.1 Ventilation
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Results are displayed in figure 7-3. Ventilation increased in all groups on exercise 
by a similar magnitude (48-59%) in both cuff and non-cuff runs.
Figure 7-3: Ventilation, non-cuff v cuff run by severity of AS
Top panel controls, middle panel mild AS and bottom panel severe AS. Data represent mean±sem (error 
bars). NC= non-cuff run, Cu= cuff run, Con= controls, Sev= severe AS. Rl= first 3 min recovery 
with/without RCO, R2= recovery 4-6min.
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Recovery ventilation with RCO tended to be higher in the AS groups than controls 
although this difference fails to reach statistical significance (see table 7-3).
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Recovery ventilation in the cuff run was significantly increased compared to the 
non-cuff run in the mild AS group. There w as a non-significant trend for the 
magnitude of the ergoreflex to be increased in the severe group. Intra-group 
analysis did not dem onstrate any significant differences in the magnitude of 
ergoreflex activation between cuff and non-cuff runs.
Ventilation Ergoreflex magnitude
Cuff Non-cuff 95% Cl P Cuff Non-cuff
recovery recovery Cu-NC (% peak) (% peak)
Controls 9.5±2.2 9.2±1.9 -0.5, 1.2 ns 17±48 8±77
Mild AS 11.8±2.9 10.8±2.2 0.2, 1.8 0.02 32±51 21±32
Severe AS 11.3±2.8 10.7±3.2 -0.5, 1.7 ns 54±54 38±58
P 0.06 ns - - 0.13 ns
Table 7-3: Cuff v non-cuff ventilation and magnitude of leg ergoreflex by severity of 
AS.
Cu= cuff recovery; NC= non-cuff recovery
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7.2.2.2 Blood p re ssu re
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There were no significant differences in either systolic or diastolic blood pressure 
between groups at rest, peak exercise or during recovery. SBP responses are 
shown in figure 7-4.
Figure 7-4: SBP non-cuff v cuff run, by severity of AS.
Top panel controls, middle panel mild AS and bottom panel severe AS. Data represent mean±sem (error 
bars). Rl= first 3 min recovery with/without RCO, R2= recovery 4-6min.
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Systolic blood pressure was higher in each group during recovery with regional 
circulatory occlusion than without. Diastolic blood pressure followed a similar 
pattern to systolic blood pressure (see table 7-4).
The magnitude of ergoreflex activation for BP was not significantly different 
between groups, classed by severity of AS. The magnitude of ergoreflex was 
significantly increased for SBP and DBP in the cuff v non-cuff run in all groups.
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Average Blood Pressure (mmHg) Ergoreflex magnitude
Cuff
Recovery
Non-Cu
Recovery
95% Cl of 
Cu-NC
P Cuff 
(% peak)
Non-cuff 
(% peak)
Controls
SBP 154±16 138±12 10.1, 19.6 <0.0001 87±37 14152
DBP 9918 89±9 6.6,13.4 <0.0001 87±44 14145
Mild AS 
SBP 164±28 148±24 9.2, 23.2 0.0003 82±51 22125
DBP 101±14 93113 4.0, 12.0 0.001 108±170 18146
Severe AS 
SBP 161±28 144±24 12.2,23.6 <0.0001 125±79 27153
DBP 96±12 88±10 4.9, 11.1 0.0001 1291109 27142
Asv AS 
SBP 152±24 139±19 7.7, 18.0 0.0001 77175 21133
DBP 9914± 92±12 2.5, 10.3 0.004 112174 37134
Svm AS 
SBP 172±28 151±26 15.9, 27.3 <0.0001 132158* 28150
DBP 97±13 88±11 6.4±12.3 <0.0001 1241110 12147
Table 7-4: Blood pressure response by group; cuff v non-cuff and magnitude of 
ergoreflex.
Cu= cuff run, NC= non-cuff run.
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7.2.3 Symptomatic v asymptomatic AS
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Subjects AS36 and C08 were again excluded from ergoreflex analysis. The 16 
patients in the symptomatic AS group were significantly older (69.2±11) than both 
the asymptomatic AS group (n=14, 45.4±20) and the controls (n=16, 48.0±18 
years), p<0.001.
7.2.3.1 Ventilation
Results are displayed in figure 7-5. There were no significant differences in 
ventilation between groups at rest or at peak exercise in either cuff or non-cuff run.
Figure 7-5: Ventilation, non-cuff v cuff run by symptomatic group.
Top panel controls, middle panel asymptomatic AS, bottom panel symptomatic AS. Data represent 
mean±sem (error bars). Rl= first 3 min recovery with/without RCO, R2= recovery 4-6min.
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Ventilation during recovery with RCO was significantly increased in the 
symptomatic group compared to controls (see table 7-5). Ergoreflex magnitude 
(cuff run) was also increased with RCO in the symptomatic AS group compared to 
both other groups.
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Absolute ventilation w as significantly higher in symptomatic patients during non­
cuff recovery compared to asymptomatic AS and controls although the magnitude 
of non-cuff ergoreflex differences did not reach statistical significance (see table 7- 
5).
Ventilation (L/min) Ergoreflex Magnitude
Cuff
recovery
Non-cuff
recovery
95% Cl 
Cu-NC
P Cuff 
(% peak)
Non-cuff 
(% peak)
Controls 9.5±2.2 9.2±1.9 -0.5, 1.2 ns 17±48 8±77
Asy AS 10.7±2.9 9.8±1.8 -0.01, 1.9 0.052 20±47 17±29
Sym AS 12.3±2.7 11.6+3.2 -0.4, 1.9 ns 67±50 44±59
P 0.015* 0.02** - - 0.01** ns
Table 7-5: Cuff v non-cuff ventilation and magnitude of ergoreflex by symptomatic 
status.
* Sym AS v controls but not Asy AS. **Sym AS v Asy AS and controls.
Intra-group comparisons of the magnitude of ergoreflex between cuff and non-cuff 
runs were not significant for the controls or asymptomatic AS, in the symptomatic 
group this difference is of borderline significance (95% Cl -3.8, 49.5, p=0.09).
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7.2.3.2 Blood p re ssu re
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There was no significant difference in systolic or diastolic blood pressure between 
the AS symptomatic groups and controls at any time point. Systolic blood 
pressure blood pressure responses are displayed in figure 7-6.
Figure 7-6: Cuff v non cuff, effect on SBP; asymptomatic v symptomatic AS.
Top panel asymptomatic AS, bottom panel symptomatic AS. R l= first 3 min recovery with/without RCO, 
R2= recovery 4-6min.
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The pattern of change of diastolic blood pressure was similar to that of systolic 
blood pressure (see table 7-4). Systolic and diastolic blood pressure was 
significantly elevated during recovery with regional circulatory occlusion compared 
to without in symptomatic and asymptomatic patients. Intra-group analysis 
showed increased ergoreflex activation in cuff v non-cuff runs for both SBP and 
DBP in both groups.
The magnitude of cuff ergoreflex activation for SBP was significantly increased in 
symptomatic AS compared to controls (95% Cl 85, 5) and asymptomatic AS (95% 
Cl 96, 14), p=0.02. There were no significant differences between groups in the 
magnitude of cuff ergoreflex for DBP or in non-cuff ergoreflex activation in either 
SBP or DBP.
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7.3 Ergoreflex magnitude associations
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Leg ergoreflex (cuff ventilation) was significantly associated with several variables 
in AS (see 7-6). The magnitude of leg ergoreflex was significantly associated with 
age, E/A ratio, aortic valve area and Vc>2 max (figure 7-7) but not with predicted 
exercise time. There was a weak but non-significant association with the slope of 
exercise VE/VCO2 . There was no relationship between ergoreflex magnitude and 
any measure of skeletal muscle strength in patients or controls. There was no 
significant correlation of ergoreflex with any anthropometric, echocardiographic or 
exercise variable in controls.
Variable R*(P)
AS Controls
Age 26.4% (0.02) 0% (ns)
AVA (VTI) 13.1% (0.05) 17.7%(ns)
E/A 24.8% (0.006) 2.8% (ns)
Vc^max 17.0% (0.02) 0.2% (ns)
Ve/VCo2 8.1% (0.13) 0.1% (ns)
Table 7-6: Association of leg ergoreflex (cuff ventilation) with anthropometric, 
echocardiographic and exercise variables.
Figure 7-7: Leg ergoreflex (cuff VE) v Vc^max in AS.
Y = 24.1543 - 7.20E-02X 
R-Sq = 0.170
AS VO 2 
(m l/Kg/m  in)
200100-100 0
AS leg ergore flex (cu ff VE)
Ergoreflex magnitude was not an independent predictor of Vc>2 max when 
considered in a multivariate regression with age.
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7.4 Summary of chapter results
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Leg ergoreflex contributes to the maintenance of post-exercise BP in AS and 
controls.
Leg ergoreflex activation contributes to the m aintenance of post-exercise 
ventilation in symptomatic AS but not asymptomatic AS or controls.
Leg ergoreflex activation w as enhanced in symptomatic AS v asymptomatic AS 
and controls.
The magnitude of leg ergoreflex (cuff Ve) activation w as a univariate, but not an 
independent predictor of exercise capacity in AS.
The magnitude of leg ergoreflex (cuff Ve) activation w as not significantly correlated 
with exercise VEA/CO2 .
8. BNP
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Sixteen controls and 34 patients had blood sam pled pre and post exercise. One 
AS sam ple post-exercise w as insufficient for analysis. BNP data were not 
normally distributed and were log transformed to allow application of parametric 
statistical analyses, (see section 2.8 and 2.10).
8.1 Mild v severe AS
All sixteen patients with mild AS and 17 with severe AS had sam ples suitable for 
analysis. Results are displayed in table 8-1. Patients with severe AS tended to be 
older than those with mild AS and controls but this difference does not reach 
statistical significance.
Age BNP Rest 
(pg/ml) 
(Log BNP)
BNP Ex 
(pg/ml) 
(Log BNP)
BNP
Ex-rest
(pg/ml)
95% Cl 
Ex-rest 
(pg/ml)
P
Controls 48.4±1 6, (4-15) 12, (9-36) 9.0 5, 16 0.001
(n=16) 8 (0.81±0.4) (1.110.4)
Mild AS 51.8±2 21.5,(10-49) 32.5,(15-65) 9.8 3, 15.5 0.003
(n=16) 2 (1.3110.6) (1.4410.6)
Severe AS 62.3±1 78.0, (23-256) 90, (24-280) 22 9.5, 39 0.001
(n=17) 5 (1.8810.6) (1.9410.5)
P 0.08 <0.0001+ <0.0001** ns - -
Table 8-1: BNP pre and post exercise by severity of AS
BNP data are presented as median, interquartile range. (BNPlog+SD). **Severe AS significantly different 
from mild AS and controls. +Each group significantly different from each other.
Resting BNP w as greater in AS compared to controls and in severe AS compared 
to mild AS. BNP increased following maximal exercise in all subject groups and 
the absolute magnitude of increase w as similar in each group.
8.2 Symptomatic v asymptomatic AS
There were 16 patients in the symptomatic and 17 in the asymptomatic AS groups. 
Results are displayed in table 8-2. The symptomatic AS group were significantly 
older than both the asymptomatic and control groups.
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Age
(years)
BNP Rest 
(pg/ml) 
(Log BNP)
BNP Ex 
(pg/ml) 
(Log BNP)
BNP
Ex-rest
(pg/ml)
95% C l 
Ex-rest 
(pg/ml)
P
Controls 48.4±18 6, (4-15) 12, (9-36) 9.0 5, 16 0.001
(n=16) (0.81 ±0.4) (1.1 ±0.4)
Asy AS 47.6±19 22, (10-86) 33,(17-114) 13.5 5, 23 0.002
(n=17) (1.38±0.7) (1.521.6)
Sym AS 67.8±12 57, (22-228) 68, (26-198) 13.8 5.5, 37.5 0.001
(n=16) (1.84±0.6) (1.8810.5)
P 0.002** <0.0001** 0.001* ns - -
Table 8-2: BNP pre and post exercise by symptomatic status.
BNP data are presented as median, interquartile range, (logBNP±SD). *Symptomatic AS significantly 
different from controls but not asymptomatic AS. **Symptomatic AS significantly different from 
asymptomatic AS and controls.
Resting BNP w as greater in symptomatic AS com pared to asymptomatic AS and 
control groups. BNP increased in all groups following maximal exercise and the 
magnitude of increase was similar between groups. Following exercise the 
difference in BNP between symptomatic and asymptomatic AS was no longer 
significant.
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8.3 Predictors of BNP
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8.3.1 Resting BNP
Significant predictors of BNP are displayed in table 8-3. BNP w as related to age, 
left ventricular m ass/m ass index and severity of AS in patients but only ejection 
fraction in controls. No other anthropometric, haemodynamic or 
echocardiographic m easures were related to BNP in AS or controls.
Variable RZ(P)
AS Controls
Age (n=34 for AS) 26.1% (0.002) 7.3% (ns)
Ejection fraction (n=15 1.3% (ns) 32.2% (0.028)
for controls)
Left ventricular mass 13.9 (0.05) 0.2% (ns)
(n=28 for AS)
LVMI (n=28 for AS) 25.0% (0.007) 0.9% (ns)
Aortic velocity (max) 29.7% (0.001) 8.1% (ns)
(n=34 for AS)
Peak pressure gradient 27.0% (0.002) 6.9% (ns)
(n=34 for AS)
Mean pressure gradient 29.0% (0.001) 3.9% (ns)
(n=34)
AVA (Vmax) (n=34 for 26.4% (0.002) 15.0% (ns)
AS)
AVA (VTI) (n=34 for AS) 25.4% (0.002) 12.8% (ns)
Table 8-3: Univariate predictors of resting plasma BNP.
Resting BNP was also significantly greater in NYHA class III (192.5, 27-407) than 
in class II (33.5,16-74) and class I (16, 9-36 pg/mL), p=0.009. (See figure 8-1).
8.3.2 Multivariate predictors of resting BNP
Age (p=0.01), maximal aortic velocity (p=0.01) and m ean pressure gradient 
(p=0.05) remained significant predictors of resting BNP on multivariate analysis.
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Figure 8-1: Resting plasma BNP by NYHA classification in AS
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(means are indicated by solid circles)
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8.4 Exercise BNP
Post exercise BNP was very closely related to resting BNP in both AS (R2=99.3%, 
p<0.0001) and in controls (R2=89.0%, pO.0001), see figure 8-2. In both AS 
patients and controls only resting BNP was an independent predictor of exercise 
BNP.
Figure 8-2: Resting v post-exercise plasma BNP in AS.
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8.4.1 Magnitude of increase in exercise BNP
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Only resting BNP(iog) was an independent predictor of exercise induced BNP in AS 
(R2=47.3%, p<0.0001) and controls (R2 66.8%, p<0.0001). See figures 8-3 and 8- 
4.
Figure 8-3: Exercise-induced increase in BNP v resting BNP(|0g).
Top panel AS, bottom panel controls.
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8.5 BNP as a predictor of exercise variables
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Associations of resting plasma BNP(|0g) with various parameters of exercise 
performance are displayed in table 8-4. BNP did not significantly correlate with 
any exercise variables in controls. In AS resting BNP(iog) correlated with VEA/CO2 
(r=0.52) and inversely with maximal aerobic capacity (Vo2max r=-0.46, and % 
predicted exercise time r=-0.41). There was a significant inverse relationship 
between resting BNP and magnitude of SBP response on exercise (r=-0.58, figure 
8-4). BNP did not significantly correlate with the magnitude of leg ergoreflex (cuff 
ventilation).
Variable R1 (P)
AS Controls
V 02max (n=33) 20.8% (0.008) 3.7% (ns)
Pred Ex time (%) (n=34) 17.2% (0.015) 1.8% (ns)
VE/VCO2 (n=33) 27.0% (0.002) 5.9% (ns)
Leg ergoreflex (VE) ns ns
SBP increase (n=34) 33.2% (<0.0001) 0% (ns)
Table 8-4: Resting BNP(iog) as a predictor of exercise performance in AS.
Figure 8-4: Log BNP rest v exercise-induced SBP increase in AS.
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BNP w as not an independent predictor of V0 2 max when considered in a 
multivariate analysis with age. When BNP is considered with left ventricular m ass 
it remains an independent predictor of predicted exercise time (p=0.04).
8.6 Summary of chapter results
Plasm a BNP is increased in severe and symptomatic AS compared to controls 
and mild/asymptomatic AS.
BNP increases following maximal aerobic exercise and the magnitude of increase 
is similar in AS and controls.
Age and AS severity are independently associated with resting BNP in AS.
The magnitude of the exercise-induced increase in BNP is strongly related to 
resting BNP in AS and controls.
Resting BNP is correlated with exercise VeA/co2 and inversely and independently 
correlated with exercise duration and the magnitude of SBP response to exercise 
in AS but not in controls.
ET-1
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Seventeen controls and 34 patients had ET-1 analysed pre and post exercise. 
ET-1 data were not normally distributed and remained non-parametric after 
logarithmic transformation.
9.1 Mild v severe AS
Of the 34 AS patients 19 were in the severe and 15 in the mild group. Results are 
displayed in table 9-1. There were no significant differences in age between the 
subject groups. Resting and post-exercise ET-1 were similar in the three groups. 
There w as no appreciable change in ET-1 on exercise in the AS patients but a 
small significant increase in the control subjects.
Age
(years)
ET-1 Rest 
(fmol/ml)
ET-1 Ex 
(fmol/ml)
ET-1
Ex-rest
(fmol/ml)
95% Cl 
Ex-rest
P
Controls 49.9±18 0.52, 0.69 0.15 0.01, 0.04
(n=17) 0.21, 1.58 0.48, 1.90, 0.38
Mild AS 51.8±22 1.00, 0.40, -0.01 -0.34, ns
(n=15) 0.28, 1.40 0.19, 1.50 0.12
Severe AS 62.0±14 0.90, 0.60, -0.02 -0.30, ns
(n=19) 0.22, 1.30 0.18, 1.30 0.22
P 0.11 ns ns ns - -
Table 9-1: ET-1 pre and post exercise by severity of AS
ET-1 data are presented as median, interquartile range.
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9.2 Symptomatic v asymptomatic AS
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There were 17 patients in the symptomatic and asymptomatic AS groups. Results 
are displayed in table 9-2. The symptomatic AS group were significantly older 
than both the asymptomatic and control groups. Resting ET-1 concentrations 
were similar in the three groups.
Age
(years)
ET-1 Rest 
(fmol/ml)
ET-1 Ex 
(fmol/ml)
ET-1
Ex-rest
(fmol/ml)
95% Cl 
Ex-rest
P
Controls 49.9±18 0.52, 0.69, 0.15 0.01, 0.04
(n=17) 0.21, 1.58 0.48, 1.90, 0.38
Asy AS 47.1 ±20 1.00, 1.13, 0.09 -0.02, ns
(n=17) 0.21, 1.35 0.24, 1.60 0.30
Sym AS 67.1±11 0.40, 0.30, -0.22 -0.55, 0.06
(n=17) 0.24, 1.55 0.01,0.80 0.005
P 0.002** ns 0.06* 0.02**
Table 9-2: ET-1 pre and post exercise by symptomatic status.
ET-1 data are presented as median, interquartile range. *Symptomatic AS significantly different from 
controls but not asymptomatic AS (see text below). **Symptomatic AS significantly different from 
asymptomatic AS and controls.
On exercise there w as a small but significant increase in controls, a trend to 
decrease the symptomatic group but no significant change in the asymptomatic 
group (table 9-2). Post-exercise ET-1 appears to be lower in the symptomatic 
group compared to controls and asymptomatic AS. Kruskal-Wallis testing of 
medians (see section 2.10.) gave a p value of borderline significance. *Post-hoc 
testing by Mann-Whitney analysis dem onstrated that following maximal exercise 
ET-1 w as significantly lower in symptomatic AS com pared to controls (95% Cl 
0.05, 1.09, p=0.02). but not asymptomatic AS (95% Cl -0.03, 1.15, p=0.08). The 
magnitude of change in ET-1 w as significantly different in symptomatic AS 
compared to the other groups; ET-1 tended to decrease  in the symptomatic group, 
increased in the controls and was little altered in asymptomatic AS (see figure 9- 
1).
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Figure 9-1: Change in ET-1 on exercise by symptomatic group.
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9.3 ET-1 associations
ET-1 was not significantly associated with age, anthropometric measures, 
echocardiographic variables or exercise performance in AS or controls. The lack 
of a relationship between resting ET-1 and AS severity is shown in figure 9-2. 
There was also no significant relationship between resting ET-1 and BNP in either 
controls or AS.
Figure 9-2: ET-1 in AS by aortic valve area.
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9.4 Summary of chapter results
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Resting and post- exercise ET-1 are similar in AS and controls.
ET-1 increases following exercise in controls, is unchanged in asymptomatic AS 
and tends to decrease in symptomatic AS.
The magnitude of change in ET-1 on exercise is reduced in symptomatic AS 
com pared to controls and asymptomatic AS.
10. DISCUSSION
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10.1 Subject recruitment and characteristics
Of the patients screened, only 26% of patients were eligible to participate in the 
study. This relatively low figure reflects the rather stringent exclusion criteria, 
which were drawn up to limit the potential contribution to exercise intolerance from 
pathological p rocesses other than AS. The com m onest reasons for exclusion 
were other valvular d isease  (36%), obstructive coronary artery d isease  (14%), 
chronic obstructive pulmonary d isease  (10%) and atrial fibrillation (5%). Also 
many patients did not m eet the inclusion criteria, i.e. they did not have AS of 
significant haemodynamic severity (22%) or were excluded because  of an inability 
to perform treadmill exercise, due either to severe peripheral vascular d isease or 
arthritis. The patient cohort is therefore not representative of the general AS 
population but w as chosen to elucidate the factors contributing to exercise 
intolerance in isolated aortic valve disease. Subjects who had aortic regurgitation 
(AR) were not excluded from this study since Doppler echocardiography identifies 
many AS patients with co-existent regurgitation. Patients with severe or 
predominant AR, judged clinically and by echocardiography and/or angiography, 
were excluded. Those with m oderate AR had to display evidence of AS with 
thickened or calcified leaflets associated with reduced opening.
The actual response rate for an unsolicited approach w as good with 52% of 
patients written to participating in the study. The control group was very well 
matched for height, weight, body m ass index, lean body m ass and male-to-female 
ratio. The patient group w as slightly, but not significantly, older. All controls were 
asymptomatic, although subjects with hypertension were not excluded since 
several of the AS patients were also being treated for high blood pressure.
10.1.1 Patient Characteristics
As in previous studies, there w as a very wide range of age in the patient cohort 
(25,75), reflecting the inclusion of patients with both congenitally bicuspid aortic 
valves and the more common degenerative AS. Similarly, there w as a wide range 
in AS severity, with calculated aortic valve a reas  varying from 0.28 cm2 to 1.56 
cm2 and peak pressure gradients ranging from 26-157 mmHg. The average 
severity of AS for the whole patient group would be at least moderate to severe,
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with peak and mean pressure gradients of 65 and 37 mmHg respectively and an 
effective aortic valve area of 0.6 cm2.
10.1.2 Symptomatic Status
Nine of the patients were completely asymptomatic, 16 were in NYHA class II and 
12 in NYHA III. Those in NYHA I were significantly younger than the other 
patients. Of the 28 patients with symptoms, a very high proportion (25/37) 
reported exertional dyspnoea, which is just slightly higher than previous 
reports(4,90). Only 10 patients had angina pectoris, which w as lower than in most 
other studies (4,81,83), but this is undoubtedly a reflection of the fact that patients 
with proven obstructive coronary artery d isease  were excluded. Similarly, syncope 
was an exclusion criteria because of the potential risk on exercise testing. 
Eighteen of the 28 symptomatic patients also complained of fatigue, but this 
symptom is seldom reported in previous studies.
10.1.3 Echocardiography
10.1.3.1 R eproducibility of M easurem ents
The intra-observer correlation coefficients for most of the echocardiographic 
m easurem ents were good to excellent (r=0.83-0.95). Those for aortic valve area 
by VTI and ejection fraction using Sim pson's rule were only moderately good 
(r=0.59 and 0.63 respectively). The fact that aortic valve area by VTI gave a 
poorer correlation coefficient than that by determined by maximal velocity (Vmax), 
is probably a reflection of the fact that the value is determined by two components: 
the maximal jet velocity and the systolic ejection period, compared to the 
maximum velocity for Vmax only. The two values, however, were very closely 
correlated, the Vmax value tending to be lower than that by VTI, particularly in 
those with less severe d isease (see figure 3-1). This finding is unexpected since 
VTI generally is regarded a s  the effective aortic valve area and Vmax corresponds 
to the point of maximal pressure gradient, which if the valve is elastic, should 
equate to the maximal area during systole(50). As the vast majority of patients 
had valve leaflet calcification, the valves may be less elastic and result in little 
change in the valve area with increased flow.
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The low intra-observer correlation coefficient for ejection fraction probably reflects 
inadequate visualisation of the endocardial surface of the left ventricle. Ejection 
fraction calculation by Simpson’s biplane method requires 80% of the endocardial 
surface to be visualised(289) and this could not be achieved in several patients 
and one control subject.
10.1.3.2 Left ventricular structure and function
As in previous studies, left ventricular systolic function w as normal in the majority 
of patients (22-25). Two patients did have wall motion abnormalities, however the 
mean ejection fraction of 51.6% for the AS group is very close to the expected 
m ean for this population(915), although slightly less than controls. Not 
surprisingly, the patients had significant increases in both left ventricular m ass and 
m ass index compared to controls(17,18). Using a crude m easure of diastolic 
function (E/A ratio), there was no significant difference between aortic patients and 
controls.
10.2 Patient subclassification
10.2.1 AS severity
10.2.1.1 Classification of AS severity
There is not uniform agreem ent in selecting which values or even m easures to use 
when grading the severity of AS(18,71-73). Historically aortic valve area has been 
used and is the preferred m easurem ent of the ACC/AHA task force on 
m anagem ent of valvular heart disease(18). The original Gorlin equation 
suggested that large increases in pressure gradient only occurred with valve areas 
<0.75cm2(38). The AHA/ACC acknowledge that the severity of AS in any 
individual may vary depending on body size, have classified an aortic valve area of 
<1.0cm2 as  severe AS(18). In the presence of normal left ventricular function they 
expect this degree of stenosis to be associated with a m ean transvalvular pressure 
gradient >50mmHg.
Clinicians in the modern era seem  more at e a se  with classification according to 
pressure gradients rather than aortic valve area(74). Indeed the ACC/AHA task 
force on sports participation quantify a mean pressure gradient >40mmHg as
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severe and <20mmHg as  mild AS in acquired disease(71). To add to the 
confusion they recommend the use of peak pressure gradient in congenital 
AS(71). Regardless of the m easure used, selecting cut-off values to classify the 
severity of a continuous variable will always be an inexact science and the 
limitation of each quantification technique should be borne in mind. It is generally 
recommended that aortic valve area and pressure gradients are examined 
together in determining the severity of AS in a given individual(55,74).
In the current study a mean pressure gradient > 30 mmHg w as chosen to select 
patients with m oderate to severe disease. Aortic valve area w as not used for this 
purpose, as  the values obtained in controls were lower than expected from 
anatomic specimens(3,4). This can be accounted for by the low mean left 
ventricular outflow tract diam eters m easured by echocardiography in both controls 
(1.65cm) and patients (1.71cm). These values are markedly lower than two 
previous American reports, 2.3cm(75), 2.29cm(62) but less so than the single 
British study 1.94cm(55). Small left ventricular outflow tract diam eters result in low 
calculated left ventricular outflow tract area and, according to the continuity 
equation(50) a low calculated aortic valve area (see equation 7, section 1.4.3). 
Accurate m easurem ent of left ventricular outflow tract diam eter is recognised as 
an important limitation in calculating aortic valve area  by the continuity 
equation(50,59,60). The average aortic valve area of the control group was 
1.5cm2 and half of the subjects had a reas lower than this, normally indicative of the 
AS range, despite having anatomically normal valves and transvalvular pressure 
gradients. For these reasons, an absolute value of aortic valve area could not be 
used reliably to classify the groups according to severity.
10.2.1.2 Discrepancy between valve area and pressure gradient
Twenty-one patients were classified as  having m oderate-severe AS with a mean 
pressure gradient >30mmHg. The eight patients who would have been re­
classified in the severe group using aortic valve area had significantly lower left 
ventricular outflow tract diam eters (1.48cm) and a reas  (1.78cm2) than the other 
patients (1.78cm and 2.60cm2). Conversely the two subjects with high mean 
pressure gradients but only mild AS by area had large left ventricular outflow tract 
diam eters compared to the other patients(see section 3.6.1.5).
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Other theoretical possibilities for the discrepancy between pressure gradients and 
aortic valve a reas are less likely to be significant. Aortic regurgitation can result in 
an increase in m easured trans-valvular pressure gradient without a significant 
reduction in aortic valve area(58). However the five patients with more than mild 
aortic regurgitation (+++ or ++++ see  table 3-5) all had high pressure gradient-low 
area or low gradient-high area. The modified Bernouilli equation w as used to 
calculate to calculate pressure gradients (equation 5) since in AS this makes little 
difference to the calculated values(47). Although the left ventricular outflow tract 
velocities are not used in this equation they were m easured a s  they are required 
for calculation of aortic valve area by the continuity equation (equation 7). The 
average reduction in pressure gradients if the proximal velocity had also been 
used are very small in the AS patients; 3.7mmhHg for peak pressure gradient and 
only 0.25mmHg for mean pressure gradient.
Aortic pressure recovery is a mechanism by which Doppler m easurem ent of 
transvalvular pressure gradient may overestimate the true gradient(54-57). This 
phenom enon is particularly apparent in patients with small aortic roots(54,55). 
The two patients (AS06 and AS08, se e  table 3-5) with high pressure gradients and 
large aortic valve a reas did not have small aortic roots making this mechanism 
unlikely a s  a cause of overestimation of pressure gradient. They did have large 
left ventricular outflow tract diameters, again leading to large calculated aortic 
valve areas.
Severe AS can be present with low pressure gradient in the presence of left 
ventricular dysfunction. Similarly the aortic valve area  may be lower than 
expected as  the reduced contractile force fails to open the calcified aortic leaflets 
fully(74). In the current study only two patients had had evidence of left ventricular 
regional wall motion abnormalities (AS 12 and AS20 se e  table 3-5). AS 20 had 
both high mean pressure gradient and low aortic valve area  in keeping with severe 
AS. AS 12 had only mild impairment of systolic function and did not have severe 
stenosis either by pressure gradient or valve area.
The absolute value of the aortic valve area is probably of less importance in this 
type of investigation than the separation of groups by aortic valve m easurem ents. 
Clearly the aortic valve area of control subjects is distinct from the aortic patients, 
with little overlap between groups (see figure 3-3). Similarly, the severe aortic 
group were significantly lower than those with mild AS.
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10.2.1.3 Symptoms and Disease Severity
There w as considerable overlap in symptomatic status between patients in the 
mild-moderate and the m oderate-severe aortic groups (table 3-9) which has been 
dem onstrated previously(106). There was a tendency for the more severe group 
to have increased symptomatology. Considering that other co-morbidities were 
largely excluded in this study, it is som ew hat surprising that ten of the mild group 
still reported symptoms. As in previous reports, several patients with severe 
d isease  were entirely asymptomatic (3,82-4,90,91,). The severity of AS was not 
significantly associated with anthropometric m easurem ents, left ventricular m ass, 
ejection fraction or E/A ratio. There w as a trend for increased NYHA functional 
classification and increased age to be associated with severe AS (see 3.1.5.5).
10.2.2 Symptomatic versus asymptomatic AS
10.2.2.1 Classification by symptomatic status
Nine of the patients were completely asymptomatic, with a further nine, who had 
only mild dyspnoea or fatigue, also classed a s  asymptomatic for subgroup 
analysis. Such a strategy which could be criticised, has been used in previous 
large studies(25,75) in assessing  the predictors of outcom e in asymptomatic AS. 
Dyspnoea, in combination with signs of heart failure, is regarded a s  a cardinal 
symptom in AS(80). However dyspnoea is frequently reported a s  an early 
symptom and is present in the majority of symptomatic patients(4,90). Clinicians 
may be reluctant to recommend aortic valve replacem ent in patients who have 
only mild limitation due to dyspnoea and fatigue since these  symptoms are non­
specific. Also in elderly subjects operative mortality increases dramatically(150- 
153) and may be deem ed prohibitive, in subjects with only mild limitation due to 
fatigue and dyspnoea , for at best, a m odest improvement in symptoms. None the 
less, the fact that patients with mild and non-specific symptoms were included in 
the asymptomatic group is likely to reduce the differences in exercise responses 
between the two groups and is a limitation of the current study.
10.2.2.2 Predictors of symptomatic status
When aortic patients were divided into symptomatic and asymptomatic groups, 
there w as a similar male to female ratio in all three groups. There were no
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differences in anthropometric m easures or left ventricular structure and function 
between the two aortic groups. Symptomatic patients, however, were significantly 
older with more severe d isease  m easured by either pressure gradient or aortic 
valve area. Other authors have dem onstrated that symptomatic patients are 
significantly older than asymptomatic subjects(106). Age and aortic valve area 
were associated with symptomatic status and peak and mean pressure gradients 
were of borderline significance(see table 3-12). However, in a multivariate model 
predicting symptomatic status, only age was of independent significance. If age > 
60 years was considered the odds ratio for being symptomatic was 8.2 (95% Cl 
1.4, 49.4, p=0.02). This tells us that in patients with haemodynamically significant 
AS, advancing age is more important in the development of symptoms than 
stenosis severity. Although somew hat surprising these results are consistent with 
previous studies which have shown a good prognosis in young patients, 
particularly those who are asymptomatic(72,111). Age is also a univariate 
predictor of clinical events in initially asymptomatic patients with severe AS but is 
not of independent significance when considered with valve calcification(25).
Advancing age may therefore be the most important determ inant in explaining why 
som e patients with similar haemodynamic severity of AS develop symptoms and 
others remain asymptomatic. The importance of age a s  a predictor of outcome 
may be related to the co-existence of asymptomatic coronary artery disease(108).
10.2.3 Physical Activity Levels
There w as no difference in physical activity levels between the groups as  
m easured by the Scottish Physical Activity Questionnaire. This finding is rather 
surprising, especially in not detecting differences between symptomatic patients 
and controls. The SPAQ has been validated a s  a m easure of physical activity in a 
healthy Scottish population(294). The questionnaire however has not been 
validated in patient populations and is probably not sensitive enough to detect 
differences in a cardiac population. A particular problem is that the type of activity 
is not weighted qualitatively. This m eans that highly intense exercise such as  
running or squash is considered equally as  a gentle walk or gardening.
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10.3 Cardiopulmonary Exercise Tolerance Testing
The current study is one of the largest on exercise testing in AS to include 
symptomatic patients. There were no complications on maximal exercise testing 
in this group of patients, som e of whom had very severe and symptomatic 
d isease. There is now a considerable body of evidence demonstrating the safety 
of exercise testing in AS (see section 1.8 and table 1.4). A strong argument could 
therefore be made for removing AS as  a contraindication to exercise testing from 
the many guidelines which are in circulation (18,124-126).
10.3.1 Rest and exercise ECG
10.3.1.1 Resting ECG
Only ten of the 37 patients had a normal ECG. Twelve patients had voltage 
criteria for left ventricular hypertrophy and 12 had repolarisation abnormalities. 
Patients with severe AS were more likely to have an abnormal ECG although 9/16 
in the mild group also had ECG abnormalities. There w as no difference in the 
proportion of symptomatic and asymptomatic subjects with an abnormal ECG and 
interestingly only two of the nine patients in NYHA class I had a normal ECG.
10.3.1.2 Exercise ECG
ST segm ent changes on exercise testing is not a reliable method for diagnosing 
obstructive coronary artery d isease in AS(137). In the current study all 12 patients 
with resting repolarisation abnormalities developed further ST depression during 
exercise and two subjects with left bundle branch block were excluded from further 
analysis.
Of the 23 patients with no resting repolarisation abnormalities 10 developed ST 
depression, despite those with a history of, or angiographically proven, obstructive 
coronary artery d isease being excluded. This proportion is slightly lower than 
reported in a similar group of patients with mild-moderate AS but patients with 
coronary artery d isease were included in that study(137). Som ewhat surprisingly, 
ST changes were seen  a s  frequently in patients with mild or asymptomatic AS 
compared to those with severe or symptomatic AS (see tables 4-1 and 4-2). From
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these data it is concluded that the exercise ECG is not a helpful investigation in 
discriminating between asymptomatic and symptomatic AS patients.
10.3.2 Symptoms limiting exercise capacity
As in previous reports, the vast majority of the patients in the current study were 
limited by fatigue, breathlessness or a combination of the two(34,194). Three of 
the nine patients in NYHA class I were limited by dyspnoea but two of the controls 
also stated breathlessness as  the reason for termination. Patients with severe AS 
tended to be limited more frequently by dyspnoea or chest pain rather than fatigue 
compared to mild AS as  has been shown previously(34). Similar differences were 
not seen  when the symptomatic and asymptomatic groups were compared. This 
may be partly explained by the fact that mildly symptomatic patients were included 
in the asymptomatic group for analysis. However when examined by NYHA class 
there were no differences in the proportions limited by dyspnoea/chest pain 
although this analysis may be limited by the small num bers in each group (see 
section 4.2.1.1)
The fact that the symptomatic patients had significantly reduced exercise capacity 
with reduced RER, peak ventilation and reduced maximum heart rate is consistent 
with symptomatic development causing early termination of the test.
Two patients had a drop in SBP during exercise and both were symptomatic at the 
time of test termination.
10.3.3 Exercise capacity
Exercise capacity w as significantly reduced in all groups of AS patients confirming 
the hypothesis (1.17.1.1).
10.3.3.1 Asymptomatic AS
Exercise duration w as 86% of predicted in asymptomatic patients, which is 
consistent with that reported previously by Otto in a similar group of subjects(75). 
V0 2 max w as 20% lower in asymptomatic patients com pared to the control group 
who were very well matched for age and sex, but this reduction just fails to reach 
statistical significance (table 4-4). The mean Vc>2 max of 25.3 ml/kg/min is also
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similar (26.7 ml/kg/min) to that reported in slightly younger asymptomatic AS
patients(24). The asymptomatic group achieved close to maximum predicted 
heart rate (90+15%), which was not significantly different from the control group. 
They did dem onstrate a reduced SBP response to exercise compared to controls( 
see  table (see table 4-4), a s  has previously been reported(24).
10.3.3.2 Mild AS
W hen one considers all patients with mild, albeit haemodynamically significant AS, 
the reductions in exercise capacity are more pronounced. There were significant 
reductions in exercise duration, V0 2 max, maximum heart rate, ventilation and RER 
compared to controls, even though these  groups were very well matched for age, 
sex and body size (tables 3-8 and 4-3).
10.3.3.3 Severe AS
Patients with severe AS, regardless of symptomatic status, tended to have 
reduced exercise capacity and a blunted haemodynamic response compared to 
control subjects. There were few statistically significant differences between the
severe and the mild AS groups however (table 4-3). They did have a lower
increase in SBP but maximum cardiopulmonary m easures were not significantly 
different between the mild and severe AS groups.
10.3.3.4 Symptomatic AS
Of more interest is the significant differences in exercise variables in the 
symptomatic compared to the asymptomatic group. Maximum heart rate, increase 
in exercise SBP (19 vs. 37 mmHg) and predicted exercise duration were all 
significantly reduced in the symptomatic group (table 4-4). Similarly, Vo2max was 
reduced by 35% although this difference may be partially explained by the fact the 
symptomatic patients were significantly older. Exercise capacity remained 
impaired however, even when corrected for age and sex  (% predicted exercise 
time estim ated from the Bruce nomogram(292), table 4-2). In this study exercise 
duration as  a percentage of predicted is probably a more meaningful m easure of 
aerobic capacity given the large age range in subjects. V0 2 max is known to 
decrease  with advancing age w hereas predicted exercise time is based on the age 
and sex  of the subject.
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The ventilatory response to exercise w as also significantly altered in the 
symptomatic group (confirming hypothesis 1.17.1.2). VE/VCO2 m easured at 
submaximal exercise intensity w as significantly increased, as  has been 
dem onstrated previously in patients with CHF(182,183). VE/VCO2 , across a wide 
range of values (30-55), w as a strong predictor of mortality at two years in 293 
patients with CHF(190). Although the symptomatic AS group were slightly older 
(68 v 59 years) than the CHF patients, VeA/C02 (AS 35 v CHF 37) and Vo2max 
(AS 16.4 v CHF 17.8 ml/kg/min) were comparable. It rem ains to be seen  whether 
VE/VCO2 and V0 2 max may be strong independent predictors of mortality or the 
need for aortic valve replacem ent in AS.
These differences in exercise performance were seen  despite patients with mild 
symptoms being included in the asymptomatic group for analysis. As can be seen  
from table 4-5 the nine patients in each group responded differently to exercise 
despite having similar ages and degree of stenosis severity. The patients in 
NYHA class I were not significantly different from the control group and the mildly 
symptomatic patients were not significantly different from the more symptomatic 
group. These findings would seem  to support the advocates of exercise testing in 
asymptomatic patients with AS as  a guide to aortic valve replacement. The fact 
that the two groups responded differently to exercise also questions the validity of 
whether mildly symptomatic patients should be included in outcome studies of 
asymptomatic AS. This is especially true a s  functional status, m easured by a 
standardised questionnaire, was an independent predictor of outcome in Otto’s 
prospective study of asymptomatic AS(75) but was not considered in Rosenhek’s 
similar study(25).
10.3.4 Predictors of aerobic exercise capacity in AS
This is the first study to report that resting haemodynamic m easures of AS severity 
are significantly associated with maximal aerobic capacity (thereby confirming the 
null hypothesis 1.17.6.1). Age, symptomatic status, aortic valve area, peak A and 
E/A ratio of left ventricular filling were all univariate predictors of aerobic exercise 
capacity (see table 4-6). The only independently significant predictors of V0 2 max 
were patient age and NYHA functional classification. It is not surprising that age is 
such a strong predictor of V0 2 imax in this study. It is well recognised that 
maximum aerobic capacity decreases with age and there w as a very large age 
range (20-84 years) of the subjects tested(174). It w as also expected that
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symptomatic status would be a significant predictor of exercise capacity since 
these patients will tend to develop symptoms on exercise resulting in early 
termination of the test.
10.3.4.1 Functional status and exercise capacity
Previous studies in AS have reported that functional classification of symptomatic 
status is poorly associated with exercise capacity(93,135). The discrepancy 
between the current study and these previous reports may be due to the fact that 
subjects with significant co-morbidity, e.g. obstructive coronary artery disease, 
which may limit exercise capacity, were excluded. However, similar to previous 
results, som e patients with only mild symptoms have severe limitation on exercise 
testing and there is a large overlap between patients in each functional class, see  
figure 4-3(93). NYHA classification, left ventricular m ass and m ass index were 
independent predictors of exercise duration (% predicted). As predicted exercise 
time is based on the sex and age of the subject, it is not surprising that age is not 
a independently associated with exercise duration.
10.3.4.2 Left ventricular mass and diastolic function
The fact that left ventricular m ass and m ass index were independent predictors of 
exercise duration probably reflects the importance of diastolic function in exercise 
limitation in AS. Left ventricular diastolic filling and stroke volume on exercise are 
inversely related to left ventricular m ass in AS(24). Oxygen pulse, which is the 
amount of oxygen consum ed per heartbeat, and is the product of stroke volume 
and arterial venous oxygen extraction, was significantly reduced in AS patients 
(tables 4-3 and 4-4). This finding is consistent with impaired left ventricular 
function. Also, the E/A ratio of ventricular diastolic filling (a crude m easure of 
diastolic function) w as a univariate predictor of V0 2 max in AS patients. This ratio 
is known to decrease  with advancing age and w as no longer significant when 
considered in a multivariate analysis with age.
10.3.5 Cardiopulmonary exercise variables as predictors of 
outcome
Clearly these  results dem onstrate that there are significant differences in the 
haemodynamic and cardiopulmonary responses to exercise in patients with
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symptomatic d isease compared to asymptomatic individuals. Symptom-limited 
exercise testing is commonly performed in most hospitals, but is rarely undertaken 
in patients with AS. It has been dem onstrated that exercise testing such patients 
is safe and provides both an objective m easure of aerobic capacity and allows 
determination of the haemodynamic response to exercise. The variables which 
seem  to give most differentiation between symptomatic (i.e. those at most risk of 
future events) and asymptomatic AS are: the increase in SBP, exercise duration 
as  com pared to predicted and the slope of VEA/CO2 which has been shown to 
provide independent prognostic information in patients with CHF(190). Other than 
measuring VEA/C0 2 , every hospital in the country has the facility to undertake 
exercise testing which might provide important prognostic information in AS.
10.4 Muscle strength and endurance
No previous studies have examined skeletal muscle strength or endurance in 
aortic valve disease.
10.4.1 Isometric strength
No significant differences in any m easure of isometric quadriceps muscle strength 
were found between the AS patients, either classified by severity or symptomatic 
status, and the controls (tables 5-1 & 5-2). Similar results have been reported in 
patients with heart failure, certainly when skeletal muscle m ass is normalised for 
body size(180,202). The absolute value of quadriceps strength (>500N) in AS 
patients in this study is higher than that reported for CHF patients of a similar age 
(<400N) with comparable maximal aerobic capacities(176,179,202). This also 
applies to the control subjects compared to those in a previous study(202). These 
different results are not directly comparable, however. The previous reports tested 
subjects isometrically at 90° or 45° w hereas the current study employed 105° and 
110°. It is not surprising that these higher angles produce greater force since they 
equate to the approximate ideal length-tension relationship for force production of 
the quadriceps muscles.
Clark et al did report that isometric muscle strength w as reduced in patients with 
mild CHF (mean V0 2 max 21.3ml/kg/min) compared to age-m atched controls(200). 
However the male to female ratio of subjects w as not given and the aerobic
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exercise capacity of the control group w as very high (mean V0 2 max 44.7 
compared to 31.3 ml/kg/min for the controls in the present study). This raises the 
possibility that the controls in Clark’s paper were either poorly sex-m atched or fitter 
and more physically active than expected for ‘normals’.
Muscle strength has been shown to be reduced in CHF patients with cardiac 
cachexia(179). The AS patients in the current study had almost identical lean 
body m asses to the control subjects and it is therefore it may not be surprising that 
no differences were detected between groups.
10.4.2 Isokinetic Muscle Testing
10.4.2.1 Isokinetic strength
There were no differences in peak isokinetic strength between any of the AS 
groups and controls (tables 5-3 & 5-4). There w as a small reduction in quadriceps 
peak torque when normalised for lean body m ass in symptomatic AS compared to 
controls, who were significantly younger. Most studies in CHF have also found no 
reduction in dynamic strength compared to controls(178,180). Clark et al did find 
decreased  isokinetic strength in patients with mild CHF, but a s  previously 
discussed, the controls were probably not adequately matched(200). The 
absolute values of peak torque in the current study cannot be directly compared to 
those in CHF patients. Different protocols, both with lower number of repetitions 
or different angular velocities(180,200), have been used and one study reported 
torque in imperial m easures(178). Standardisation of protocols in similar future 
studies is required to allow meaningful comparison of results.
10.4.2.2 Isokinetic muscular endurance
Various param eters of muscular endurance were m easured in this study. Total 
quadriceps (and normalised) work was significantly reduced in symptomatic AS 
patients compared to controls (table 5-6). Normalised quadriceps total work was 
also reduced in the severe AS patients compared to controls (table 5-5). Muscular 
endurance in CHF patients has also shown to be reduced(178,180,202).
These results would tend to indicate a reduced ability to perform repetitive 
muscular work in patients with severe and symptomatic AS. They must be
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interpreted with caution, however. Firstly, three of the patients were unable to 
complete the required 25 contractions. Secondly, there w as wide variation in the 
endurance m easures in each group (see table 5-5 and figure 5-1). Thirdly, the 
fatigue index in many of the subjects was surprisingly small. This suggests that at 
least som e subjects paced them selves throughout the 25 contractions despite 
instructions to the contrary and strong verbal encouragem ent throughout the test. 
An example of such a patient is given below.
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Figure 10-1: Isokinetic test, bad example.
2 0 0
E
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o
This figure shows that peak torque generated is virtually constant throughout the 
25 contractions. Some symptomatic subjects actually had fatigue indices greater 
than 100 indicating no fatigue (figure 5-2).
A good example of an isokinetic test is shown in figure 10-2.
Figure 10-2: Isokinetic test, good example
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2 0 0
This figure demonstrates that peak isokinetic torque is achieved with the third 
contraction and then there is a gradual decline in the initial high level of torque 
throughout the test. Skeletal muscle strength and endurance testing is dependent 
upon the central drive or effort from the subject(291). Clearly, at least some of, the 
subjects in this study gave a submaximal effort which may partly explain the 
reduced endurance results.
Fatigue indices are not regarded as the best or most reliable measure of isokinetic 
endurance. Total work is felt to be a more reliable marker of isokinetic endurance
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than fatigue index(290). Quadriceps total and normalised work were reduced in 
symptomatic patients (table 5-6). Normalised work w as also reduced in severe AS 
(table 5-5). Also, as  the three patients unable to complete the isokinetic test were 
all female, their omission probably results in falsely high values for the isokinetic 
test rather than lowering endurance m easures. Therefore, despite the limitations 
discussed earlier, It is likely that the reductions in quadriceps work in AS patients 
are significant although at least part of the differences may be explained by the 
older age of the symptomatic group.
10.4.3 Skeletal muscle predictors of exercise capacity
All of the strength and endurance m easures other than fatigue indices were 
significantly correlated with V0 2 max (see table 5-7), as  is the case  for 
CHF(176,179,200) The authors of these previous papers have proposed that the 
association between exercise capacity and strength m easures is evidence in 
favour of the muscle hypothesis in CHF(191). T hese previous reports could be 
criticised for not including control subjects(176), not including age a s  a predictor of 
exercise capacity(176,200) and not examining independent predictors by 
multivariate analysis(179).
The strength and endurance univariate predictors of V0 2 max in AS patients would 
seem  to lend support to the muscle hypothesis. However correlations were 
generally higher in the controls than in the patients. Also once age was 
considered, none of the skeletal muscle variables were independent predictors of 
exercise capacity in either controls or patients. W hen predicted exercise time, 
which corrects for age and sex, w as considered none of the skeletal muscle 
variables were significant predictors of aerobic exercise capacity. These data 
suggest that skeletal muscle strength and endurance are strongly related to age, 
which is the strongest predictor of maximal aerobic capacity.
These results therefore necessitate rejection of hypothesis 1.17.2. The 
differences between the severe/symptomatic AS groups and controls are likely to 
be a s  a result of the differences in age between the patient and control groups, or 
an inability of the patient group to give maximal effort on isokinetic testing.
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10.4.4 Skeletal muscle predictors of Ve/Vco2
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Although strength and endurance m easures were not independent predictors of 
exercise capacity this w as not the case  for exercise VEA/CO2 . All of the isometric 
strength m easures were significantly associated with VEA/CO2 in patients and 
controls (see table 5-8). Only normalised peak isometric strength (in AS and not in 
controls) was of independent significance when considered in a multivariate 
analysis. This finding does suggest that there may be a link between skeletal 
muscle abnormalities and the increased ventilatory response to exercise seen  in 
AS (see tables 4-1 and 4-2), and which has previously been dem onstrated in CHF 
and mitral stenosis(182,290).
10.5 Ergoreflex activation
The leg and arm experiments in the current study provide further support of a work 
sensitive reflex (ergoreflex), with afferents arising in skeletal muscle, involved in 
cardiorespiratory control.
10.5.1 Blood Pressure
All of the subject groups dem onstrated a sustained increase in absolute and 
percentage increase in DBP and SBP on recovery from both arm and leg exercise 
with RCO than without (see tables 6-3 and 7-4). Control cuff inflation in the leg did 
produce a small but significant increase in SBP and DBP, but this w as much less 
than that seen  during RCO following exercise. Control cuff inflation of the upper 
limb produced minimal changes in BP, although the exercise responses were very 
similar in magnitude to that seen  with lower leg exercise. Similar results have 
been reported in CHF, CAD and healthy controls (see table 10-1). The magnitude 
of ergoreflex for BP was only significantly increased in symptomatic patients after 
leg exercise compared to both controls and asymptomatic AS. In CHF, ergoreflex 
activity is enhanced for both DBP and SBP after leg(226) and handgrip(213) 
exercise compared to controls. Although not significant the actual magnitude of 
leg ergoreflex DBP differences are very similar e.g. 37% higher in symptomatic AS 
com pared to healthy controls versus 44% and 38% in the two CHF papers (see 
table 10-1).
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The ventilatory responses to localised exercise differed in the patient and the 
control groups.
10.5.2.1 Controls
There were no differences between cuff and non-cuff recovery after either 
handgrip exercise or leg exercise. The magnitude of ergoreflex activity was not 
enhanced during recovery with RCO (tables 6-2 and 7-3). These results are 
consistent with those in healthy controls previously tested in our laboratory with leg 
exercise(226) (table 10-1). It should be noted that although the controls in 
Piepoli’s  paper dem onstrated enhanced ergoreflex activity following RCO after 
handgrip exercise(213), these subjects all had CAD and therefore cannot be 
considered to be ‘normal’.
10.5.2.2 Mild v severe AS
Absolute ventilation during recovery with cuff inflation was significantly greater 
than non-cuff recovery in patients with severe AS after arm exercise (table 6-2), 
and in patients with mild AS after leg exercise (table 7-3). The magnitude of 
ergoreflex activity tended to be higher in both AS groups than controls but these 
differences did not reach statistical significance.
10.5.2.3 Symptomatic v asymptomatic AS
Following handgrip exercise, there was a non-significant increase in recovery 
ventilation during RCO in the symptomatic group com pared to the non-cuff run 
(table 6-4). The magnitude of (cuff) ergoreflex activity was not significantly 
elevated however; symptomatic AS 51% v asymptomatic AS 36% v controls 18%, 
p=0.12. Recovery ventilation after leg exercise w as significantly increased in 
symptomatic AS com pared to controls and asymptomatic AS both with and without 
RCO (table 7-5).
The magnitude of cuff ergoreflex activity w as significantly increased in 
symptomatic patients despite there being no difference in absolute ventilation 
during cuff and non-cuff recovery in this group (table 7-5). It may seem
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paradoxical that the ergoreflex should be increased in the symptomatic AS group 
when there w as no difference in the absolute ventilation between recovery with 
and without RCO. This may be explained by the fact that non-cuff ventilation 
tended to be slower to return to baseline in symptomatic AS than the other groups 
(non-cuff ergoreflex, se e  table 7-5 and figure 7-5). Also the magnitude of 
ergoreflex calculation (equations 9 and 10) does not take into consideration the 
actual differences in ventilation between cuff and non-cuff runs, but the percentage 
increase over resting ventilation persisting during the three minutes recovery 
period.
10.5.3 Ergoreflex comparative studies.
Table 10-1 outlines the main results of ergoreflex studies in various cardiac 
populations incorporating the present results in AS. All of the studies have used 
very similar methodology based on the protocol described by Piepoli et al(213).
Study Ex
Dx
Subjects 
No Age M/F
v o 2 Ventilation
(L/min)
Rest Ex
Ergoreflex (%) 
VE SBP DBP
Piepoli(213) HG CHF 12 60 9/3 14.6 7.5 20.2 86* 89* 98*
CAD 10 59 9/1 28.3 7.6 14.3 54 54 54
Grieve(226) Leg CHF 10 66 ? ? 8.0 12.7 39* 91* 86*
Con 9 62 ? ? 7.6 12.8 -1 48 49
McCann HG Con 17 49 11/6 32.1 8.6 14.0 18 79 81
Asy AS 13 48 8/6 22.8 8.6 15.3 35 88 55
Sym AS 18 70 10/7 16.2 9.2 15.0 51 103 74
Leg Con 16 48 10/6 31.9 8.4 13.0 17 87 87
Asy AS 14 45 9/5 25.3 9.1 13.8 20 77 112
Sym AS 16 64 9/7 16.4 9.2 14.1 66* 132* 124
Table 10-1: Ergoreflex studies in cardiac populations.
Ex=exercise, HG= handgrip exercise; leg= ankle dorsiflexion, Dx=diagnosis; Con=controls; V 0 2= VC^max 
(ml/kg/min).Asy AS= asymptomatic AS, Sym AS = symptomatic AS. ♦Ergoreflex activation significantly 
greater in patient than control group.
In Piepoli’s  study the exercise duration tended to be longer in both control (6.4min) 
and CHF (4.9min) subjects than in the current study (controls 3.1 min, symptomatic 
AS 2.9 min). This difference is probably due to slight variation in the protocol. 
Although both studies used rhythmic handgrip exercise at 50% maximum
McCann, G.P. 2001 Chapter 10 185
voluntary contraction, Piepoli used a frequency of 40 contractions per minute 
w hereas in the current study 60/min w as used. The higher frequency resulted in 
earlier fatigue although the metabolic load placed on the subject groups was 
similar a s  m easured by peak exercise Vo2 and VC02(226).
The peak exercise ventilation seen  in CHF patients following handgrip exercise 
(20L/min) was markedly increased compared to the AS patients in this study 
(15L/min) and CHF patients following leg exercise (12.7L/min). This difference 
may in part be explained by the peak exercise values in the current study being 
averaged over the last 30s of exercise w hereas Piepoli may have used single 
breath m easurem ents which would tend to give higher values(213). Another 
possibility is that the ventilatory response to exercise (VEA/CO2) is higher in CHF 
than in AS patients. Against this assumption is the fact that CHF patients 
achieved a comparable peak ventilation to AS patients after leg exercise and the 
mean value of VEA/CO2 for the symptomatic AS group is very similar to that 
previously reported for a large cohort of CHF patients(190).
10.5.3.1 Leg v arm ergoreflex.
Ergoreflex activation w as significantly increased after leg but not handgrip exercise 
in symptomatic AS. In CHF, both leg and arm exercise results in enhanced 
ergoreflex activation(213,226). It is not surprising that the leg and arm ergoreflex 
results are significantly different. One can imagine that when a patient develops 
significant cardiac compromise, activities which require large muscles and high 
energy expenditure would be the first to be avoided. If skeletal muscle 
abnormalities are primarily the result of physical deconditioning then one would 
expect the leg musculature to be affected before the upper limbs. It is possible 
that peripheral muscle abnormalities in CHF result from the systemic action of 
neurohormonal increases, such a s  catecholam ines and TNF-a(181).
10.5.4 Ergoreflex Associations
Previous studies have not examined the relationship between ergoreflex activity 
and ventilatory response to exercise, exercise capacity, symptomatic status or 
m easures of d isease severity.
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In AS patients, leg ventilation ergoreflex w as inversely related to V0 2 max (r=-0.41, 
see  figure 7-7). Ergoreflex activity w as not however an independent predictor of 
V0 2 max when considered with age and w as not significantly associated with 
exercise duration (% predicted). There was only a w eak (r=0.28) non-significant 
correlation with VE/VCO2 and no relationship to skeletal muscle strength or 
endurance. There were significant correlations in AS with both E/A ratio and 
aortic valve area but both these variables are also related to age. There were no 
significant correlations in controls.
10.5.5 Mechanism of ergoreflex activation
Localised handgrip exercise has been shown to reduce skeletal muscle pH(296) 
and leads to an increase in systemic blood lactate concentration in CHF but not in 
normal subjects(297). Animal studies support the role of metabolic receptors in 
skeletal muscle a s  the afferents to ergoreflex activation(221,222). In the current 
study all groups dem onstrated sustained increases in BP with RCO following both 
leg and handgrip exercise consistent with m etaboreceptor activation. RCO is 
however an unnatural physiological stimulus. All subjects reported discomfort with 
RCO after exercise and two AS patients could not tolerate control cuff inflation in 
the leg. A further two subjects were excluded from leg ergoreflex analysis 
because of a limited increase in exercise ventilation but striking increases in 
ventilation following cuff inflation after exercise. Pain cannot therefore be 
discounted a s  the main aetiological factor in ergoreflex activation in the current 
study.
If pain cau ses  ergoreflex activation however, it should not explain the differences 
seen  between the symptomatic AS patients and other groups with regards to 
increases in ventilation The symptomatic aortic patients may have experienced 
more discomfort if the local skeletal muscle changes were more pronounced with 
earlier metabolic distress a s  in CHF, perhaps increasing lactate and hydrogen ion 
concentration and decreasing phosphocreatine(196,199). Moreover, the neural 
afferents involved in the ergoreflex are mediated by pain fibres, or very similar 
group III and IV nerve fibres(298,299). It is possible that pain or discomfort may 
be an integral component in ergoreflex activation.
Non-cuff ergoreflex activation is a more physiological m easure of the rate of 
recovery from localised exercise. There were non-significant increases in non-cuff
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ergoreflex activation in AS but these  cannot be regarded a s  evidence for 
enhanced ergoreflex activity, a s  the products of metabolism are not trapped in the 
exercising muscles and may stimulate ventilation by other mechanisms(296).
10.5.6 Significance ofergorefiex activation in AS
Ventilation ergoreflex activity was enhanced in symptomatic AS following leg 
exercise compared to both asymptomatic patients and controls. If ergoreflex 
activation was an important contributor to the enhanced ventilatory response and 
exercise intolerance seen  in AS, one would expect it to be strongly related to both 
exercise capacity and VEA/CO2 . Ergoreflex magnitude w as not independently 
predictive of Vc>2 max and w as not significantly related to VEA/CO2 . Importantly, it 
was also not correlated with m easures of leg skeletal muscle strength or 
endurance.
It seem s unlikely that significant skeletal muscle abnormalities exist in AS that 
cause enhanced ergoreflex activation, enhanced ventilatory response to exercise 
and result in exercise intolerance. The ergoreflex w as related to age and as  the 
symptomatic patients were older than the other groups, age cannot be excluded 
as  the cause  for enhanced activity in this study. H ypotheses 1.17.3.1 and 
1.17.3.2, that ergoreflex activity is enhanced in AS, must be therefore be rejected.
10.6 BNP
In various cardiac conditions BNP levels are correlated with left ventricular m ass, 
particularly in hypertension(246,300). In CHF BNP is correlated with left 
ventricular end diastolic pressure, pulmonary capillary w edge pressure, right atrial 
pressure and inversely with ejection fraction(229). In AS patients, Prasad et al 
have dem onstrated that the severity of AS, m easured by m ean pressure gradient, 
is an independent predictor of plasma BNP levels(251). Most BNP in humans 
appears to be synthesised and secreted from the left ventricle(231). In AS 
patients it seem s that the most likely stimulus to secretion of BNP is wall stress, 
particularly end systolic stress(252)
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10.6.1 Resting BNP
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BNP w as significantly increased in AS patients com pared to controls, as  has been 
previously demonstrated(251), confirming hypothesis 1.17.4.1. Furthermore, BNP 
w as significantly greater in severe and symptomatic AS compared to mild and 
asymptomatic AS (tables 8-1 and 8-2).
10.6.1.1 Predictors of BNP
Factors which were significantly associated with plasm a BNP levels in AS on 
univariate analysis included age, left ventricular m ass / m ass index and AS 
severity (table 8-3). BNP was significantly greater in NYHA class III compared to 
class II and I. Maximal aortic velocity and m ean pressure gradient were all 
independently associated with resting BNP. It is not surprising that aortic velocity 
and mean pressure gradient were predictors of BNP since both of these variables 
are directly related to left ventricular peak systolic pressure which is a major 
determinant of left ventricular end systolic wall stress. Wall stress in the current 
study could not be m easured as  simultaneous blood pressure recordings were not 
obtained with echocardiography.
It is surprising that age remains a multivariate predictor of BNP in AS patients. 
Age w as not a significant predictor in control subjects and although diastolic 
function is known to deteriorate with ageing, one would expect that the 
haemodynamic effects of pressure overload from AS would counteract the effects 
of ageing. It is difficult to explain why ejection fraction w as weakly associated with 
resting BNP in control subjects. No other echocardiographic or haemodynamic 
variables, including left ventricular m ass were similarly associated.
10.6.2 BNP Response to Maximal Exercise
BNP increased in all subject groups following maximal exercise and the magnitude 
of increase was very similar between groups. There have been many similar 
reports in patients with cardiac d isease (table 1-6) but also in healthy controls(234- 
236,239). The magnitude of increase is generally small, with median increases on 
exercise of 9 pg/ml in controls, 10 pg/ml in mild AS and 22 pg/ml in severe AS 
(table 8-1). It is difficult to directly com pare the magnitude of increase in BNP in 
the current study with previous reports. All of the published data on exercise
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responses in BNP have reported the results a s  m ean + SD, when the results from 
the current investigation are clearly non-parametric in distribution.
Several groups have dem onstrated that the rise in BNP on exercise is related to 
left ventricular m ass index(234,244,246), but the strongest predictor of the 
increase in BNP is resting BNP(246) and has been confirmed in the current study 
in both controls and AS subjects (figure 8-3 and 8-4). Given what is known about 
the synthesis and secretion of BNP, it is not surprising that those with the highest 
resting levels dem onstrate the greatest increase on exercise. Unlike ANP, only a 
small am ount of BNP is stored in secretory granules and the majority is secreted 
via a constitutive pathway(229,301). It is hypothesised that those subjects with 
elevated resting levels of BNP will have higher m essenger RNA concentrations 
and activity and are able to synthesise and secrete more BNP in response to an 
increase in left ventricular wall stress on exercise. As in previous studies, reduced 
clearance of BNP on exercise or haemo-concentration cannot be excluded as 
contributors to the increased plasma levels following exercise.
10.6.3 BNP as a Predictor of Exercise Capacity
Elevated levels of BNP have been dem onstrated to be significantly associated with 
reduced aerobic exercise capacity in patients following myocardial infarction and in 
those with heart failure(241,250,238). In the AS patients in the current study, 
resting BNP w as significantly correlated with VEA/CO2 (r=0.52) and inversely with 
V0 2 max (r=-0.46), confirming hypothesis 1.17.4.2. BNP w as also significantly and 
independently inversely correlated with exercise time a s  a percentage of predicted 
and with the magnitude of increase in SBP on exercise (table 8-4).
10.6.4 BNP as a Potential Prognostic Marker in AS
BNP has previously been shown to confer prognostic information in patients 
following myocardial infarction, even independent of left ventricular function(253). 
Such useful prognostic indicators are sorely needed in AS, particularly to help 
define the ideal time for recommending aortic valve replacem ent in patients with 
severe d isease. Waiting until the development of symptoms is not an ideal 
situation. Firstly, a small number of completely asymptomatic patients 
(approximately 1-2% per year) will die suddenly(25,91). Secondly, there is
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significant morbidity and mortality whilst on the surgical waiting list with worsening 
of the prognostic profile for surgical outcome(159).
Other than the development of symptoms due to significant AS, there are few 
markers which reliably predict outcome. Surrogate markers looking at the rate of 
d isease  progression or predictors of aortic valve replacem ent have generally been 
used. Evidence of left ventricular systolic dysfunction and increased pressure 
gradients, particularly in elderly subjects tend to indicate a worse outcome(90). 
Exercise testing has recently been proposed a s  a possible investigation on which 
to recommend aortic valve replacement(16,131). In the current study, resting BNP 
was significantly associated with predicted exercise time and a blunted SBP 
response to exercise, both of which have been suggested a s  indications for aortic 
valve replacement(16). W hether BNP has the necessary  sensitivity and specificity 
to predict outcome requires to be tested in a prospective study of AS.
10.7 ET-1
10.7.1 Resting ET-1
Resting ET-1 concentrations were not significantly different in the aortic groups 
com pared to controls, thus rejecting hypothesis 1.17.5.1. These results also 
contradict those previously reported in aortic valve d isease, although two of these 
reports have not been specifically in patients with AS, but combining either 
patients with aortic regurgitation(280) or also patients with mitral stenosis(281).
10.7.2 ET-1 response to exercise
There were no significant differences in ET-1 following maximal exercise between 
any of the groups, thus confirming the null hypothesis 1.17.5.1.
The magnitude of response to exercise w as different however, particularly in 
symptomatic AS compared to controls. The controls dem onstrated a very small, 
statistically significant, increase on exercise which would be consistent with 
previous studies in healthy volunteers(260,264,266,270). ET-1 tended to 
decrease  on exercise in symptomatic subjects, but not in asymptomatic AS. This 
is a different response compared to patients with CHF where endothelin tends to 
increase(271,275,302). Other authors have reported non-significant decreases in
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patients with heart failure, due to various aetiologies, on treadmill 
exercise(273,274). It is difficult to hypothesise m echanism s for the differences in 
endothelin response to exercise in the groups because  of the lack of any 
significant associations of ET-1 with echocardiographic, haemodynamic or 
exercise variables. As ET-1 w as not a predictor of exercise capacity, hypothesis
1.17.5.2 is rejected.
Since ET-1 was sampled almost immediately (<1 min) following exercise, it is 
possible that the maximum response was not obtained although this should not 
result in different responses between groups(262,263).
10.7.2.1 ET-1 reduction on exercise in symptomatic AS
The reduction in endothelin on exercise in symptomatic subjects may be related to 
the abnormal peripheral vasodilatation on exercise which occurs in patients with 
AS and syncope(103). Patients with syncope were excluded in the present study 
because of the potential risks of exercise testing. The seventeen symptomatic 
subjects currently studied would be expected to have similar haemodynamic 
responses on exercise a s  those with syncope.
If inappropriate left ventricular baroreceptor activation occurs on exercise with an 
initiated vagal response(101), then ET-1 production should fall since it is 
stimulated by catecholamines(256). Another possible m echanism to explain the 
fall in ET-1 in symptomatic AS is the role of BNP. BNP may cause  vasodilation by 
inhibiting the production and/or release of ET-1 (256). The symptomatic AS group 
had significantly increased resting and post-exercise levels of BNP compared to 
control subjects. It is possible that symptomatic patients had the greatest 
inhibitory effect on ET-1 synthesis and release, although there were no direct 
correlations between BNP and ET-1 to lend support to this theory.
10.7.3 ET-1 and exercise capacity
The fact that ET-1 was not significantly associated with either V0 2 max or VE/VCO2 
in patients or controls also contradicts a previous report in CHF patients and 
controls(275). The significant correlations in this previous study were probably 
spurious, a s  a result of small subject numbers and largely influenced by outlying 
subjects in each group, obviously strengthening the relationship.
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A major limitation of the current results is that ET-1 is primarily a paracrine / 
autocrine hormone and therefore plasma levels may not be an accurate reflection 
of tissue levels in the endothelium(256).
10.8 Conclusions
10.8.1 Cardiopulmonary exercise testing
Aerobic exercise capacity, maximum heart rate, SBP response, RER and oxygen 
pulse are reduced in severe and symptomatic AS.
The ventilatory response to exercise (VEA/CO2 slope) is increased in severe and 
symptomatic AS.
Age and NYHA functional class and are independent predictors of V0 2 max in AS. 
Left ventricular m ass/m ass index and NYHA are independent predictors of 
exercise duration.
10.8.2 Skeletal muscle strength and endurance
Isometric strength is not reduced in AS.
Isokinetic endurance is not reduced in AS.
Quadriceps strength (normalised for lean body m ass) is an independent predictor 
of exercise VEA/CO2 .
10.8.3 Arm ergoreflex
Ergoreflex activation contributes to the m aintenance of BP, but not ventilation, 
following handgrip exercise in AS and controls.
Arm ergoreflex activation is not enhanced in AS.
The magnitude of arm ergoreflex activation is not a predictor of VEA/CO2 or aerobic 
exercise capacity.
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Leg ergoreflex contributes to the maintenance of BP in controls and AS.
Leg ergoreflex activation contributes to the m aintenance of ventilation in 
symptomatic AS but not in controls or asymptomatic AS.
The magnitude of leg ergoreflex activation is neither a predictor of exercise 
VEA/CO2 nor an independent predictor of Vc>2 max.
10.8.5 BNP
Plasm a BNP is increased in severe and symptomatic AS compared to controls 
and mild/asymptomatic AS.
Age and AS severity are independently associated with resting BNP in AS.
BNP increases following maximal aerobic exercise and the magnitude of increase 
is similar in AS and controls.
The magnitude of the exercise-induced increase in BNP is strongly related to 
resting BNP in controls and AS.
Resting BNP is correlated with exercise VEA/CO2 and inversely and independently 
correlated with exercise duration and the magnitude of SBP response to exercise 
in AS but not controls.
10.8.6 ET-1
Resting and post- exercise ET-1 are similar in AS and controls.
ET-1 increases following exercise in controls and tends to decrease in 
symptomatic AS.
The magnitude of change in ET-1 on exercise is reduced in symptomatic AS 
compared to controls and asymptomatic AS.
McCann, G.P. 2001 Chapter 10
10.9 Future research
194
Many exercise variables have been identified in this study which not only 
differentiate AS patients from controls and severe AS from mild AS, but potentially 
more importantly, symptomatic from asymptomatic patients.
The variables which seem  to give most differentiation between symptomatic (i.e. 
those at most risk of future events) and asymptomatic subjects are the increase in 
systolic blood pressure, exercise duration a s  com pared to predicted and the slope 
of VEA/CO2 which has been shown to provide independent prognostic information 
in patients with CHF(190). In this study plasma BNP is independently associated 
with exercise duration, exercise SBP and VEA/CO2 and may provide prognostic 
information in AS, similar to that following Ml(254). These differences are 
apparent despite mildly symptomatic patients being included in the asymptomatic 
group for analysis. Given the different responses to exercise of the asymptomatic 
and mildly symptomatic patients these results are likely to underestim ate the 
differences between truly asymptomatic and symptomatic patients.
It is apparent that nearly all the pre-eminent clinicians publishing in the field of AS 
agree that exercise tolerance testing gives additional objective evidence in the 
assessm en t of these patients which may be taken into account when 
recommending the optimal timing of surgery in asymptomatic patients. W hat is 
abundantly clear is that there is currently no evidence from blinded prospective 
trials indicating that exercise variables are independent predictors of outcome. 
This thesis gives indirect evidence to support the role of exercise testing in AS by 
demonstrating different responses in symptomatic and asymptomatic AS.
It is therefore recommended that a large prospective study assessing  the 
usefulness of exercise variables (exercise capacity, SBP response, V0 2 max and 
VEA/CO2 ) and resting BNP in predicting outcome should be performed. 
Symptomatic patients should be included so that one may com pare responses in 
this group of high risk subjects with the relatively good prognostic group of 
asymptomatic patients. It would be imperative that the results of the exercise data 
remain blinded, to ensure that decisions regarding surgery are not influenced by 
clinician’s  possible bias in the value of exercise testing.
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APPENDIX A
Order of Testing
Testing w as undertaken over two half days unless patients were travelling from 
outwith the Glasgow area in which case  the tests  were split into morning and 
afternoon sessions with a one hour break.
Day one:
History taking for Inclusion/exclusion criteria,
NYHA classification and medication.
Anthropometric measurements (2.2) and resting 
BP. Echocardiography (2.3)
Venepuncture for BNP and ET-1 (2.8.1)
Familiarisation to treadmill. (2.6.1)
3 min resting ventilatory data 
Symptom limited Bruce protocol 
Venepuncture for exercise BNP and ET-1. (2.8.1)
Quadriceps Isometric strength (2.4.4) 
Isokinetic muscular endurance (2.4.5)
Day two:
Order of leg / arm exercise randomised.
Arm Ereoreflex (2.1 A} Lee ereoreflex (2.7.21
Control cuff inflation Control cuff inflation
Non-cuff or cuff run in Non-cuff or cuff run in
randomised order, 15 min randomised order, 15 min
between runs between runs
Scottish Physical Activity Questionnaire 
completed (2.9)
